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S um m a ry
Many tumours, such as pancreas, lung and stomach cancers are not efficiently treated 
using current methodologies. New treatments are required which operate by previously 
unexplored mechanisms.
One novel approach to cancer treatment utilises bioreducible prodrugs which act on 
hypoxic cancer cells. These cells occur in solid tumours when a tumour becomes so large 
that diffusion alone cannot supply the innermost cells with sufficient oxygen. This 
phenomen facilitates selective reduction o f bioreducible prodrugs in cancer cells. Another 
recent approach to selective cancer chemotherapy uses antibody directed enzyme 
prodrug therapy (ADEPT). By creating an antibody-enzyme conjugate which adheres 
specifically to cancer cells and then administering a prodrug which is activated by the 
aforementioned enzyme, tumour regression can be induced.
Initial attempts to determine the structure activity relationships for bioreducible 
heterocyclic 7V-oxides were centred on six potential prodrugs, each o f  which 
incorporated a pyridine N-oxide, and their six non-oxygenated counterparts. By 
incorporating pendant arms (-CHX), which have the potential to act as alkylating agents, 
it was hoped that a second mode o f toxicity could be created, which would broaden the 
clinical potential o f such compounds. The two structural classes o f  pendant arms which 
were investigated were halides (X=C1, Br or I) or carbamates (X=OCONHR). Biological 
evaluation revealed that all o f the halides had IC50 values in the micromolar range or 
lower and, as expected, the carbamates were considerably less toxic.
Since the reduction potentials o f heterocyclic A^oxides are dependent on the ring system 
they contain, further compounds were investigated. The first examples o f  these were 
based on a quinoline skeleton, which had pendant functionality (-CHX) at the 2-, 3-, or
4-postion o f  the ring. The biological evaluation o f  these 12 compounds revealed that the 
2-substituted isopropyl- and phenyl-carbamates had different toxicological profiles to 
their 3- and 4-substituted derivatives and that, like the pyridine derivatives, the free bases 
were all more toxic then their AAoxide counterparts.
The final series o f  //-oxides investigated was based on a quinoxaline skeleton with two 
substituents (-CHX), and incorporating either halide- or carbamates. This series allowed 
an investigation into the relative toxicity o f mono- and di-A/-oxides. This investigation 
showed that the toxicity differential under oxic conditions between 
bis(hydroxymethyl)quinoxaline bis(phenylcarbamate) di-N-oxide, its mono-iV-oxide and 
free base was 1:5:32. This toxicity differential was not reflected in the oxic:hypoxic 
screening which showed a similar toxicity for all o f the compounds under oxic compared 
to hypoxic conditions.
The lack o f selective toxicity which was seen in all o f the heterocyclic compounds 
synthesised, even those which had highly toxic free bases, is an indication that reduction 
o f the N-oxides does not occur under hypoxic conditions. Electrochemical investigation 
o f  several compounds revealed that one possible cause o f  the lack o f  selectivity was that 
the reduction potential o f  these compounds was outwith the range that could be 
accomplished within hypoxic cells.
Another class o f bioreducible anticancer agents which was studied included nitrobenzene 
and nitrothiophene derivatives. O f the eight target compounds which were synthesised, 
one, 5-hydroxymethyl-l,2-dimethoxy-4-nitrobenzene phenylcarbamate, showed itself to 
be particularly toxic to a cell line which contains primarily enzymes that are capable o f  
single electron reduction. Because this compound was much less active in cells which 
contain high levels o f the obligate two-electron reduction enzyme DT-diaphorase, it was 
assumed that this compound was reduced by both one- and two-electron processes, but 
that only the one electron reduction process leads to the generation o f  toxic species.
Synthesis o f  compounds suitable for use in ADEPT was investigated and a synthetic 
methodology for the formation o f  such a compound was devised. Implementation and 
optimisation o f  this methodology led to the formation o f a precursor, which could readily 
have any nucleophilic drug attached to it.
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1. L ist of A b r evia tio n s
ADEPT Antibody Directed Enzyme Prodrug Therapy
AEC Antibody-Enzyme Conjugates
BCE Af,Af'-Bis(chloroethyl)ethylenediamine
bp Boiling Point
Cbz Benzyloxycarbonyl
conc. Concentration
d Doublet
dAMP Deoxyriboadenosine monophosphate
DBTDA Dibutyltin diacetate
DCC Dicyclohexylcarbodiimide
DCE 7V,TV-Bis(chloroethyl)ethylenediamine
DCM Dichloromethane
dCMP Deoxyribocytidine monophosphate
dGMP Deoxyriboguanosine monophosphate
DIC Diisopropylcarbodiimide
DMF Dimethylformamide
DNA Deoxyribonucleic Acid
dNMP Deoxyribonucleoside monophosphate
dTMP Deoxyribothymidine monophosphate
HCR Hypoxic Cell Cytotoxicity Ratio
HMPA Hexamethylphosphoramide
HPLC High Pressure Liquid Chromatography
IR Infrared
LDA Lithium Disopropylamide
M Molar
/w-CPBA weta-Chloroperoxybenzioc Acid
MHz Megahertz
mp Melting Point
MTX Methotrexate
1
NMR Nuclear Magnetic Resonance
q Quartet
s Singlet
t Triplet
TFA Trifluoroacetic Acid
THF Tetrahydrofiiran
TLC Thin Layer Chromatography
2. In tr o du c tio n
2.1 Background
2.1.1 Occurrence o f cancer
Cancer is one o f the major causes o f death in the western world. In 1989 it resulted in 
over 163,000 deaths in the U K.1 This is equal to over a quarter o f all morbidities. 
Currently over 250,000 new cases o f cancer are diagnosed every year, with over 70% of 
new cancers being found in people aged over 60. Data on some o f the most common 
cancers are summarised in Graph 1 and Graph 2 .1 Extrapolation from the statistics 
currently gathered indicates that 1 in 3 people alive today will die o f cancer unless new 
treatments are developed.
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3
Statistics from the U.S.A.,2 shown in Graph 3 and Graph 4, indicate that cancer is also 
rife in other developed countries, with over 1 million cases diagnosed each year. During 
the same year the death rate from all forms o f cancer in the U.S.A. was half a million.
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2.1.2 Effectiveness o f  cancer therapies
Some o f most telling facts are those gathered in the UK showing 5 year survival rates for 
those people diagnosed with cancer (see Graph 5 and Graph 6). Since the methods used 
in cancer treatment are similar in all developed countries, these statistics are probably 
representative o f those in all developed countries. If the patient is still alive after 5 years 
the treatment is generally considered curative. Results show that our treatment o f some 
types o f cancer is excellent. Skin cancer is readily visible to both patient and doctor and 
so is rapidly detected and treated. The surgical removal o f skin cancer is particularly 
successful when followed up by chemotherapy, and leads to cures for 97% o f patients. 
Other cancers are more difficult to treat. In particular lung cancer, the most common 
cancer in British men, has only an 8% five year survival rate.
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The poor survival o f patients in the UK from many forms o f cancers, and the high death 
rate in the USA, show that current cancer therapies have limited efficiency and that new 
treatments are required.
2.2 A history of anticancer chemotherapy
2.2.1 Alkylating agents
The first nitrogen mustard to be recognised as a treatment for cancer was 
mechlorethamine ( l ) .3 Its mechanism o f action, shown in Scheme 1, requires the lone 
pair on the nitrogen to displace one of the chlorine atoms to generate an aziridinium ion 
(2). This species is highly electrophilic and may be attacked by many nucleophilic sites 
within the cell, including those on DNA bases such as 3, resulting in the formation o f a 
monoalkylated DNA species (4). Since mechlorethamine (I) has two arms capable of 
alkylation, further intramolecular attack will occur to give another aziridinium ion (5). 
The initial binding o f mechlorethamine (1) to DNA brings the second aziridinium ion (5)
5
into close proximity to other regions o f the DNA, so allowing a second alkylation to 
occur rapidly, forming either an intra-strand link or an inter-strand DNA crosslink (6).4
M<
HN
Me,
DNA
OH
4 DNA
Me,\ ©
OH
NH
NH
DNA DNA
5
v
OHOH
Me
NH
-D N ADNA
6
Scheme 1 -  Alkylation o f DNA by nitrogen mustards.
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Electrophilic species have been shown to be attacked by several sites in DNA. The sites 
on the bases guanine (7), adenine (8), cytosine (9) and thymine (10) which experiments 
have shown to most commonly attack electrophiles are shown in Figure 1.5
HN
Guanine 7
N H
/
Adenine 8
NH,
HN
H
N
H
Cytosine 9 Thymine 10
Figure 1 -  Reactive nucleophilic sites on DNA.
Monofunctional alkylating agents are only capable o f  binding to one strand o f  DNA. 
Such binding inhibits the ability o f DNA to act as a template during D NA  synthesis6 so 
reducing the efficiency o f  cellular replication. Bifunctional alkylating agents are 
considerably more potent7 since they have the potential to generate DNA  crosslinks. 
Such crosslinks make the separation o f  DNA into its single stranded form impossible. 
Since DNA replication can only occur via this single stranded form, crosslinking halts 
replication. The increased damage to DNA synthesis which bifunctional alkylating agents 
cause over monofunctional agents is only part o f the equation. Bifunctional agents are 
also more effective, since the crosslinks they produce are not readily repaired by those
• ocellular processes that repair DNA damage caused through monoalkylation.
One o f  the greatest limiting factors in the therapeutic use o f  mechlorethamine (1) is its 
poor stability. Under physiological conditions it has a half life o f around 1 minute.9 The 
ready availability o f the nitrogen lone pair o f mechlorethamine (1) and the presence o f a 
good intramolecular leaving group contribute to the molecule’s high reactivity. Many
7
analogues have been produced which allow the nitrogen lone pair to delocalise into an 
aromatic ring so making the molecule less nucleophilic. Two such analogues, shown in 
Figure 2, are melphalan (11) and chlorambucil (12), both o f  which have half lives o f  
between 20 minutes and VA hours.
Cl H2
^  Melphalan (11)
Cl
/  V /  C 0 2 H
Chlorambucil (12)
Figure 2 -  Melphalan (11) and chlorambucil (12).
An alternative approach is to administer a phosphamide prodrug such as 
cyclophosphamide (13),10 which is shown in Scheme 2. This is metabolised in the liver 
by the cytochrome P-450 oxidase system to form 4-hydroxycyclophosphamide (14),11 
which tautomerises to give the aldophosphamide (15). This is unstable and 
spontaneously breaks down, via a phosphonate species (16), to form the free nitrogen 
mustard (17).
Because the breakdown o f the prodrug cyclophosphamide (13) relies on enzymatic 
activation, followed by a long series o f  chemical reactions, the release o f  the highly toxic 
free drug (17) is slow. The prodrug cyclophosphamide (13) is relatively stable in aqueous 
solution and experiments in living systems have shown that its half life is 7 hours.9
8
Cytochrome P-450 
oxidase system
HN HN
OH
Cyclophosphamide (13)
°>n
^  n h 2 c h o
o ©
NH
Scheme 2 -  Metabolic activation o f cyclophosphamide (13).
2.2.2 Antimetabolites
One o f  the fundamental principles behind drug design is the development o f  drugs which 
mimic compounds that naturally occur in the body. When applied to cancer 
chemotherapy this principle led to the development o f antimetabolites. These compounds 
generally inhibit DNA synthesis and operate most efficiently during a short section o f  the 
cell cycle. For this reason they are most effective on those cells which are proceeding 
rapidly through the cell cycle. This includes many cancer cells as well as certain normal 
tissue such as bone marrow and the cells which make up the epidermis o f  the gastro­
intestinal tract. Attack on rapidly dividing normal cells is the cause o f  most o f the side 
effects o f  antimetabolic drugs.
Work on the use o f  folic acid (18) analogues (see Figure 3) for anticancer treatment 
started after Farber et al. showed that administration o f the folate analogue aminopterin 
(19) led to temporary remission in children with acute leukaemia.12 This analogue was 
soon replaced by methotrexate, MTX (20),13 although no clinical comparison has been 
carried out which determines the therapeutic benefit o f MTX (20) over aminopterin 
(19).14 Nonetheless, the therapeutic benefit o f MTX (20) has been widely proven, being 
curative against choriocarcinoma.15 It has also shown promise when used in combination
9
with other agents, being effective against lymphocytic leukaemia and some solid 
tumours.14
Folic acid (18) is normally metabolised to dihydrofolate, FH2 (21), and subsequently 
tetrahydrofolate, FH4 (22), by the enzyme dihydrofolate reductase, DHFR16 (see Scheme 
3). The FH4 (22) generated is formylated at N-10 to give 10-formyl-FFLj (23), which is 
transformed into 5 , 10-methenyl-FH4 (24) and finally into 5 , 10-methylene-FH4 (25). 
Alternatively FH4 (22) may be methylated by serine hydroxymethyl transferase to give 
5 , 10-methylene-FH4 (25). This then acts as donor o f a methyl group to dUMP generating 
dTMP, with accompanying oxidation o f  FH4 (22) to FH2 (21). The folate derivative 10- 
formyl-FH4 (23) is also required in the synthesis o f the purine bases. Both o f  the above 
processes generate the reduced folate species FH2 (21 ), in producing essential building 
blocks for DNA. However, folate in the diet is normally required in only trace amounts 
since the FH2 (21 ) produced in these biochemical pathways is normally regenerated by 
enzymatic reduction with DHFR to produce FH4 (22).
The folate analogue MTX (20) acts as a competitive inhibitor o f  DHFR, since it binds to 
the enzyme’s active site.17 When MTX (20) is present, DHFR is inhibited and so the 
oxidised FH2 (21) cannot be reduced to form FH4 (22). This lack o f  FH4 (22) will stop 
synthesis o f  nucleotide bases and as such selectively kill cells which are utilising nucleic 
acids as building blocks for DNA. These are normally rapidly dividing tumour cells. 
However, like many other drugs that are antiproliferative, side effects are caused by the 
action o f  MTX (20) on normal cells which are dividing during the course o f  treatment.
R
c o 2h
R=OH R -H  Folic Acid (18)
R=NH2 R -H  Aminopterin (19)
R=NH2 R -C H 3 Methotrexate (20)
Figure 3 -  Structure o f folic acid and its analogues.
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Scheme 3 -  Biochemical pathway to DNA bases utilising folate.
Other antimetabolites include pyrimidine mimics, such as 5-fluorouracil (26), shown in 
Scheme 4. Once administered this agent is biosynthesised to 5-FUTP and 5-FdUMP. 
Incorporation o f 5-FUTP into rRNA results in the non-formation o f  ribosomes,18 or the 
formation o f  functionally impaired ribosomes.19 Similar incorporation into mRNA leads 
to its impaired translation into proteins.20 However, the mode o f  action o f  5- 
fluorouracil (26) is believed to be due to the affect o f 5-FdUMP, which binds irreversibly
11
to the enzyme thymidilate synthetase, 21 so stopping the transformation o f dUMP into 
dTMP, an essential component in DNA.
5-FUTP
HN
5-Flourouracil (26)
5-FdUMP
V
RNA
Thymidilate
Synthase 
dUMP -------------► dTMP
u
DNA
Scheme 4 -  Mode o f action o f 5-fluorouracil (26).
2.2.3 Natural products
Historically important natural products utilised in cancer chemotherapy include the 
anthracycline antibiotics shown in Figure 4. The earliest such drug used was 
daunorubicin (27).22 Later its hydroxy derivative, doxorubicin (28), was isolated from 
Streptomycespencetius and was shown to be o f even greater therapeutic benefit.23 These 
drugs have many different modes o f action including DNA intercalation,24 futile cycling 
o f a quinone radical25 (see Section 3.2.2), interaction with cellular membrane proteins26 
and interactions o f  the DNA-drug adduct with topoisomerase II27 (an enzyme used to 
unwind DNA during its replication).
12
OMe O R=CH3 Daunorubicin (27)
R=CH20H Doxorubicin (28)
Me'
HO H2N
Figure 4 -  Anthracycline antibiotics used as anticancer agents.
Several Vinca alkaloids have shown antitumour activity. Vinblastine (29) and vincristine 
(30) (see Figure 5) are secondary metabolites isolated from the periwinkle plant 
(Catharanthus rosea). They bind to dimers o f  the protein tubulin, leading to the
together to form a microtubule, a structure consisting o f 13 parallel strands o f tubulin 
dimers. The microtubules in a cell are normally in a state o f  dynamic equilibrium, 
constantly depolymerising and repolymerising. However, if  a microtubule inhibitor is 
added, the tubulin dimers released on depolymerisation are absorbed into a tubulin 
dimer-alkaloid aggregate, and so are not free to repolymerise. The uses o f  microtubules 
in the cell are varied, but one o f their key roles is in forming the mitotic spindle which is 
essential for cellular replication.29 Since rapid replication is a feature o f  many tumour 
cells, addition o f a microtubule inhibitor to a tumour can result in tumour regression.
formation o f  tubulin dimer-alkaloid aggregates.28 Tubulin dimers normally come
M e02C
OH
£  HO C 0 2CH3
R=CH3 Vinblastine (29)
R=CHO Vincristine (30)
Figure 5 -  Vinca alkaloids used as anticancer agents.
MeO OCOCH3
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The natural product taxol, which was purified in 1971,30 has the opposite effect to that 
o f  the vinca alkaloids, in that it promotes excessive random microtubule formation. This 
has the effect o f  arresting the cell cycle during mitosis, and as such is the bases o f the 
anticancer properties o f taxol.31
2.3 The effects of tumour physiology on cancer 
treatment
2.3.1 Background
Cancer arises due to the undifferentiated proliferation o f  a genetically altered cell. A solid 
tumour is formed if  the initial cancer cell divides rapidly, whilst remaining attached to the 
surrounding tissue.
Since tumour cells simply divide and do not differentiate, a solid tumour will lack the 
ordered morphology which normal tissue possesses. Since the rate o f  tumour cell growth 
outstrips that o f  the surrounding tissue, the intercapillary distance will increase, resulting 
in areas o f  tumour which are depleted o f materials, such as oxygen, which are supplied 
through vascular structure.32 Each cell which lies between the blood vessel and the 
innermost cells o f  the tumour will absorb some oxygen for its normal metabolism 
resulting in a concentration gradient being set up within the tumour, as shown in Figure 
6 .
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Figure 6 -  Tumour physiology.
Those tumour cells which border capillaries will be sufficiently oxygenated to grow 
rapidly, allowing the tumour to enlarge. Cells further from capillaries will be hypoxic, 
having just enough oxygen to maintain themselves, whereas cells lying even more distant 
from capillaries do not have sufficient oxygen to support themselves and so die. The 
process defined above is diffusion limited and results in regions o f  chronic hypoxia. 
However, other regions o f transitory acute hypoxia can also arise. They are caused by 
the temporary closure o f capillaries which pass through the tum our.33 The exact reason 
for this phenomenon is a yet unknown, but may be caused by either release of 
vasorestrictive agents from the tumour cells, or by a build up o f pressure against the 
capillary’s wall.
2.3.2 Evidence o f hypoxia
When three-dimensional spheroids composed o f tumour cells were cultured as a model 
for solid cancers, they developed hypoxic centres as they reached a diameter o f 0.35 
mm.34 Hypoxia was also observed in transplanted mouse tumours that were larger than 1
T S  • • •m m : Neither o f these results are generally applicable to normal human tumours since in 
each case the tumour was isolated from any vascular structure. However, the results 
infer the possibility o f chronic hypoxia in other tumours under physiological conditions.
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In the mid 1950s sections cut through tumours showed that tumour chords with a radius 
o f  200 pm or greater had a central necrotic region. Only when the radius o f  the cord fell 
to 160 pm or below was no necrosis observed. The authors compared these results with 
theoretical calculations. These showed that diffusion alone would fail to distribute any 
significant level o f  oxygen to the innermost cells o f  tumour chords with a radius o f  
145 pm or greater. However, one o f the assumptions made was that the chord 
contained no capillaries. Dissections o f other tumours have shown this not to be the case 
for many tumour types. Almost all o f  the tumours investigated showed some 
vascularisation, although the percentage o f tumour area made up o f  blood vessels was 
considerably less than in normal tissues. In addition, the ratio o f  vascular tissue to other 
tissue types decreases with increasing tumour size.37 During the period o f tumour 
growth between 8 and 10 g the intercapillary distance exceeds 185 pm. This is a distance 
which a more detailed theoretical analysis predicts will give necrotic areas.
55 mmHg
12 mmHg 
10 mmHg 
7 mmHg
5 mmHg
2 mmHg
Figure 7 -  Tumour oxygen distribution.
Even exhaustive measurements o f hypoxia in 45 different types o f  cultured tumour tissue 
and transplanted tumour tissue38 cannot be taken as positive proof o f  hypoxia within a 
naturally growing tumour. Evidence o f  necrosis within dissections o f  tumours is more 
compelling but this does not necessarily provide detailed evidence on the degree o f  
hypoxia within living tumours. Ideally we require direct measurement o f  hypoxia within 
growing human tumours. This has been done using a glass covered platinum electrode, 
placed within a syringe needle.39 The needle can be guided through a tumour using 
computer tomography and the partial pressure o f oxygen measured after each 5 mm o f  
increasing penetration into the tumour. These results showed a partial pressure o f  
between 42 and 90 mmHg in the normal tissue surrounding the tumour and a
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concentration gradient within most o f  the tumours tested. An average set o f  results is 
shown in Figure 7. These indicate a partial pressure o f  only 12 mmHg in the outer 5 mm 
layer o f  the tumour, with the partial pressure falling to 2 mmHg within the central 
necrotic region.
2.3.3 Implications for therapy
The protective effect o f  hypoxia on radiotherapy has been known about for some time. 
Theoretical calculations40 show that the amount o f  radiation required to kill varying sizes 
o f  tumours increases greatly if they have even very small areas o f  oxygen depleted within 
them (see diagram reproduced40 in Figure 8). For example, a dose o f  4,300 rads would 
cure 90% o f  well-oxygenated tumours which had a diameter o f  75 mm. To have the 
same effect on a tumour which has a small anoxic core (1% by mass) requires a dose o f  
8,000 rads, whilst a fully anoxic tumour would require 10,000 rads. In general the dose 
response curve o f  oxic cells is 3 times greater than hypoxic cells, with the dose required 
to kill the majority o f  hypoxic cells within a tumour reaching a point where irreversible 
damage to surrounding normal tissue can occur.41
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Figure 8 -  Effects o f  hypoxia within tumours on the effectiveness o f  radiotherapy.
Although the largest doses o f radiation which can be safely given do kill almost all the 
oxic cells in a tumour, many o f the hypoxic cells survive. Since these cells are now on the 
periphery o f  the tumour they are in a more oxygenated environment. Experiments have 
shown that although hypoxic cells exist in a static state, once reoxygenated they grow at
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the same rate as cells which have never been exposed to periods o f  oxygen deprivation.42 
Hence these cells can re-establish the tumour after radiotherapy.43 For this reason 
fractionated regimes consisting o f several smaller doses o f  radiation were given. After 
each dose the cells which were resistant due to hypoxia were left to reoxygenate before a 
further dose o f  radiation was given. Repeating this process several times can provide a 
more effective cancer treatment. However, the beneficial effect is limited by the rate and 
degree o f  reoxygenation o f the hypoxic regions within solid tumours. Both o f  these 
factors vary widely between different tumour types.44
Tumours with hypoxic regions are also resistant to many forms o f  chemotherapy. One o f  
the reasons for this is the near static state into which a cell enters into under conditions 
o f  severe hypoxia. In this state cells have been found to stay in the G1 phase o f  the cell 
cycle 45 Because many o f the drugs already discussed are only toxic during specific 
sections o f  the cell cycle, such as DNA replication, these drugs may cause no cellular 
damage to cells in a static state. Alternatively, the drugs produce damage which the cell 
has time to repair before the cell reaches that part o f its life cycle where the effect o f  the 
damage would be expressed.
The simplest form o f resistance to understand arises due to the poor diffusion o f  drugs 
into the nonvascularised centre o f the tumour. As the drug diffuses out from the 
vasculature it interacts with tumour cells as it permeates towards the tumour’s centre. 
This interaction results in damage to the cell and the detoxification o f  the drug. Hence as 
the drug diffuses from the capillaries towards the tumour’s centre, the proportion o f  
active drug decreases along with its therapeutic effect. In reality things are slightly more 
complicated. Many drugs obey this simple model, however there are a few others which 
are uniformly distributed throughout solid tumours, whilst some are actively retained 
within the hypoxic core.46 Ideally we would like to produce a drug which could travel 
through the solid tumour tissue unaffected, and only become toxic once it has reached 
the otherwise resistant hypoxic region (see Figure 9).
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Figure 9 -  Diffusion o f a bioreducible prodrug into a solid tumour.
Such a situation could arise if a prodrug was administered which was selectively 
activated by the very factor which makes solid tumours resistant to radiotherapy— their 
low oxygen concentration. The potential o f hypoxic cells to carry out the reductive 
activation o f prodrugs to form cytotoxic agents was first suggested in 197247 and has 
since been widely explored. The selective toxicity o f such compounds tow ards hypoxic 
over oxic cells is quantified by the compound’s hypoxic cell cytotoxicity ratio, HCR 48 
This is a ratio o f the IC 50 o f the compound under oxic conditions divided by that under 
hypoxic conditions (IC 50 is the concentration required to produce a 50% reduction in the 
number o f cells in a culture compared to the control). The higher a com pound’s HCR the 
more selective it is towards hypoxic cells.
2.4 Outline of subsequent chapters
The major classes o f bioreducible drugs which have been studied in the last 20 years are 
discussed in Chapter 3, with particular attention being given to recent developments and 
areas which are related to other work detailed in this thesis. Included within this chapter 
are nitroaromatic compounds, quinones, heterocyclic jV-oxides and transition metal 
complexes. Each class o f bioreducible agents relies on reduction o f a prodrug, which
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occurs selectively in the hypoxic regions o f  tumours. The eventual outcome o f this is the 
production o f  toxic species which lead to cell death.
Molecules which can be used as prodrugs for antibody directed enzyme prodrug therapy 
(ADEPT) are also discussed in Chapter 3. This field is rapidly developing and will no 
doubt produce compounds o f  clinical value in the near future.
The following 3 Chapters discuss the syntheses o f  those compounds generated as 
prospective tumour selective agents. Chapter 4 details the synthetic methodology behind 
the production o f  three separate classes o f  heterocyclic V-oxides. This methodology gave 
rise to many compounds, o f which 6 pyridine carbamates, 6 pyridine halides, 12 
quinoline carbamates, 4 quinoxaline halides and 6 quinoxaline carbamates were evaluated 
biologically. These results, as well as the biological test data gained from the other 
compounds tested are given in Chapter 7.
The syntheses o f  16 nitroaromatic compounds and 2 aromatic amines are discussed in 
Chapter 5. Various methods for carrying out nitro group reduction are examined and 
their effects on benzenoid and thiophene based nitroaromatics summarised. Also included 
in this Chapter is the attempted formation o f  a series o f thiophene dimers.
The synthesis o f molecules suitable for use as prodrugs for ADEPT is discussed in 
Chapter 6. This includes formation o f both spacer and specifier sections, as well as the 
strategy employed to couple these two subunits successfully. A partial synthesis o f  a 
suitable drug to be fused with the spacer-specifier is then discussed, as well as a probable 
method o f  linking the whole molecule together.
As previously mentioned, the biological test data are presented and evaluated in Chapter 
7. This includes an analysis o f the effect o f  carbamate as opposed to halide functionality 
on the pendant arms o f the prodrugs, and the large differential toxicity exhibited between 
free bases and their A-oxides. Furthermore, comments are made concerning the effect o f  
both a fused ring system, and one or two nitrogens in the heterocyclic ring skeleton o f  
these compounds. Combining this information gives an indication o f  the structure activity 
relationships o f  such compounds.
Finally the conditions employed to bring about the chemical transformations discussed in 
Chapters 4, 5 and 6 are laid out in Chapter 8. Also given in this Chapter are methods o f
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purifying the compounds formed, and their detailed characterisation. Confirmation o f  the 
identity o f  these compounds is also demonstrated from, either accurate mass 
spectroscopy or microanalytical data.
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3. S elec tive  Ca n c e r  
C h em o th er a py
3.1 Nitroaromatics
3.1.1 Background
All nitroaromatics are reduced via a complicated pathway which gives rise to several 
different toxic intermediates49 (see Scheme 5). The first step is addition o f  an electron to 
a nitroaromatic species (31) to generate a cytotoxic free radical (32). This may occur by 
either radical transfer from radiation induced CO2 radicals, or by enzymatic reduction 
under hypoxic conditions. The nitro radical (32) is then either converted back into the 
initial nitroaromatic species (31) with generation o f superoxide radical, or reduced, to 
form a hydroxylamine (33), and subsequently an amine (34).
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Scheme 5 -  Reduction mechanism for nitroaromatics.
3.1.2 Mechanism of action of nitroimidazoles
One o f  the first clinically useful nitroaromatics was misonidazole (35), which is used as a 
radiosensitiser for hypoxic regions o f tumours. Experiments have shown that 
misonidazole (35) binds to DNA and protein.50 This effect is only observed after 
reduction. Varghese and Whitmore initially postulated50 that the mode o f  interaction o f  
misonidazole (35) may be through the hydroxylamine (36) produced upon bioreduction. 
Later they proposed the pathway shown in Scheme 6,51 where water attacks the 5- 
position o f  the hydroxylamine (36) generating an unstable species (37). This undergoes
22
proton transfer to form either a stable intermediate (38) which can be isolated, or a ring 
opened compound (39). This electrophilic species is then attacked by water, producing a 
species (40) which fragments to give glyoxal (41) and a guanidine (42). Evidence to 
support this mechanism came from NMR studies, which showed glyoxal-DNA adducts 
formed in a system which contained both misonidazole (35) and a source o f reducing 
power.
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Scheme 6 -  Bioreduction and associated breakdown o f misonidazole (35).
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An early nitroaromatic compound which showed particular promise as a hypoxia 
activated prodrug was RSU 1069 (43), which combined a bioreducible nitroimidazole 
with an aziridine moiety (see Figure 10). Like misonidazole (35) it exhibited DNA  
binding after reduction, however it is capable o f  further binding through its aziridine 
moiety. This gives RSU 1069 (43) the potential to generate DNA crosslinks.52
OH
N 0 2
OH
N 0 2
RSU 1069 (43) RSU 1137 (44)
Figure 10 -  Nitroimidazole radiosensitisers and bioreducible agents.
The compound RSU 1137 (44) is an analogue o f RSU 1069 (43) which contains no 
aziridine moiety. After reduction o f a sample o f  RSU 1137 (44), the compound showed 
rapid binding to DNA (see Graph 7).52 This effect can be attributed to binding via its 
only active group, its reduced nitroimidazole. Non-reduced RSU 1069 (43) has only the 
aziridine moiety available for DNA binding. This site is much less reactive than the 
reduced nitro moiety and hence this compound takes time to bind to DNA. After 
reduction o f  part o f  a sample o f RSU 1069 (43) both the fast and slow binding 
behaviours were observed. Those molecules in the reduced state bound rapidly, with the 
non-reduced molecules binding more slowly, through their aziridine moieties.
Experiments52 have also shown that both the reduced and non-reduced forms o f RSU 
1069 (43) cause strand breaks in DNA, with the reduced form showing a greater and 
more rapid binding to DNA. Addition o f phosphate to the medium inhibited strand 
breakages, implying that reduced RSU 1069 (43) is capable o f binding to the phosphate 
backbone o f  DNA. Strand breaks are not observed with misonidazole (35) or RSU 1137 
(44), indicating that although the reduced nitroimidazole may associate with DNA it 
does not lead to strand breaks, as this requires the aziridine moiety. The exact means o f  
association between the reduced nitroimidazole in RSU 1069 (43) and DNA is not 
known, but unlike misonidazole (35) it does not involve a glyoxal derivative. It is 
possible that binding occurs via the hydroxylamine which may be more stable and so 
longer lived in RSU 1069 (43) and its derivatives than in misonidazole (35) and its 
derivatives.
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Graph 7 -  Graph o f  Binding ratio vs Time.
In an attempt to determine whether there are other binding sights for RSU 1069 (43) in 
DNA, Silver and O’Neill carried out binding experiments with the 4 different 
deoxyribonucleoside monophosphates, dNMP. 53 Results showed different rates o f  
binding for the different dNMPs. Since the pKa values o f  the phosphate groups in each 
dNMP are similar, the difference in binding rates o f  the dNMPs to reduced RSU 1069 
(43) must be due to binding o f  RSU 1069 (43) to other sites in the nucleosides in 
addition to the phosphate groups. Analysing the dNMP-RSU 1069 (43) adducts showed 
that dTMP and dCMP bind to DNA only through their phosphate groups, whereas 
dAMP also binds at one site on its base portion, and dGMP at two. Clues as to the 
location o f  the binding sites on the base portions came come from experiments with 
mitomycin C (60),54 which showed that the exocyclic amine o f guanine (7) and adenine 
(8) as well as the amide oxygen o f  guanine (7) may act as nucleophiles which attach to 
aziridine.
Alkylation at the phosphate sites in DNA leads to direct strand breakage, whereas 
alkylation at the bases leads to adducts which will result in strand breaks only after 
enzymatic excision or chemical degradation o f  these adducts. By measuring the number 
o f  direct strand breaks in comparison with those detected after chemical degradation it is 
possible to determine that only a small minority o f  the damage (2%) is caused by attack 
on the phosphate group.55
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The above results show that RSU 1069 (43) interacts with DNA via its aziridine moiety, 
becoming linked to guanine and adenine bases; and to a lesser degree the phosphate 
backbone. The method o f binding o f the reduced nitroimidazole portion o f  the molecule 
is not yet fully understood.
3.1.3 Effect of the heteroaromatic ring on activity
A  series o f  5-nitrofurans was synthesised with amide linked substituents on the 2- or 3- 
position.56 These amide analogues were chosen as a suitable synthetic target since they 
have less negative one-electron reduction potentials (E\)51 than RSU 1069 (43). e \  o f  
RSU 1069 (43) is -389 mV whereas E\ values o f the analogues synthesised were in the 
range -210 to -350 mV. It was hoped that these less negative reduction potentials would 
make these analogues more susceptible to reduction in hypoxic cells.
Results showed these compounds to be much better radiosensitisers than RSU 1069 
(43), with the degree o f  sensitisation being dependent on both the reduction potential 
and the structure o f the compound. However, the HCRs o f  these compounds are small, 
with the best value o f  5.6 being exhibited by a derivative (45) which contained both a 
hydroxyl group and a moiety capable o f forming an aziridine in its side chain (see Figure 
11).
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Figure 11 -  The active fiiran analogue (45).
It is possible that the poor HCRs o f the nitrofuran series o f compounds could be due to 
their reduction potentials being too low, so allowing bioactivation in oxic cells. 
However, the fact that the most hypoxia selective member o f  the series has a similar side 
chain to RSU 1069 (43) implies that the structure o f  these compounds is at least as 
important as their reduction potentials, in determining their structure activity 
relationships.
Another series o f derivatives which was based on thiophene,58 showed a comparable 
pattern o f  therapeutic action to the fiiran analogues. Their activity as radiosensitisers was
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at least partially related to their reduction potentials, but they were poor hypoxia 
selective anticancer agents.
A  similar behaviour was seen in azole derivatives59 which contained either one or three 
nitrogen atoms in their heterocyclic rings. These compounds had very similar steric bulk 
to the highly selective compound RSU 1069 (43) and the pyrazole derivatives had a low  
reduction potential. However, they showed relatively little selectivity for hypoxic cells. 
The most selective derivative was the triazole (46) shown in Figure 12, which had a 
HCR o f  3.3. In contrast its pyrrole analogue (47) showed no specificity towards hypoxic 
cells.
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Figure 12 -  Analogues o f RSU 1069 (43) with triazole or pyrrole rings.
With all o f  the analogues which had an alteration in their heterocyclic rings the degree o f  
hypoxic selectivity they expressed was reduced considerably when compared to the lead 
aziridine compounds. This was the case even when the steric or electrochemical 
properties o f  the compound were very similar to RSU 1069 (43). The most active 
derivatives were those which had both the hydroxy and aziridine moieties in their 
pendant arms. The strict limitations on structure for reactivity could be due to a 
requirement for the compound to interact with an enzyme which induces bioreduction, or 
for the reduced product to then interact with DNA. Either way, it appears that 
bioreducible imidazoles such as RSU 1069 (43) have a very closely defined structure 
activity relationship, with those compounds which already exist having a near optimum 
structure for selective activity.
3.1.4 Analogues of RSU 1069 (43)
Although RSU 1069 (43) has shown promising selectivity in vitro, phase 1 clinical trials 
showed unacceptably high levels o f  emesis in patients.60 Hence, various analogues were 
developed, including RSU 6145 (48)61 and PD 130908 (49),62 which are shown in 
Figure 13. These compounds had similar functionality to RSU 1069 (43) but had their
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aziridine moiety masked as a bromoethyl group. After administration, the nitrogen lone 
pair should displace the halogen resulting in formation o f an aziridine. Studies63 have 
shown that the detrimental toxicity o f these compounds is directly related to the amount 
o f  aziridine formed. Since aziridine formation after administration o f the new analogues 
is a gradual process, presumably balanced by metabolism o f  the drug, the adverse
toxicity o f  these compounds should not be as great as that produced by RSU 1069 (43).
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Figure 13 -  Derivatives o f  RSU 1069 (43) with reduced emetic effect.
3.1.5 Molecules with complementary functionality
All the nitroaromatics so far mentioned have had only one group which becomes active 
on bioreduction. The more potent compounds also contain a second group which may 
associate with DNA. However, this second group is active in the molecule even before 
bioreduction and could therefore confer toxicity to oxic cells and so reduce the HCR o f  
that compound. One possible reason why this non-selective attack is not frequently 
observed could be because the rapid binding o f  the reduced nitroaromatic portion o f  the 
drug to DNA allows the non-selective group to interact with the DNA more rapidly than 
drug which is free in the cytoplasm o f the tumour cell. In oxic cells this early DNA-drug 
interaction will not occur and so the increase in toxicity o f  the inherently toxic drug 
under these conditions would not be as pronounced as in hypoxic cells.
By ensuring that no functional groups on any prodrug were toxic prior to reduction it 
should be possible to produce compounds which are more selective. One possible 
approach would be the synthesis o f  compounds which have one bioreducible centre, 
which upon bioreduction activates a further moiety. However, earlier results have shown 
that the aziridine-containing nitroimidazoles mentioned above are very sensitive to 
modifications. They would not be suitable lead compounds for such a series, and an 
alternative nitroaromatic compound needs to be employed.
Such complementary functionality involving nitroaromatic compounds was first seen in
an adduct (50) o f  /?ara-hydroxymethylnitrobenzene and 5-fluorouracil (26),64 which is
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shown in Scheme 7. When the nitro group in this compound is reduced to the amine 
(51), it provides a lone pair which donates electrons into the conjugated system and so 
results in the cleavage o f the antimetabolite, 5-fluorouracil (26).
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Scheme 7 -  Bioreductive activation o f (50) to release 5-fluorouracil (26).
Other studies65 have concentrated on compounds which break down on bioreduction to 
release differentiation promoting agents, such as short chain fatty acids. These fatty acids 
result in the reversion o f  the cancerous characteristics o f  tumour cells. Within the same 
series, compounds were synthesised which contained halomethyl groupings. The 
mechanism o f  action o f these compounds was believed to be derived from the 
electrophilic species (52) produced after break-up o f  the compound. This break up 
would be very rapid, so ensuring that a high concentration o f  electrophilic species was 
present in the cell. These species could then be attacked by DNA. Both the fatty acid 
releasing compounds, and members o f this series containing halomethyl groups, 
prolonged the life o f  mice which were bearing tumours. However, detailed oxic/hypoxic 
testing was not carried out.
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3.2 A/-Oxides
3.2.1 Background
Heterocyclic iV-oxides provide a new avenue for bioreducible drug research. They rely 
on the ability o f  a hypoxic cell to reduce an N-oxide to its free base. Where a classical 
pro-drug utilises the toxicity o f the drug formed upon activation o f  the pro-drug, N- 
oxides rely on toxic events which are integral to the reduction process itself. The 
archetypal bioreducible jV-oxide is 3-amino-l,2,4-benzotriazine-l,4-di-Ar-oxide, also 
known as tirapazamine, WIN 59075 or SR 4233 (53). This compound was first reported 
by Zeman et al.66 and is shown in Figure 14.
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Figure 14 -  SR 4233 (53) and its reduction products.
3.2.2 Mechanism of action of SR 4233 (53)
Detailed studies67 have shown that when SR 4233 (53) is added to cells in an oxic 
environment minimal cell killing occurs. Under oxic conditions SR 4233 (53) has an IC50 
o f  between 50 and 200 pM depending on the type o f  cell line used. However, under 
hypoxic conditions an increase in toxicity o f  between 20 and 200 fold occurs, with a 
minimum IC50 value o f  3 pM being exhibited by the human tumour cell line HT 1080. 
The degree o f  hypoxic selectivity is directly related to the rate o f  metabolism o f SR 4233 
(53) in that cell line.
During the reduction o f  SR 4233 (53), HPLC studies67 have shown that concentrations 
o f  the reduced metabolites o f SR 4233 (53) build up. The primary metabolite is the two- 
electron reduced product, SR 4317 (54). However, in some cell lines a noteworthy, but 
still minor amount o f  the four-electron reduced product, SR 4330 (55), was observed. 
Since toxicity occurs even in cells which do not produce appreciable amounts o f  SR 
4330 (55), it can be assumed that the toxic event occurs via interaction with, or through
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other process earlier in the bioreductive pathway to, the two electron reduced product 
SR 4317 (54), and that reduction o f SR 4317 (54) or SR 4233 (53) directly to SR 4330
(55) does not play a significant role in the toxicity o f SR 4233 (53).
The nature o f  the damage which causes cell death has also been investigated.68 SR 4233 
(53) produces both single and double strand breaks. This DNA damage is not repaired 
by the enzyme produced by the gene uvrA. Since this enzyme is responsible for the 
repair o f  damage to DNA caused by molecules which add extra bulk to DNA, such as 
would occur if  a drug formed an adduct with DNA, we can say that either a direct SR 
4330 (55)-chromosome adduct never occurs, or that such an adduct quickly falls apart. 
The major repair enzyme for damage induced by SR 4233 (53) is produced from the
gene uvrC. This enzyme usually repairs damage caused by ionising radiation.
ESR studies69 after reduction o f  SR 4233 (53) have indicated the formation o f both the 
superoxide radical anion, and a one-electron reduction product which has the electron 
centred primarily on the 1-nitrogen. The half life o f  the radical o f  SR 4233 (53) has been 
shown70 to be 8 ms under hyoxic conditions, but only 0.4 ms when oxygen is present. 
This is attributed to futile cycling, where the oxygen from the medium reacts with the 
reduced product o f  SR 4233 (53) to regenerate the starting material and the superoxide 
radical. If we limit the cell’s defensive mechanisms against superoxide radicals by 
inhibiting catalase, SR 4233 (53) becomes toxic even under oxic conditions.71
i
; From all the above information it is possible to make several deductions about the
I metabolism o f  SR 4233 (53) and its mode o f toxicity (see Scheme 8).
|
l
i
1t
i'
i
I
31
o ©
• ©
NH
O©
SR4233 (53)
0 ©
I
/ V @ v
NH
DNA-H
OH
DNA
O© O©
I
NH' NH
57 OH 58
D NA -H
O©
DNA
NH
SR 4317 (54)
Scheme 8 -  Putative bioreductive pathway for SR 4233 (53).
The initial event is an enzyme mediated reaction, which produces a radical centred on the 
1-nitrogen o f  the heterocyclic compound. This event occurs in both oxic and hypoxic 
cells, but not necessarily to the same extent. If the cell is under oxic or mildly hypoxic
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conditions, a proportion o f  this newly generated radical species (56) will be transformed 
back into its starting material, with the production o f a superoxide radical. When oxygen 
depletion is low enough to allow the 1-nitrogen centred radical species (56) to persist for 
long enough to diffuse to surrounding DNA this species interacts with it. The mode o f  
interaction is not a covalent linking, but a hydrogen radical abstraction from DNA  
generating strand breaks. It is not yet known whether the one-electron reduction product
(56) abstracts a hydrogen radical from DNA, with the species formed (57) dehydrating 
to form SR 4317 (54), or whether dehydration is the first step, forming a new radical
(58) which in turn abstracts a hydrogen radical from DNA.
3.2.3 Enzymes involved in bioreduction of SR 4233 (53)
Experiments have shown that cells are able to repair damage caused by ionising radiation 
more easily than an equivalent degree o f strand breaks caused by SR 4233 (53).67 A 
detailed investigation72 showed that CHO cells can repair almost all o f  the strand breaks 
caused by radiation. However, the damage caused by SR 4233 (53) becomes increasingly 
difficult to repair as the concentration o f drug given increases. At 25 pM more than 85% 
o f chromosome double strand breaks are repaired. This value fell to less than 10% as the 
dose was increased to 100 pM. These results are attributed to the strand breaks caused 
by SR 4233 (53) being localised, producing local areas o f  concentrated damage which 
are difficult to repair. This theory is consistent with the production o f  many short lived 
toxic species centred on an enzyme. When the enzyme is in close proximity to the DNA  
the toxic species produced generates strand breaks, with the concentration o f  breaks 
being proportional to the concentration o f drug administered.
Chemically induced reduction o f SR 4233 (53)70 resulted in the formation o f  the same 
two products seen in enzymatic reduction. From this it was assumed that after the initial 
enzyme mediated reduction step the remainder o f  the pathway to the mono- or di-A- 
oxide need not be enzyme mediated.
Initial studies showed that the enzymes cytochrome P450, cytochrome P450 reductase, 
xanthine oxidase, aldehyde oxidase and DT-diaphorase are capable o f  reducing SR 4233 
(53)13 However, in both animal and human tumour cell lines, no relationship between 
either xanthine oxidase or aldehyde oxidase concentration, and bioreduction o f  SR 4233 
(53) was observed.74
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Using HPLC analysis o f  the metabolites o f  mouse liver microsomes Walton et al.15 
showed that reduction o f  SR 4233 (53) to SR 4317 (54) was diminished by up to -70%  
when cytochrome P450 was inhibited. Purified samples o f  cytochrome P450 reductase 
with an activity equal to that in the microsomes were able to metabolise SR 4233 (53) to 
SR 4317 (54) at up to 30% o f the rate o f  whole microsomes. Introducing inhibiting 
antibodies for this enzyme, to the microsomes, reduced the rate o f  drug metabolism by 
-20% . When cytochrome P450 was then also inhibited by carbon monoxide the rate o f  
drug metabolism fell to 85% o f its initial level. These results indicate that in this system 
the two cytochromes play a major part in the bioreduction o f  SR 4233 (53).
DT-diaphorase catalyses obligate two-electron reduction, and is overexpressed in some 
tumour cell lines.76 This enzyme has been shown to metabolise SR 4233 (53), producing 
first the two-electron reduction product and then the four-electron reduction product.77 
Cytochrome P450,78 cytochrome P450 reductase,78 and DT-diaphorase79 have all been 
shown to exist in cancer cells. Given that the toxicity o f  bioreducible /V-oxides arises 
from one-electron reduction products, any cancer cell which is capable o f  metabolising 
the iV-oxide in a manner which would bypass this toxic event would be resistant to 
bioreducible N-oxides. However, although this obligate two-electron reduction would be 
a problem in treatments using SR 4233 (53), other bioreducible agents80 are available 
which are activated by this two-electron reduction process, so allowing us to treat 
tumours which have developed resistance to SR 4233 (53), by producing increased 
levels o f  DT-diaphorase.
3.2.4 Effects of reduction potential on activity
Many analogues o f SR 4233 (53) have been prepared with either the amino substituent 
on the 3-position changed, and/or functionalisation added to the carbocyclic ring. 
Experiments with these compounds81 have shown no connection between their HCRs 
and either their partition coefficients, or steric properties. The only factor which was 
found to effect both a compound’s toxicity and its HCR is its reduction potential (see 
Graph 8 and Graph 9). For /V-oxides it would be desirable to measure their one electron 
reduction potentials, since this reduction generates the cytotoxic intermediates. 
However, such measurements are by no means simple, hence it is much more common to 
quote the two electron reduction potential EVl.
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Effect o f the reduction potential o f analogues o f SR 4233 on their toxicity.
All the compounds tested showed little toxicity if their reduction potentials fall below 
-400 mV, with their toxicity gradually increasing to a plateau as their reduction 
potentials tended towards -200 mV where all the vV-oxide is efficiently reduced. 
However, since those compounds with less negative reduction potentials can also be 
reduced in oxic cells, their selectivity towards hypoxic cells drops. Their selectivity is 
also adversely effected at more negative potentials since at these potentials even hypoxic 
cells cannot induce bioreduction. For an optimum HCR a balance has to be obtained. 
The optimum reduction potential is around -320 mV, and this compares favourably with 
the reduction potential o f  SR 4233 (53) at -322 mV.
3.2.5 Effects ofpH on the cytotoxicity of SR 4233 (53)
The lack o f  vascularisation in solid tumours not only inhibits the uptake o f  oxygen into
the centre o f  these tumours, but also inhibits removal o f  metabolic products. Such
metabolic products, for example CO2 and lactic acid, result in a reduced pH at the centre
81o f these tumours. The reduction potentials shown in Graph 8 and Graph 9 were 
measured at pH 7.4 using a dropping mercury electrode, and demonstrate how reduction 
potentials affects the in vitro hypoxic cell cytotoxicity ratio. Other studies82 have shown
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how the reduction potential o f  SR 4233 (53) varies as the lower pH found in the 
intercellular region o f  tumours is approached. Graph 10 shows that there is a near linear 
relationship between reduction potential and pH, within the range pH 2 to pH 8.5. This 
graph shows that a less negative potential is required to bring about reduction under 
acidic conditions. It is possible that this effect is due to protonation o f  the amine side 
chain making SR 4233 (53) more liable to reduction. This effect was seen to be 
translated to an increase in DNA strand breaks under hypoxic conditions as the acidity 
increased.
-700
-600 -
-500 -
-400 -
iu -300 -
-200 -
-100  -
1 2 3 4 5 6 7 8 9  10
pH
Graph 10 -  Reduction potential vs acidity.
Other studies83 * 84 have shown that although the toxicity o f  SR 4233 (53) is low to oxic 
cells, the degree o f toxicity towards several different cell lines under oxic conditions 
increases markedly as the degree o f  acidity increases. However in contradiction to earlier 
results82 no potentiation was observed under hypoxic conditions.
The results o f  Tocher et al.82 may help to explain why SR 4233 (53) has a higher HCR 
than its reduction potential would suggest (see Graph 9). When the drug is in oxic cells it 
is more difficult to reduce since the relatively high pH leads to a more negative reduction 
potential. However, as the drug diffuses into the hypoxic regions o f  solid tumours, the 
reduction event will become easier as the reduction potential o f  the drug becomes less 
negative with decreasing pH. The importance o f this phenomenon is not yet known. It
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may be limited because the increased acidity in solid tumours exists predominantly in the 
intercellular region, and the intracellular fluids are closer to normal physciological pH.
3.2.6 Effects of oxygen concentration on the cytotoxicity o f SR 4233 (53)
Graph 11 shows how the toxicity o f SR 4233 (53) remains almost constant over a range 
o f  oxygen concentrations up to 10 mmHg.85 Many other drugs [e.g. RSU 1069 (43)] 
show a linear decrease in toxicity over the same concentration range. This makes SR 
4233 (53) particularly suitable for treatment o f  those tumours in which only partial 
hypoxia exists.
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Graph 11 -  Change in toxicity with changing oxygen concentration.
3.2.7 Second generation benzotriazine-di-N-oxides
Many analogues o f  SR 4233 (53) have been synthesised and their properties 
investigated.81,86 These analogues are based on the benzotriazine-di-7V-oxide skeleton
(59), shown in Figure 15, with modifications to R and R1. The selectivity o f  these 
compounds is shown in Table 1.
Although addition o f functionality to the carbocyclic ring in some cases (e.g. SR 4495) 
leads to an increase in absolute hypoxic toxicity, any modification to this ring reduced 
the HCR o f  the compound. Hence the later derivatives86 all had unsubstituted 
carbocyclic rings. Salt formation through a modified heterocyclic ring caused a reduction
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in both the absolute toxicity and the HCR, and is unlikely to feature in any more 
advanced analogues. The unsubstituted benzotriazine-di-A-oxide (SR 4482) gave 
varying results, but these were never significantly better than SR 4233 (53).
O©
O©
Figure 15 -  Benzotriazine-di-/V-oxide skeleton (59).
SR Number R R1 Relative Toxicity HCR
4482 H H 1.75 37.5
4444 H OMe 1 1
4452 H NHCOMe 2 1
4483 7-Me NHCOMe 2.25 2
4453 H NHCOCH2COMe 0.75 7.5
4495 6-C1 n h 2 4 35
4233 (53) H n h 2 1 75
4466 7-OCH2CH=CH2 n h 2 0.75 17.5
4454 7-Me n h 2 0.6 19
4318 7-C1 0'N H 4+ 0.02 12.5
4451 7-CF3 O’ Na+ 0 N/A
4499 6-Me, 7-Me n h 2 0.25 12.5
4355 H O’ Na+ 0.01 7.5
4450 7-OMe OH 0 N/A
4233 (53) * H n h 2 1 64.5
4482* H H 1.8 70.9
4754* H NHCH2NEt2 0.8 70.0
4755* H NH(CH2)3NEt2 0.5 104.5
* Data o f  Minchinton et al. 86
Table 1 - Biological activity of benzotriazine-di-/V-oxide analogues
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Noteworthy but small improvements in selectivity were observed only in substituted 
amine derivatives, but this was not carried over to in vitro testing. This could be because 
the amide was not able to form a protonated species, which would result in a lowering o f  
its reduction potential in vivo. All o f these results imply that SR 4233 (53) is close to the 
optimum structure for antineoplastic activity, and any analogues which are to be more 
effective will need to incorporate additional active functionality.
3.3 Quinones
3.3.1 Background
The use o f  the antibiotic mitomycin C (60), shown in Figure 16, was one o f  the first 
hypoxia selective tumour therapies employed, and it is still in clinical use. At the 
beginning o f  the 1980s it was shown to attack hypoxic cells selectively, in preference to 
their oxic counterparts.87 However its relatively low HCR o f  2s8 may limit its 
therapeutic uses. Another problem is the extreme dependence o f  oxygen concentration 
on activity. Only at partial pressures o f  0.3 mmHg or less will mitomycin C (60) be 
efficiently reduced.89 This partial pressure is much lower than certain other bioreducible 
compounds such as SR 4233 (53) (see Section 3.2.6). Because o f  this, mitomycin C (60) 
will only be activated in vitro when extreme hypoxia is present. This restricts the area o f  
a tumour over which mitomycin C (60) can be effective, but may limit side effects caused 
by bioreduction in non-cancerous cells.
NH
Figure 16 -  Structure o f  mitomycin C (60).
3.3.2 Mechanism of action of mitomycin C (60)
• • • •  90It has been known for a long time that mitomycin C (60) induces DNA crosslinking, 
but the exact method has only recently been elucidated. Studies with reduced mitomycin 
C in solution with DNA have shown91 that two guanine and one adenine sites on DNA
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may act as nucelophiles. This was determined by degradation and NMR studies on the 
adducts (61, 62 and 63) shown in Figure 17.
NH
NH
Mitomycin C-Guanine Adduct (61)
NH
OH
Mitomycin C-Guanine Adduct (62)
NH
OH
Mitomycin C-Adenine Adduct (63)
Figure 17 -  Structure o f mitomycin C-nucleoside adducts.
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Experiments also identified the electrophilic site on mitomycin C (60) at which binding to 
D N A  initially occurs, as being the C-l carbon on the aziridine91 Furthermore this 
methoxy group is not present in any o f the adducts isolated. Later studies92 identified 
adducts where the purine bases were linked to both the aziridine site and the C-10 
exocyclic methylene group, with replacement o f the carbamate moiety. As well as the 
direct linkage o f mitomycin C (60) to DNA, damage is also caused by futile cycling,93 as 
described in Section 3.2.2. Evidence for this is seen in the formation o f  superoxide and 
hydroxide radicals in oxygenated systems containing mitomycin C (60).94
Given that the methoxy group o f mitomycin C (60) is lost early on in the pathway and 
that experiments have shown that the activity o f mitomycin C (60) increases as the pH is 
lowered,95 a reasonable first step in the bioactivation pathway o f  mitomycin C (60) 
would be protonation o f the methoxy group, giving 64 (see Scheme 9). The lone pair on 
the amine nitrogen would then donate electrons into the ring system expelling methanol, 
with the unstable product (65) losing a proton to generate a compound (66) with an 
extended conjugated system.
Once the correct pattern o f conjugation was established, reduction o f  the quinone would 
then occur, either via two one-electron steps, initially forming the hydroquinone free 
radical and subsequently the hydroquinone (67), or by direct two-electron reduction. The 
newly formed phenolic hydroxyl could then donate electrons into the ring system, 
opening the aziridine ring and creating a highly electrophilic species (68) which would be 
readily attacked by DNA, forming an adduct (69). Elimination o f  the carbamate, 
followed by attack by DNA would give a mitomycin C-DNA crosslinked product (70). 
Computer modelling has shown that this product sits tightly in the minor groove o f  
DNA,92 and this is thought to make such crosslinks highly resistant to cellular repair.96
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Scheme 9 -  Bioactivation pathway for mitomycin C (60).
3.3.3 Enzymes involved in bioreduction of mitomycin C (60)
Several enzymes could be involved in the one electron reduction o f  mitomycin C (60) 
including cytochrome P450, cytochrome P450 reductase, xanthine oxidase and xanthine 
dehydrogenase. The primary enzyme is believed to be cytochrome P450 reductase which
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has been shown to reduce mitomycin C (60) under hypoxic conditions.97 This theory 
was based on the evidence that the reduction would not occur in the absence o f  
NADPH. Furthermore, addition o f  carbon monoxide did not inhibit the reduction, as 
would occur if  cytochrome P450 was the principle enzyme involved. It is also believed 
that xanthine oxidase plays a minor role in the biochemical reduction o f  mitomycin C
(60) since it is only capable o f carrying out reduction o f  mitomycin C (60) 25 times 
slower that cytochrome P450 reductase,98 and its concentration in the cell is very low.97
It was thought originally that DT-diaphorase does not play a role in the bioactivation o f  
mitomycin C (60).97 The authors believed that the toxic interaction o f  mitomycin C (60) 
with DNA occurred only through the free radical, and if  DT-diaphorase played any role 
in the metabolism o f mitomycin C (60), it was protective, leading to a bypassing o f  the 
toxic free radical, producing the semiquinone directly. However, although the normal 
function o f DT-diaphorase is to detoxify quinones by avoiding free radical metabolites,99 
it could activate mitomycin C (60) if DNA linking occurred after a two electron 
reduction, through the semiquinone. Later experiments have shown that DT-diaphorase 
leads to increased cytotoxicity o f mitomycin C (60), but only at reduced pH.
3.3.4 Direct analogues of mitomycin C (60)
Due to the many limitations o f mitomycin C (60) as a bioreducible drug (see Section 
3.3.1) there has been an effort to find more active and selective drugs. One example is 
porfiromycin (71), which has an HCR o f 5 (see Figure 18).101 With synthetic analogues a 
link has been established with high activity in vitro and a less negative reduction 
potential. Likewise activity in vivo has been linked to a high permeability ratio which 
allows the compound to pass easily through the cell membrane.102 Structural 
requirements for active analogues have been determined as the aziridine ring and a 
leaving group at C -10,103 as well as, perhaps surprisingly, the methyl group at C-6.104
O
Figure 18 -  Structure o f porfiromycin (71).
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3.3.5 Minimal structure quinone analogues
Work on mitomycin C (60) has shown that quinones can be preferentially reduced, in 
hypoxic compared to oxic conditions, by cellular enzymes. The species produced will be 
toxic if  the newly generated electron-rich semiquinone can activate a moiety capable o f  
alkylation. The simplest analogues (72) would contain only the quinone and moieties 
capable o f  alkylation. A method by which such compounds might operate is shown in 
Scheme 10. These compounds rely on the electrons from the semiquinone (73) produced 
upon bioreduction o f  the quinone (72) aiding in the expulsion o f an ortho leaving group, 
generating an electrophilic species (74) which can be attacked by DNA to form an 
adduct (75). In general such compounds are made with two such leaving groups giving a 
molecule with the potential to form DNA crosslinks (76).
OH
OH 74OH 73
▼
OH OH
DNA
OH 76
DNA
OH 75
Scheme 10 -  Theoretical mode o f  action o f  bis(alkylating) quinones.
Studies on naphthoquinones with the general structure (77) shown in Figure 19,105 have 
shown that such compounds have the ability to increase the lifespan o f  a mouse 
implanted with a tumour by a factor o f  2. When only one o f  the R groups has the 
potential to leave, the dose required to produce a similar effect is greater. The 
therapeutic effect is similar regardless o f whether the potential leaving groups are halides 
or esters. This implies that the reduction o f  these compounds is the process which 
determines their therapeutic effects, with any leaving group attached being quickly
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expelled by the newly formed semiquinone. Furthermore, the lack o f  structural specificity 
to reduction implies that this reduction is either non-enzymatic or that the enzymatic 
process has very poor substrate specificity.
O
Figure 19 -  Naphthoquinone skeleton (77).
One o f  the problems which such compounds probably face is the relatively negative 
reduction potential they possess, with typical values being -500 mV or less.106 Reduction 
o f  compounds with such a negative potential is extremely rare in hypoxic cells. This may 
help to explain why some members o f  this series show no therapeutic effect.107
In systems where one R group has the potential for alkylation, but the other group is 
strongly electron withdrawing, then the activity o f this compound is reduced.108 When 
simple functionalisation {e.g. methyl groups) was added to the B ring in naphthoquinones 
very little modification in activity was observed.109 However, in a series o f  quinone 
carbamate derivatives, substitution o f the quinone ring with electron donating groups 
enhanced the compound’s activity.110 These results support the theory that the electrons 
released from the reduced quinone are required to expel a leaving group, so generating 
an electrophilic site which DNA can attack. If electron density is removed from the 
quinone ring o f  a compound, by the presence o f an electron withdrawing group on the 
quinone ring, then the compound’s activity decreases.
One o f  the earliest compounds which showed high selectivity towards cancer cells was 
3,6-diaziridinyl-2,5-bis(ethoxycarbonylamino)-l,4-benzoquinone, AZQ (78). This agent 
crosslinked DNA as well as causing DNA strand breaks.111 The strand breaks were 
associated with radical damage caused as superoxide radicals produced when the 
semiquinone generated by reduction o f AZQ (78) was oxidised back to the quinone. This 
was confirmed by addition o f  superoxide dismutase which completely inhibited strand 
breakage. The crosslinks were not inhibited by superoxide dismutase, and occurred much 
more readily with the reduced form o f the drug. Although this damage was assumed to
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be caused by electrophilic attack on the aziridine by DNA, this does not explain how the 
formation o f  an electron donating hydroxy group on the drug increased its activity. A 
mechanistic explanation might be that the initial link between AZQ (78) and DNA is by 
nucleophilic attack on the aziridine o f the non-reduced form o f  the drug, resulting in 
formation o f  an adduct (79) (see Scheme 11). Once this initial link is made and the drug 
is bioreduced, the free lone pair generated can expel the carbamate group generating a 
highly electrophilic site which can form a crosslink to the adjacent strand o f  DNA.
DNA
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Scheme 11 -  Possible means o f attack o f  AZQ (78) by DNA.
3.3.6 Second generation analogues
Knowledge o f  the mechanism o f action o f mitomycin C (60), and evidence o f  the
effectiveness o f aziridine-containing quinones lead to the production o f  EO-9 (80).112
This combines the above functionalities to give 3 potential sites o f  action; one aziridine,
and two hydroxy groups which on bioreduction o f  the molecule are capable o f leaving to
generate electrophilic sites (see Figure 20). EO-9 (80) has been shown to double the
110time taken for a given increase in the size o f tumours implanted in mice. In addition 
experiments have shown that it is a good substrate for DT-diaphorase.113 However 
experiments with EO-9 (80) have shown that the HCR o f  cells which are high in DT- 
diaphorase can be essentially zero, whereas cells with low levels o f the enzyme have an 
HCR o f  over 750.114 This can be attributed to EO-9 (80) being such a good substrate for 
DT-diaphorase that it is reduced even in oxic cells.115 Since DT-diaphorase is 
overexpressed in several tumour cell lines80 this would allow EO-9 (80) to target cancer 
cells even if  they were not hypoxic. This should allow the drug to be effective against a 
broad range o f tumours.
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Electrophilic and potentially electrophilic sites
OH
OH
Figure 20 -  Alkylation sites on EO-9 (80).
3.4 Transition metal complexes
3.4.1 Background
The kinetic stability o f transition metal complexes is closely tied to their electron 
configuration. Low spin d6 complexes are by far the most stable since all their electrons 
are in bonding/nonbonding orbitals, as shown in Figure 21. Hence, their ligands remain 
attached when the complex is added to water. However, when these complexes are 
reduced, they produce highly labile d1 species. In a low spin state they will have one- 
electron in an antibonding orbital, whilst in a high spin state two-electrons are in 
antibonding eg* orbitals (see Figure 21). These less stable states will allow the complexes 
to exchange their ligands with water rapidly when in aqueous solution. If the initial 
ligands on the compound are cytotoxic then reduction o f the complex will result in the 
release o f  these toxic ligands and therefore cell death. Such complexes could be used as 
hypoxia selective prodrugs, becoming active only after reduction in solid tumours.
Unlike many other bioreducible anticancer agents, which generate short lived cytotoxic 
species, transition metal complexes generally release alkylating agents which may diffuse 
out o f  the hypoxic regions o f a tumour and into the surrounding tumour tissue. This 
could allow cell kill even in the oxic regions which surround areas o f  hypoxia within the 
tumour, making these compounds more effective in vivo.
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Orbital level diagram for a first row transition metal d 6 octahedral complex
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Figure 21 -  Electron configuration o f transition metal complexes.
3.4.2 Cobalt and chromium complexes
Both cobalt (III) and chromium (III) display the kinetic properties detailed above. First 
generation complexes incorporating these metals have been synthesised116 and their 
biological activity tested.117 Initial complexes had up to 4 aziridines complexed to the 
metal as well as other ligands. These complexes did not show any selectivity for hypoxic 
cells. It was proposed that the cobalt (III) cf complexes are reduced to d 7 complexes in 
all cells, but in oxic cells they are quickly re-oxidised before ligand exchange can occur.
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However, due to the weak binding o f monodentate ligands to transition metals, these 
ligands can exchange rapidly with water before re-oxidation can occur, hence toxicity is 
conferred even to oxic cells.
In an attempt to increase the stability o f  these complexes, cobalt analogues were 
prepared in which bidentate ligands, with alkylating potential, were used (see Figure 
22 ) . 118 When A^/V-bis(2-chloroethyl)ethylenediamine (BCE) was used as a bidentate 
ligand, the compound formed (81) had no selectivity. However some o f  the complexes 
which had the general structure 82 and incorporated a N,N-b\s(2- 
chloroethyl)ethylenediamine, DCE, ligand did show selectivity. The most selective 
compound SN 24771 (83) had a 20-fold selectivity (measured at 90% cell kill), whereas 
its analogue (84), which differs only in having no methyl substituted at the 3-position o f  
the pentane-2,4-dione ligands, has less than 2-fold selectivity. This difference was 
attributed to the reduction potential o f the non-selective analogue being low enough to 
allow considerable reduction even in oxic cells.118 However, this does not correlate with 
the equally low selectivity o f  the ethyl analogue (85) which has a reduction potential very 
similar to the active analogue SN 24771 (83) (see Table 2).
Cl
BCE Complex (81) DCE Complex (82)
83: R=Me 84: R=H 
85: R=Et
Figure 22  -  Cobalt-mustard complexes.
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Compound R Substituent E*(m V) Selectivity
SN 24771 (83) Me -305 20
(84) H -235 1.9
(85) Et 350 4.9
Selectivity values refer to 90% kill, not 50% as used for other bioreducible agents. 
The compound SN 24771 (83) has an HCR o f 2.01 measured at 50% kill.117
Table 2 -  Properties o f cobalt complexes with different R groups
The use o f  even the active complex SN 24771 (83) in vivo will be limited, since like 
some other bioreducible drugs it requires a very low oxygen concentration for effective 
activation (0.27 mmHg) .119 Future analogues will be required in order to elucidate the 
structure activity relationship, and to develop compounds which are activated at higher 
oxygen concentrations.
3.5 Combinational Therapies
3.5.1 Background
Tumours with hypoxic regions are particularly difficult to treat, due to the resistance o f  
these regions to many conventional forms o f therapy. However, bioreducible drugs are 
only activated in the oxygen deficient sections o f a tumour. In some cases the active 
species appear to be only transitory,72 and do not persist for long enough to diffuse out 
o f the hypoxic regions o f a tumour and into surrounding tissue. This limits the area o f  
the tumour over which these drugs can be effective to the hypoxic zones. This limit 
could be overcome if either a greater proportion o f the tumour could be made hypoxic, 
or if two types o f  therapy were given simultaneously, one to act on the hypoxic cells and 
another on the oxic tumour cells.
3.5.2 Vasoconstrictive agents
Flavoneacetic acid, FAA (86 ), shown in Figure 23, has been demonstrated to reduce 
blood flow in tumours by 85%.120 This in itself is enough to cause some cell death, as 
the tumour cells are starved o f both oxygen and nutrients. However, administration o f  
FAA on its own is o f  little clinical value. Administration o f  FAA (8 6 ) to restrict blood
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flow and so increase the degree o f hypoxia within tumours, followed rapidly by 
administration o f SR 4233 (53) to take advantage o f the induced hypoxia, results in an 
increase in cell death over administration o f either agent on its own, 121 complete tumour 
necrosis being shown after 24 h exposure. More recently a combination o f  SR 4233 (53) 
and methylxanthenoateacetic acid, DMXAA (87) has been used. However, this system 
gives similar results to those achieved when FAA (86 ) was utilised, but requires only one 
tenth o f  the concentration o f vasorestrictive agent required to achieve similar results 
when using FAA (8 6 ).122
OHOH
FAA (86 ) DMXAA (87)
Figure 23 -  Potent vasorestrictive agents, FAA (8 6 ) and DMXAA (87).
3.5.3 Radiotherapy
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SR 4233 (53) does not act in the same manner as a classical radiosensitiser. When 
used in combination with radiotherapy on well-oxygenated cells no radiosensitisation 
was observed. However, when it was administered along with a fractionated course o f  
radiation to hypoxic tumours, only 0.01% o f the tumour cells remained viable. This 
toxicity is significantly more than the additive effects o f the radiation (2%) or drug 
treatment (20%) alone. The enhancement o f radiotherapeutic effects occurs even if the 
drug is given up to 2 hours prior to irradiation. This suggests that such combined therapy 
would be particularly useful for areas o f chronic hypoxia, since the area sensitised by SR 
4233 (53) need not be hypoxic at the time o f administration o f the radiation.
The enhancement o f radiotherapy by SR 4233 (53) is not limited to external sources o f  
radiation. Significant enhancements in the activity o f  radioimmunotherapy (see Section 
3.6.2) have also been shown, with124 or without hyperthermia.125
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Treatments have been devised which reduce the level o f hypoxia in solid tumours and so 
make them more sensitive to radiotherapy. At the simplest level allowing the patient to 
breathe an oxygen rich atmosphere, known as carbogen (95% oxygen, 5% carbon
• • 1 9 A
dioxide), increases the oxygen concentration in their blood. Since the initial
concentration o f  oxygen in the blood is higher than would otherwise occur, the distance
over which the oxygen gradient can extend into the tumour, before radiation resistance is
reached, is also increased. An alternative approach is to administer a drug which induces
greater blood flow, such as nicotinamide. It is believed that this drug operates by
diminishing the amount o f chromic hypoxia in tumours, by lowering the interstitial fluid 
127pressure.
When carbogen and nicotinamide were simultaneously administered, prior to irradiation, 
they produced a dose modifying factor o f up to 1.6.128 That is, treatment resulted in a 
degree o f  cell kill that would otherwise require a dose o f radiation 1.6 times greater than 
that applied when the drug was present. However, this enhancement o f  the 
radiotherapeutic effect was less than that produced by combining irradiation with SR 
4233 (53), which resulted in a dose modifying factor o f up to 2.4 .128 These results show 
that hypoxia need not be thought o f  as a hindrance to radiotherapy, which should be 
removed. Rather, hypoxia can be used as an enhancement to the radiotherapeutic effect 
when hypoxia selective radiosensitisers are used.
The unusually sustained cytotoxicity o f SR 4233 (53) at higher oxygen concentrations
oc
(see Section 3.2.6) makes it particularly suitable for combination with radiotherapy. 
Graph 12 shows how the combination o f radiotherapy and SR 4233 (53) is highly toxic 
at all oxygen concentrations, whereas RSU 1069 (43) combined with radiotherapy is less 
effective in treating tumour cells with are mildly hypoxic. This is because cells in a mildly 
hypoxic state are still radiation resistant, but are not hypoxic enough to facilitate 
bioreduction o f  RSU 1069 (43) to any significant degree.
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Graph 12 -  Effects o f  oxygen concentration on combined chemotherapy/radiotherapy.
3.5.4 Photodynamic therapy
Many chemical entities have the ability to react when exposed to light. If the resulting 
species are toxic, the parent compound could be used as an anticancer agent which is 
only activated when illumination is applied externally. The most studied compound o f  
this class is Photophrin, which decomposes on exposure to light at 630 nm to produce 
singlet oxygen. When Photophrin is administered it is taken up by the vasculature 
endothelial cells and does not penetrate into the tumour. Experiments have shown that 
when illumination is applied, damage is mainly limited to the vasculature structure.129 It 
is reasonable to assume that tumour cell death results from the resulting deprivation o f  
oxygen and nutrients from the tumour.
The hypoxia generated by photodynamic therapy can be exploited by a bioreducible 
drug, activating it to generate a toxic species. Treatment involves injection with 
Photophrin and SR 4233 (53). SR 4233 (53) can penetrate into the tumour readily since 
the tumour initially has an adequate blood supply. When the Photophrin, which has by 
now accumulated in the vasculature endothelial cells, is activated by illumination, 
hypoxia is induced. The high concentration o f  SR 4233 (53) which has accumulated in 
the tumour is then activated and cell death occurs. Application o f  this procedure with SR 
4233 (53) has so far only shown minimal therapeutic value.130 However, when using 
disulfonated aluminium phthalocyanine as the photodynamic drug in combination with
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RSU 1069 (43), a 2 fold increase in the tumour re-growth time was observed when 
compared to photodynamic therapy alone.131
5.5.5 Inhibition of DNA repair
Although the initial damage caused to DNA, by both ionising radiation and 
chemotherapeutic agents is generally high, this level o f damage is greatly reduced after 
the cell carries out its repair processes. If these processes could be inhibited, the effect o f  
antitumour drug treatment on DNA would be greatly amplified.
One enzyme which is responsible for DNA repair is poly(ADP-ribose) polymerase. This 
can be inhibited by small molecules such as 3-aminobenzamide. When this 
chemopotentiator is given in combination with anticancer drugs such as cisplatin an 
increase in toxicity is observed.132 A new ring closed analogue o f  3-aminobenzamide is 
PD 128763 which is -6 0  times more potent. This compound enhances the effect o f  the 
bioreducible drug RSU 1069 (43) by a factor o f 36.133
3.6 Antibody Directed Enzyme Prodrug Therapy 
(ADEPT)
3.6.1 Prodrug therapy
The difference in enzyme concentrations between tumour cells and normal cells has been 
known for some time, and has been exploited in enzyme activated prodrug therapy. One 
early example was the nitrogen mustard (88 ), shown in Figure 24, which was found to be 
much more cytotoxic (LD50 117 mg kg’1) than its naphthalene derivative (89) (LD50 
1300 mg kg’1) .134
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Figure 24 -  Structure o f aromatic mustards
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The pattern o f  toxicity exhibited by the benzenoid mustard (8 8 ) can be explained by the 
process outlined in Scheme 12. The mustard (88 ) is initially oxidised in the liver to form 
the para-hydroxy derivative (90), which is then detoxified by formation o f  the 
glucuronide (91). This is then released into the blood stream, and diffuses into both 
tumour and normal cells. Some tumour cells have been shown to express a highly 
elevated level o f  the enzyme 13-glucuronidase (~5 times that o f normal cells) . 135 Within 
these cells selective hydrolysis o f  the ester (91) occurs to form a hydroxyaromatic 
mustard (90) (LD50 29 mg kg'1). This is highly toxic since the phenolic lone pair can 
assist in the formation o f the reactive aziridine-containing species (92).
C k  .C l C k  Cl C k  X I
HO
OH
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Stream
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G
92 90 91
Scheme 12 -  Possible method o f  enzymatic activation o f  the aromatic mustard (88 ).
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3.6.2 Antibody targeting
Monoclonal antibodies can be raised to proteins which are expressed by tumour cells and 
exhibited on their outer membrane. When these antibodies are attached to a cytotoxic 
drug or toxin, they are then delivered specifically to the tumour cells. In this approach 
every molecule o f  drug would need to be bound to a separate antibody. Additionally, 
binding o f  the drug or toxin to the antibody must be done in such a way as to generate a 
species stable enough to reach its target site. These and other limitations o f  such “magic 
bullet” treatments have been fully reviewed. 136
To avoid the problems outlined above, radioimmunotherapy was developed. This relied
for its toxicity on radioactive elements which were incorporated into the structure o f  the
antibody. The antibody-source is generated by binding a multidentate ligand to the
monoclonal antibody and then adding the source (indium 111 or yttrium 90) which is
allowed to chelate.124 Once administered the antibody-source adduct attaches to an
antigen on the tumour cell’s membrane. The radiation released for the source would then
act on the tumour in a more localised manner than that delivered by an external source.
Although this method has shown some success137 it is severely limited by the poor
attachment o f the antibody conjugate to the tumours. Studies showed that only 0.00001
1 ^ 8
to 0.01% o f  the administered conjugate is present per gram o f tumour. The poor 
activity could be explained by the crude method used in attaching the multidentate ligand 
to the antibody. This simply involves stirring an anhydride o f the ligand with the 
antibody. This anhydride may be attacked by that portion o f the antibody which would 
otherwise attach to the tumour, so rendering the antibody inactive.
An alternative approach is to tag monoclonal antibodies onto liposomes— phospholipid
spheroids, which in this case contain cytotoxic drugs— to generate immunoliposomes
(see Figure 25). The viability o f individual antibodies on the liposome is not as important
as it is in radioimmunotherapy, since each liposome has over 50 antibodies attached to
it.139 Experiments have shown that binding o f  the liposomes can be very efficient with
84% o f  the immunoliposomes binding to tumour cells within 2 hours.140 Once these
immunoliposomes attach to the tumour they are engulfed within endosomes. If the
balance o f  lipids in the immunoliposome is correct the liposome will fuse with the
1
endosome so releasing its toxic contents into the cell.
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Figure 25 -  Mode o f  action o f  an immunoliposome.
3.6.3 Combining antibodies with enzymes
If  the technologies of enzyme activated prodrugs and antibody targeting are combined, a 
more selective species can be generated. Application o f  antibody directed enzyme 
prodrug therapy (ADEPT) to the liposome system requires the synthesis o f  a drug-free 
liposome which has both antibodies and enzymes attached to its surface (an immuno- 
enzymosome). The antibodies allow the immuno-enzymosome to bind to the tumour, so 
placing the enzyme in close proximity to the tumour. If  a prodrug is then added it will be 
activated only at the tumour site and so lead to selective cell death. This process was 
applied with the enzyme B-glucuronidase and lead to cell death when a prodrug was 
administered.141 However this is not a good system for use in vivo since B-glucuronidase 
is found in several human tissues.1,5 This could allow the prodrug to be activated in 
normal tissue and so reduce selectivity.
An alternative to the immuno-enzymosome approach is to link the enzyme directly to the 
antibody (see Figure 26). Although the problem of poor antibody viability still exists in 
this method, it is possible to flush any unbound antibody-enzyme conjugates (AEC) out 
o f  the body prior to prodrug administration leaving only 1% of the antibody unbound in 
the bloodstream.142 Since many prodrug molecules can be activated catalytically by only 
a few AEC, a low concentration o f  AEC at the tumour site is not a problem. In addition 
such low levels reduce the amount of foreign protein in the body and hence reduce any 
adverse immune response.
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Figure 26 -  The ADEPT process in action.
3.6.4 ADEPT in use
The first example o f  an AEC ADEPT system used the enzyme carboxypeptidase G 2 .14' 
This system has the advantage o f  using an enzyme which is not present in humans, so 
ensuring that the peptide bonds it hydrolyses can only be cleaved by the AEC and not in 
normal cells. Using this system with a prodrug such as 93 ,144 leads to cleavage o f  the 
peptide bond and formation o f  the free drug (94), which then acts as an alkylating agent 
(see Scheme 13). The major problem with analogues o f  this type, is that the prodrug (93) 
is not completely inactive. At best such prodrugs are 17 times less able to alkylate than 
the free drug, whilst other analogues have a selectivity as low as 2. This prodrug 
instability could cause cellular damage prior to activation and so reduce specificity. 
However in vitro experiments have shown that the prodrug itself causes minimal cell 
death .145 This may be carried over to the in vivo results, but clinical trials are as yet 
incomplete.146
A further example o f  the use o f  peptidases as activating enzymes in A D EPT is the 
breakdown o f  a methotrexate-phenylalanine analogue (95) by the enzyme 
carboxypeptidase A 147 (see Scheme 14). This AEC breaks the amide bond between the 
M TX  subunit and the peptide, generating free M TX (20). The cytotoxicity o f  the AEC- 
M TX  prodrug treatment towards cancer cells is similar to that o f  free M TX  (20 ) .147 
However, in vivo work has not been reported. One possible limitation o f  this approach is
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that the MTX (20) released after enzymatic cleavage only acts on cancer cells which are 
progressing through the cell cycle. Molecules which release certain other drugs, such as 
alkylating agents, upon enzymatic activation have the benefit o f  showing at least some 
activity to cells which are in a static state.
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Scheme 13 -  Activation o f  a mustard prodrug (93) by carboxypeptidase G2.
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Scheme 14 -  Activation o f MTX prodrug (95) by carboxypeptidase A.
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3.6.5 Prodrugs with carbamate linkages
Another promising class o f  peptidases used for ADEPT is 13-lactamases.148 The AEC 
incorporating these enzymes is capable o f cleaving the peptide bond in cephalosporin- 
drug conjugates (96) (see Scheme 15). The lone pair o f  electrons on the 13-lactam 
nitrogen can then assist in expelling any drug which is attached to the 3 '-position leaving 
a conjugated imine (97).
OH
\  13-lactamase
Drug
96 97
Scheme 15 -  Release o f drug by enzymatic cleavage o f a cephalosporin amide bond.
The drug MTX (20) was attached to a cepham nucleus via nucleophilic displacement o f  
the cepham alkyl iodide by the terminal carboxyl group o f MTX (20) . 149 This is a general 
procedure which can be used to attach any drug which has a suitable nucleophilic site. 
Other conjugates which have been formed include the DAVLBHYD [an analogue o f  the 
alkaloid vinblastine (29)]-cepham sulphoxide conjugate (98) shown in Figure 27.
Both the prodrugs containing MTX (20) were good substrates for the AEC. However, 
each prodrug proved to be as toxic prior to activation as the free drugs themselves. 
However, the DAVLBHYD conjugate (98) was 5 times less active then the free drug, 150 
and a good substrate for the AEC generating free DAVLBHYD .151 When activated by 
tumour cells, which had been previously exposed to the AEC, a cytotoxic species was 
released which resulted in tumour regression in mouse xenografts.150
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Figure 27 -  Structure o f the DAVLBHYD conjugate (98).
Earlier studies with a prodrug which lacked the C0 2 -linkage between DAVLBHYD and 
cepham sulfoxide were unsuccessful. Although the lactam o f  the DAVLBHYD-cepham  
sulfoxide conjugate (98) was hydrolysed by the AEC, the resulting species did not 
readily release free DAVLBHYD since it has too poor a leaving group. 152 Further 
evidence for the use o f  prodrugs which incorporate a releasable CO2 from a carbamate 
type linkage comes from the synthesis o f a mustard-cepham prodrug (99), which 
incorporates a carbamate linkage. This compound readily breaks down when exposed to 
the AEC releasing the free drug153 (see Figure 28).
H ©
Figure 28 -  Breakdown mechanism o f the mustard-cepham prodrug (99).
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Because the carbamate linkage is relatively stable under physiological conditions, and 
generates a good leaving group after activation o f  the prodrug, it has been used 
extensively for ADEPT. Usage o f a carbamate linkage between the prodrug fragment 
which acts as the enzyme's substrate, and the drug fragment, is not limited to prodrugs 
which are activated by any particular class o f enzyme.
3.6.6 Spacer units in ADEPT prodrugs
An a-galactosidase-containing AEC has been used to activate another carbamate linked 
prodrug (100) which generates daunorubicin (27) on cleavage o f the glycosidic bond 
(see Figure 29).154 A noteworthy inclusion in this molecule is the benzene ring spacer 
which has no function in the activity o f the released drug. It serves only to distance the 
enzymically recognised portion from the cytotoxic portion. Because drugs used in 
ADEPT are often large, the steric bulk o f the prodrug conjugate may interfere with the 
action o f  the enzyme, inhibiting the ability o f the enzyme to act on the specifier and so 
blocking the activation o f the prodrug. For this reason a spacer can be used, allowing 
more efficient enzyme-substrate recognition, so facilitating prodrug breakdown leading 
to drug release.
OH
"OH
OMe OH
OH
OH
Me‘ H©
HO HNHO
HOi
Figure 29 -  Breakdown mechanism o f an ADEPT prodrug (100) with spacer groups.
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4. Syn th e s is  of H ete r o a r o m a tic  
N-  OXIDES
4.1 Overview
The initial aim was to produce compounds with a similar mode o f  action to SR 4233 
(53), which also had the potential for alkylation. It was hoped that this two-pronged 
attack would give a compound with a high HCR, as seen with the bioreducible alkylating 
agent RSU 1069 (43). Another goal was to determine the basic structural requirements 
for compounds which undergo enzymatic one-electron reduction. To this end, simple 
model systems were chosen, each incorporating at least one heteroaromatic ring and one 
leaving group.
4.2 Pyridine derivatives
4.2.1 Background
Initial studies were centred on compounds with only one heteroatom, one aromatic ring 
and two potential leaving groups. Compounds with two leaving groups were chosen 
because o f  their increased toxicity, which arises due to their ability to crosslink DNA (see 
Section 2.2.1). Carbamates were chosen as suitable leaving groups since they are stable 
enough to travel through the body and diffuse into hypoxic tissue without reacting with 
any o f  the intervening tissue. Only when the prodrug is activated will it be sufficiently 
reactive to allow alkylation by DNA. The use o f  carbamates as leaving groups which 
require assistance from elsewhere in the compound has precedence in imidazole 
anticancer drugs.155 To confirm the above theory and to take into account the possibility 
that the carbamates may not be sufficiently reactive, compounds with halomethyl groups 
were also synthesised.
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4.2.2 Synthesis of carbamates
The procedure employed is outlined in Scheme 16 and required reaction o f  
2 ,6 -bis(hydroxymethyl)pyridine (101) with an isocyanate in dichloromethane, using a 
dibutyltin diacetate (DBTDA) catalyst. It was hoped that this would generate a 
biscarbamate which could then be oxidised to form its A-oxide.
OxidationIsocyanate
R R O© R
101 103: R=OCONH7Pr 107
104: R=OCONHEt 108
105: RO CO N H Ph 109
106: R=0C0NH/?-C6H4N02
R=OCONHzPr
R=OCONHEt
R=OCONHPh
Scheme 16 -  Route to formation o f pyridine analogues.
When this route was attempted with three moles o f  isopropyl isocyanate to each mole o f  
diol (101) and a 3 hour reaction time, a mixture o f  two products was generated. These 
products could not be separated by recrystallisation, but were successfully purified by dry 
column flash chromatography, to give a more polar (102) and a less polar (103) product 
in a 1:1.4 ratio (see Scheme 17).
Isocyanate
HO OH
HNCOO OH
Isocyanate 
DBTDA  
„C H 2C12
101
OCONHHNCOO 103
Scheme 17 -  Synthesis o f bis(hydroxymethyl)pyridine mono- and bis-
(isopropylcarbamate).
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The NMR spectrum o f the less polar compound (103) showed a doublet, with a shift 
o f  6  1.14, which had an integral that corresponded to 12 protons. These hydrogens are 
the C H (C #3)2 o f  the two isopropyl groups, each o f which is coupled to its CH(C££3)2 
hydrogen (J 6.4 Hz). Further evidence for this product being the biscarbamate came from 
the NH signal at 8  4.78, which also had an integral that corresponded to two protons. 
The symmetry that such a compound possesses was evident by the presence o f  only one 
peak generated by the methylene hydrogens adjacent to the heteroaromatic ring. The 
downfield region o f the spectrum showed two signals, one corresponding to the 
hydrogens attached to the 3- and 5-positions (hereafter referred to as meta-Hs) and one 
signal for the hydrogens on the 4-position (hereafter referred to as the para-Hs). Both o f  
these signals occurred at their expected chemical shifts, 156 and had a coupling o f  7.7 Hz. 
This coupling is consistent with a m-p coupling in a pyridine ring.157
The more polar compound (102) had a similar ]H NMR spectrum, but showed only 
6  hydrogens in the far upfield area. This implies the presence o f  only one 
isopropylcarbamate, and this situation would arise only if mono substitution had 
occurred. Identification o f  the product was confirmed by signs o f  the lack o f  symmetry in 
the compound, such as the presence o f  two JH NMR signals corresponding to the 
methylene protons. One signal for the methylene group next to the carbamate at 8 5.11, 
and another at 8  4.62 can be attributed to the hydroxymethyl group. The lack o f  
symmetry was also observed in the 13C NMR spectrum, which showed peaks for the 
methylene carbon atoms at 8 66.8  (carbamate) and 63.3 (alcohol). As expected, this 
doubling o f methylene signals was not observed in the spectrum o f  the biscarbamate
(103). Additionally, the downfield region o f the spectra was consistent with that 
expected for a substituted pyridine ring.158
The IR spectrum o f  both the mono- (102) and bis-carbamate (103) showed all the 
expected absorbance bands.159 Of particular note was the presence o f  two C =0  
stretching modes in the spectrum o f the biscarbamate (103) [1720 and 1690 cm'1]. Such 
dual C= 0  stretching modes are characteristics o f both amides and carbamates but may 
overlap to give a single signal, as with the monocarbamate (102) [1740 cm'1]. In addition 
the lack o f  any absorbance due to an isocyanate stretch (-2250 cm'1) indicates that the 
purification process has removed o f any unreacted isocyanate.
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Later reactions using longer reaction times and/or a larger excess o f  isocyanate ensured 
completion o f the reaction giving only the biscarbamate (103). As well as the 
bis(isopropylcarbamate) (103) the same extended reaction gave the bis(ethylcarbamate)
(104) and bis(phenylcarbamate) (105) in excellent yields (93, 95 and 94% respectively) 
and with high purity. The structures o f  the products and lack o f  both starting material 
and monocarbamate were confirmed in each case by the spectroscopic methods outlined 
above. In addition, the formation o f  the required products was deduced from accurate 
MS, and the purity o f the products confirmed by microanalysis.
Attempted production o f the bis(4-nitrophenylcarbamate) (106) by the above method 
resulted in complete consumption o f the starting diol (101), but 3 impurities were noted 
on TLC. The two smaller impurities and remaining 4-nitrophenyl isocyanate were 
removed by recrystallisation o f the crude product from DMSO/water. The removal o f  
starting material was later confirmed by the IR spectrum o f the purified product which 
showed no signs o f  the characteristic band, at -2250  cm'1, caused by an isocyanate. The 
more prominent impurity was not removed since, like the product, it was also highly 
insoluble. The poor solubility o f the product also inhibited purification by 
chromatographic methods.
On examination o f the 4-nitrophenyl isocyanate starting material, it was found to contain 
the same impurity as the product. Attempted purification o f  the isocyanate was 
unsuccessful, since the 4-nitrophenyl isocyanate had very similar solubility to the 
impurity.
The lH NMR spectrum o f the recrystallised product showed the expected peaks 
associated with the bis(4-nitrophenylcarbamate) (106). The only additional peaks were 
small multiplets in the region attributed to the hydrogens attached to a 4-nitrophenyl 
aromatic ring. The 13C NMR spectrum showed a similar picture, with very small peaks at 
8  117.9 (CH, o-Ar), 8 125.2 (CH, m-Ar), 8 141.6 (C, p-Ar) and 8 145.7 (C, s-Ar). A 
further peak was observed at 8 151.9 (C) which can be attributed to a carbonyl. This 
implies that the impurity was 4-nitrophenylcarbamic acid, produced by hydrolysis o f  the 
isocyanate. However even a freshly ordered sample o f  4-nitrophenylisocyanate still 
contained this impurity.
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The IR spectrum o f the recrystallised product showed broadly the same absorbancies as 
that o f  the bis(phenylcarbamate) (105) but with additional bands at 1500 and 1330 cm' 1 
due to the asymmetrical and symmetrical stretching o f a conjugated nitro group. Neither 
the IR nor mass spectra were o f any aid in confirming the previous identification o f the 
impurity due to its structural similarity to bis(4-nitrophenylcarbamate) (106).
Although the amount o f contamination o f  the bis(4-nitrophenylcarbamate) (106) by 4- 
nitrophenylcarbamic acid was relatively small— only slight impurities being shown in the 
downfield region o f both the l3C and ^  NMR spectra— this compound was not taken on 
to its N-oxide since its poor solubility made any further reactions difficult.
4.2.3 Synthesis of N-oxides of carbamate derivatives
The earliest production o f  pyridine N-oxides was carried out in 1926.160 This process 
utilised perbenzoic acid to oxidise the parent species, pyridine, to its N-oxide. Since that 
time many different oxidising agents have been employed. For compounds which are 
substituted at the 2 -, or 2 - and 6 -positions o f the pyridine ring, the formation o f an 
N-oxide is generally slow, due to steric and/or electronic effects. 161 These are generally 
overcome by forcing conditions, such as hydrogen peroxide in trifluoroacetic acid (TFA) 
which generates trifluoroperacetic acid in situ.
Since the pyridine biscarbamates (103, 104 and 105) so far synthesised were substituted 
at both the 2 - and 6 -positions it was thought prudent to use forcing conditions to 
generate their respective N-oxides (107, 108 and 109). It was hoped that this would 
generate the N-oxide without affecting the carbamate functionality. Evidence to support 
this comes from the successful oxidation o f the pyridine ester 110 by Hamana et cil. ,162 
to its N-oxide (111), which occurred without degeneration o f  the ester functionality (see 
Scheme 18).
h 2o 2
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Schem e 18 -  Oxidation o f the acetate ester o f  2-hydroxymethylpyridine (110).
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Production o f  the N-oxide was attempted with bis(hydroxymethyl)pyridine 
bis(isopropylcarbamate) (103) using TFA/H2O2. Formation o f the N-oxide was almost 
instantaneous, producing only one product and baseline material. Care had to be taken to 
stop the reaction rapidly and avoid heating, or several byproducts were formed. These 
might include products due to hydrolysis o f  the carbamates. After this hydrolysis, further 
impurities could be formed by deoxygenation o f the resulting species by the general 
method outlined in Scheme 19.163 This process requires reaction o f  the newly formed N- 
oxide (112) with an equivalent o f peracid (113) which is reduced to its acid (114). This 
process also generates an unstable intermediate (115) from the N-oxide (112 ), which 
spontaneously breaks down, by elimination o f oxygen, to form its free base (116). 
Isolation o f  the compound produced proved difficult, with large amounts o f  baseline 
material present even after short reaction times.
O
Scheme 19 -  Deoxygenation o f N-oxide containing heteroaromatics.
To overcome these problems the milder oxidising agent /weta-chloroperoxybenzoic acid
(w-CPBA) was used.164 Reaction o f each o f the biscarbamates (103, 104 and 105) gave
the required N-oxides (107, 108 and 109). These showed no impurities even prior to
crystallisation, and were isolated in moderate yields (43, 68  and 48% respectively). The
products were identified spectroscopically and showed spectra not dissimilar to their free
bases. The only noteworthy differences were the addition o f  bands in the IR spectra
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corresponding to N -0  stretching at 1200-1300 cm*1; slight changes in the chemical shifts 
o f  the atoms comprising the pyridine ring and attached methylene groups; and the 
expected differences in the accurate mass spectra.
4.2.4 Synthesis of halides
To broaden the range o f leaving groups, it was decided to produce a series o f  dihalo 
derivatives. Should the biological testing show that no alkylation occurred with the 
carbamate derivatives then the addition o f more labile groups might prove beneficial. The 
route which was finally utilised to produce the six new target compounds (117-122) is 
outlined in Scheme 2 0 .
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Scheme 20  -  Synthetic route to dihalopyridines.
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Production o f  the first compound in the series, 2,6-bis(bromomethyl)pyridine (117), was 
initially carried out by heating 2,6-bis(hydroxymethyl)pyridine (101) at reflux with 46- 
48% hydrobromic acid. This is a well proven procedure for the synthesis o f 2,6-
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bis(bromomethyl)pyridine (117),165 but gave poor yields, which were never greater than 
46% after recrystallisation. Varying the reaction time from the initially suggested 2 hours 
to 3, 6  and then 6 V2 hours resulted in crude yields o f 6 6 , 70, 66  and 57% respectively. 
This suggests that a reaction time o f between 3 and 6 hours would be the optimum. In 
addition to the required 2,6-bis(bromomethyl)pyridine (117), the crude sample isolated 
also contained a large amount o f sodium chloride. This artificially raised the apparent 
crude yield, when in reality a much smaller amount o f the desired product had been 
formed. A more accurate assessment o f the amount o f  2,6-bis(bromomethyl)pyridine 
(117) generated is given by the recrystallised yield which is relatively poor.
In an attempt to improve the yields o f 2,6-bis(bromomethyl)pyridine (117) an alternative 
procedure was carried out utilising phosphorus tribromide. This reagent has been shown 
to be effective for bromination o f hydroxymethyl groups attached to unsaturated 
systems.166 Initial reaction o f the starting diol (101) with PBr3 in dichloromethane 
(DCM) gave incomplete reaction, with a 26% yield o f 2,6-bis(bromomethyl)pyridine 
(117) isolated. It was thought that part o f the reason for incomplete reaction was due to 
the formation o f  an insoluble salt between the starting material (101) and the HBr 
produced on reaction o f  PBr3. The poor solubility o f the salt reduced its availability for 
bromination. When the reaction was repeated with excess pyridine in the system, to 
remove any HBr generated, the reaction did not progress any further, with large amounts 
o f  starting material remaining. Even heating the starting diol (101) at reflux in neat PBr3 
did not lead to a greater degree o f reaction.
An alternative method o f preparing bis(bromomethyl) derivatives utilises 
triphenylphosphine (123) and molecular bromine (124). This system has shown itself to
167 •be useful in cases where PBr3 has failed to give the required product. The mechanism 
o f  bromination is outlined in Scheme 21 and relies on the attack o f  triphenylphosphine 
(123) on molecular bromine (124) to form a triphenylphosphine-bromide complex (125). 
This is then attacked by an alcohol (126) to form an (alkyloxy)triphenylphosphonium 
bromide salt (127). Formation o f the salt has been shown to be very rapid, 168 producing 
a complex stable enough to be isolated.169 Nucleophilic attack by an iodide ion then 
occurs at the carbon adjacent to the oxygen, with resulting cleavage o f  the carbon- 
oxygen bond. This process generates the required alkyl halide (128) and 
triphenylphosphine oxide (129). When this process was applied to the starting diol (101)
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only a 19% yield o f  product was obtained. Since this yield was below that first obtained 
using hydrobromic acid, the original reaction conditions, with only slight modifications to 
the reaction time, were utilised for all subsequent preparations o f 2 ,6 - 
bis(bromomethyl)pyridine (117).
Ph3P|' + |B r— Brl
123 124
^ Ph
+ R— Brl
Ph Ph
129 128
+ I Brl
R— OH
+ I Brl
Scheme 21 -  Bromination o f an alcohol (126) using triphenylphosphine (123) and
molecular bromine (124).
Formation o f  2,6-bis(chloromethyl)pyridine (118) is also outlined in the paper by Baker 
et al.165 and involves heating 2 ,6 -bis(hydroxymethyl)pyridine ( 101) with neat thionyl 
chloride (130) for 4 hours. When this reaction was attempted it was found to give the 
required product reliably, in moderate yields and with high purity. The method outlined 
in the literature was modified slightly by replacing the benzene used in the workup, with 
its much less hazardous substitute, toluene. The reaction mechanism is shown in Scheme 
22 and involves attack on the sulfur atom o f thionyl chloride (130) by an alcohol (126), 
to form a strong phosphorus-oxygen bond. The resulting compound (131) then breaks 
down, with accompanying rearrangement, to form an alkyl chloride (132) and sulfur 
dioxide.
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Scheme 22  -  Chlorination o f an alcohol (126) using thionyl chloride (130).
The final halopyridine for which a synthesis was attempted was 2,6- 
bis(iodomethyl)pyridine (119). A direct synthesis from 2,6-bis(hydroxymethyl)pyridine 
(101) was initially planned, using refluxing hydriodic acid to bring about the 
transformation. This reagent has proven to be useful in bringing about substitution o f  
hydroxy groups with iodine in good yield.170 However when 2,6- 
bis(hydroxymethyl)pyridine (101) was used only 2,6-dimethylpyridine (133) was isolated. 
This is perhaps not unexpected given the reducing powers o f hydriodic acid and the 
extended reaction time.
The reaction occurring is depicted in Scheme 23 and arises after the initially formed 2 ,6 - 
bis(iodomethyl)pyridine (119) is attacked at one o f its iodines by an iodide ion, to 
generate molecular iodine and the cationic species (134). This reaction is facilitated by 
the stability o f the anion formed, which can delocalise into the aromatic ring. The anionic 
species (134) is highly reactive and may attack many different types o f  compound in the 
reaction mixture. If it attacks water, to abstract a proton, a methyl pyridine (135) is 
formed. This could then undergo further iodine mediated reaction to give 2,6- 
dimethylpyridine (133). However, there are many electrophilic species in the reaction 
mixture [such as the 2,6-bis(iodomethyl)pyridine (119) formed earlier in the reaction] 
which could also react with the anionic species (134). Hence, many products will be
formed, none in particularly high yield. This helps explain why only a 12% yield o f  2,6- 
dimethylpyridine (133) was isolated from the reaction mixture.
119 134
N
135
\
‘CH3
133
Scheme 23 -  Decomposition o f  2,6-bis(iodomethyl)pyridine (119).
The formation o f  2,6-bis(iodomethyl)pyridine (119) was eventually accomplished in an 
acceptable yield (65% after recrystallisation) and purity, by halide exchange on 2,6- 
bis(chloromethyl)pyridine (118). This type o f reaction is well documented and is named 
after its discoverer Hans Finkelstein.171 The reaction is brought about by adding sodium 
iodide to a solution o f  an alkyl chloride or bromide. To produce 2,6- 
bis(iodomethyl)pyridine (119), its alkyl chloride (118) was used as a starting material in 
preference to the alkyl bromide (117) simply because synthesis o f  the chloride (118) was 
more reproducible and gave higher yields than synthesis o f the bromide (117).
An outline o f the reaction is shown in Scheme 24 and requires the iodide ions to attack 
the a-carbon o f  the alkyl chloride (118), with displacement o f  chloride ions. The new 
alkyl halide (136) generated can then undergo further halogen exchange to produce the 
required product, 2,6-bis(iodomethyl)pyridine (119). Under normal conditions this 
reaction would be in equilibrium, with the newly formed alkyl iodide (136) being 
transformed back into its chloride (118). This problem is overcome by using acetone as a 
solvent since the sodium chloride generated on production o f  the alkyl iodide (136) is 
insoluble in the solvent used resulting in removal o f this salt from the system, by 
precipitation, which drives the reaction towards the required products.
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Scheme 24 -  Mechanism o f action o f the Finkelstein reaction.
Confirmation o f  the structure o f the alkyl halides synthesised was obtained by the usual 
means. The NMR and IR spectra o f all three derivatives were very similar. It was 
particularly difficult to determine whether the transformation o f  2 ,6 - 
bis(chloromethyl)pyridine (118) into 2,6-bis(iodomethyl)pyridine (119) had occurred 
since these compounds had almost identical R f values, NMR spectra and IR spectra. 
Confirmation that the product had been formed was most readily available from MS, 
which showed several fragments associated with an iodinated species and no fragments 
corresponding to any chlorinated species.
The MS o f  the dichloro- and dibromo-derivatives (118 and 117) showed multiple peaks 
for each fragment, due to chlorine and bromine existing as two different isotopes. The 
MS o f  the chloro derivative (118) showed molecular ions at m/z 178 (10.4%), 176 
(61.9%) and 174 ( 100 .0%). These correspond to species with 2x37C1, lx 37Cl and lx 35Cl, 
and 2x 35C1 respectively. Since the ratio o f the isotopes 37C1:35C1 is 24.5:75.8 we would 
expect a dichlorinated molecule to give three peaks with a relative intensity o f  
1 (2x37C1):6 ( l x 37Cl and lx 35Cl):9 (2x35C1). This is consistent with the results obtained 
from the mass spectrum.
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One area o f  the IR spectrum o f interest is the finger print region, where the C-halogen 
stretch occurs. The compounds synthesised showed peaks at 680 cm' 1 (C-Cl), 600 cm' 1 
(C-Br) and 568 cm' 1 (C-I). This reduction in wavenumber with increasing halide mass is 
consistent with a spring analogy, where increasing the weight attached to a spring 
increases its period. This coupled to the similarity in the rest o f  the IR spectra indicated 
that the only structural feature to have changed in the compounds 117-119 was their 
halide.
4.2.5 Synthesis of N-oxides of halide derivatives
The dibromo- and dichloro-compounds (117 and 118) did not form .N-oxides as readily 
as their carbamate derivatives. Only partial oxidation occurred when the reaction was 
carried out with /w-CPBA at room temperature, even after several days. This reduction in 
reactivity is probably due to the documented effects161 o f  steric bulk, caused by halogens 
at the 2 - and 6 -positions o f  a pyridine ring, on reactivity towards peracid oxidation. 
Increasing the severity o f the reaction by heating at reflux, brought about complete 
oxidation, to create 2,6-bis(bromomethyl)pyridine N-oxide (120 ) and 2,6- 
bis(chloromethyl)pyridine N-oxide ( 121) .
When peracid oxidation was applied to 2,6-bis(iodomethyl)pyridine (119), 
decomposition occurred, producing no isolatable product. It was thought that this could 
be due to oxidation o f  the iodine in 2,6-bis(iodomethyl)pyridine (119). This would 
generate a hypoiodite (137) (see Scheme 25), which could then act as a leaving group, 
generating a resonance stabilised cation (138). The cation is highly electrophilic and may 
react with many different components o f the system, giving a large mixture o f  products, 
none o f  which was produced in large enough quantity to be readily isolated and 
characterised. The required product was finally realised by utilising the Finkelstein 
reaction on 2,6-bis(chloromethyl)pyridine N-oxide ( 121), to generate 2 ,6 - 
bis(iodomethyl)pyridine N-oxide ( 122) in 89% yield.
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Scheme 25 -  Over oxidation o f 2,6-bis(iodomethyl)pyridine (119).
4.3 Quinoline derivatives
4.3.1 Background
The pyridine derivatives previously synthesised were produced to determine the 
minimum structural features which were necessary in bioreducible, heteroaromatic, N- 
oxide anticancer agents. The therapeutic effect o f these compounds can be used as a 
reference point. By comparing the activity and selectivity o f any new compounds that are 
synthesised with these reference compounds and looking at the structural differences it 
should be possible to determine which additional structural features are necessary for 
maximum therapeutic benefit. One feature which is present in many previously 
synthesised compounds, such as SR 4233 (53), is a fused ring system. A planar 
hydrophobic region within the drug may be necessary to allow the drug to fit more 
closely within a hydrophobic pocket in the enzyme which facilitates its bioreduction. To 
test this theory a series o f quinoline derivatives were synthesised.
The commercially available starting material for the quinoline synthesis (see Scheme 26)
was quinolinecarboxaldehyde, which is obtainable as the 2-, 3 - ,  and 4-isomers. A  full set
o f  carbamate and halogen derivatives for each o f the above three isomers would
constitute 36 compounds for biological testing. This was considered excessive, therefore
it was decided to narrow down the range o f initial targets. Since the pyridine derivatives
had already determined the relative activity o f each o f the possible leaving groups, it
should only be necessary to discover how these values would be changed by the addition
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o f  a fused ring to the system. With this in mind the isopropyl- and phenyl-carbamates o f  
each quinoline isomer were chosen as representative targets.
CHO OH
139: 2-isomer 
140: 3 -isomer 
141: 4-isomer
142: 2-isomer 
143: 3-isomer 
144: 4-isomer
OCONHR
/w-CPBA/DCM
RNCO/DCM/
DBTDA
OCONHR
O ©
148: 2-isomer 
149: 3-isomer 
150: 4-isomer
145-150 
a: R=/Pr 
b: R=Ph
145: 2-isomer 
146: 3-isomer 
147: 4-isomer
Scheme 26 -  Synthetic route to quinoline derivatives.
4.3.2 Reduction
The first step in the reaction is reduction o f  the aldehyde to its alcohol. Due to the ready 
susceptibility o f  aldehydes to reduction, only a mild reducing agent was required. A  
suitable agent is sodium borohydride, which was first used in organic synthesis by 
Chaikin and Brown in the late 1940s.172 When this reagent was applied to methanolic 
solutions o f  the aldehydes 139-141, their corresponding alcohols 142-144 were produced 
readily, in excellent yield (78-93%) and with high purity.
The IR spectra o f  the alcohols showed a strong OH stretch. For each o f  the isomers the 
band produced by this stretch was broad, and occurred in the region 3140-3220 cm"1. 
This indicates that these hydrogens are participating in hydrogen bonding. None o f  the 
products showed any signs o f  contamination with starting materials in either their !H or 
13C NMR spectra, which had no peaks in the far downfield region that could be 
attributed to an aldehyde.
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Full assignment o f the NMR spectra o f nearly all o f  these compounds was made, even 
down to the long range J4 coupling constants in the quinoline ring, which were around 
1 Hz. Only for a very few compounds was the resolution o f the spectra too poor to make 
such a distinction. With the 4-substituted derivatives the protons attached to the 2- and
3-position were particularly easy to identify since their J3 coupling was, as expected, 157 
much smaller than the other J3 couplings in the compound.
4.3.3 Synthesis of carbamates and their N-oxides
The isopropyl- and phenyl-carbamates (145a+b, 146a+b and 147a+b) were synthesised 
by the same method as that previously applied to the pyridine series. In general this gave 
good yields, however many o f the reactions produced a small amount o f  an impurity. 
Although the amount o f  impurity was too small to allow its isolation and 
characterisation, the NMR spectra o f the crude products did show extra peaks which 
were derived from the isocyanate portion o f the reaction mixture. These impurities were 
easily removed by either column chromatography or crystallisation from an alcoholic 
solvent.
The carbamates were transformed into their N-oxides using w-CPBA. The workup used 
to isolate the isopropylcarbamate N-oxides (148a, 149a, 150a) was accomplished by 
flushing the reaction mixture through a short basic alumina pad and eluting with 
methanol. This removed the acidic residue from the reaction mixture, giving better yields 
than the bicarbonate wash employed for the pyridine series o f  compounds. The 
phenylcarbamates (145b, 146b and 147b) were much less soluble than their pyridine 
analogue (109), and precipitated out o f the reaction mixture, so allowing easy isolation.
As with the pyridine derivatives, these quinoline N-oxides showed similar spectra to their 
free bases, with an additional IR peak corresponding to N -0  stretching. The NMR 
spectra showed a movement o f the peaks produced by atoms in the ring system. This 
resulted in a separation of, and therefore precise identification of, the peaks in the C 
NMR spectra produced by the atoms in the carbocyclic ring. These peaks occurred at 
shifts which correlated closely with those stated in the literature.173
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4.4 Pyrazine derivatives
4.4,1 Background
With the quinoline derivatives an attempt was made to produce compounds more 
reminiscent o f  SR 4233 (53) than the pyridine derivatives, by the addition o f  a fused 
aromatic ring. Another area to investigate would be a series o f aromatic heterocycles 
which have two nitrogens in the same ring. Such a system would allow us to synthesise 
both mono- and di-A-oxides, and so determine the effect o f  both the number o f  nitrogens 
in the heterocyclic ring, and the degree o f oxidation. This was attempted using a series o f  
pyrazine based compounds shown in Scheme 27.
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Scheme 27 -  Attempted synthesis o f pyrazine derivatives.
4.4.2 Attempted synthesis
The planned route involved esterification o f pyrazine-2,3-dicarboxylic acid (151) to 
generate its diester (152), which could then be reduced to form 2,3-
79
bis(hydroxymethyl)pyrazine (153). This two step route was planned in preference to the 
direct reduction o f  pyrazine-2,3-dicarboxylic acid (151) by borane, since previous studies 
within our group had indicated that a heterocyclic ring with adjacent acid groupings 
would not survive these more drastic conditions.174 Finally the diol (153) could be 
transformed into its biscarbamate (154) and subsequently its mono- (155) and di-A-oxide 
(156)
The esterification was brought about by stirring the acid (151) in a solution o f methanol 
which had a stream o f hydrogen chloride gas passing through it. This resulted in the 
production o f  the required dimethyl pyrazine-2,3-dicarboxylate (152), which was 
identified by the usual means. Noteworthy spectroscopic changes between the starting 
material (151) and the product (152) include additional ester signals in the !H NMR and 
13C NMR spectra at 5 4.04 and 5 53.4 respectively.
Esters can be reduced by moderately powerful hydride reducing agents. In view o f  the 
sensitivity o f  the pyrazine ring, it was decided to use the mildest possible reducing agent. 
Lithium borohydride has been shown to reduce esters successfully, 175 whilst leaving 
many other functional groups untouched. When this reagent was applied to dimethyl 
pyrazine-2,3-dicarboxylate (152) using standard conditions176 with only slight 
modifications, the required product (153) was not obtained. The !H NMR spectrum o f  
the crude product showed it to be a mixture o f  ester and alcohol, but showed no peaks in 
the aromatic region, and additional peaks at 5 2.1 and 2.3. This implies partial reduction 
o f  the ester to the alcohol, with the aromatic ring being reduced to form a saturated 
product. The reaction mixture was not separated and characterised since the required 
product had obviously not been formed. Attempted use o f an alternative reducing agent, 
lithium aluminium hydride, gave similar results but with a considerably reduced reaction 
time.
The most promising system utilised DIBAL as a reducing agent. The crude product from 
this reaction showed NMR signals consistent with the desired product (153), with no 
other peaks detected. However, the product was isolated as a brown tar, which showed 
excessive streaking on TLC, consistent with polymerisation. Reducing the reaction 
temperature failed to lead to a purer product, hence this route was abandoned.
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4.5 Quinoxaline derivatives
4.5.1 Background
The final series o f analogues which were produced was based on the quinoxaline 
skeleton. This incorporates the advantages o f both a fused ring system and a ring 
containing two heteroatoms. Additionally quinoxaline mono- and di-A-oxides have lower 
reduction potentials than either pyridine A-oxides or quinoline A-oxides. 177 It was hoped 
that this series o f  compounds would provide information on the effects o f  heteroatom 
number, the degree o f  oxidation, and the reduction potential, which were not determined 
from the pyrazine series.
4.5.2 Synthesis of halides
The commercially available starting material 2,3-bis(bromomethyl)quinoxaline (157) was 
readily converted into a mixture o f its mono- and di-A-oxides by reaction with TFA in 
H2O2 solution (see Scheme 28). In the very early stages o f the reaction only the mono-A- 
oxide (158) was formed. However, isolation o f this compound was not viable, due to the 
limited degree to which the reaction had progressed. Within 1 hour, traces o f  the di-A- 
oxide (159) were detected by TLC, but it took a further AV2 hours until most o f the 
starting material had reacted, leaving a mixture o f the mono- and di-A-oxides, (158) and 
(159). The mixture was separated chromatographically, to give starting material (157) 
(5%) and an approximately 50:50 mixture o f the mono (39%) and di-A-oxides (41%), 
(158) and (159).
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Scheme 28 -  Synthetic route employed to quinoxaline derivatives.
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The bis(iodomethyl) derivative (160) was produced by the Finkelstein reaction, which 
had proven effective in the past. The starting material and product had very similar 
melting point ranges (starting material 153.7-155.4 °C, product 156.0-157.0 °C), 
however a mixed melting point confirmed the two materials to be different since it 
showed considerable melting point depression (142.0-145.2 °C). The identity o f  the 
product was further confirmed by spectroscopic techniques. Due to the small size o f  the 
samples o f  the mono and di-A-oxides, (158) and (159), no attempt was made to 
transform them into their bis(iodo) derivatives.
Transformation o f  the bis(bromomethyl) compound (157) into its bis(formate ester) 
(161), would give a compound which could then be readily hydrolysed to form the 
bis(hydroxymethyl)quinoxaline (162). Since this compound would be required for 
carbamate production, it seamed reasonable to utilise it as a means o f  producing 2,3- 
bis(chloromethyl)quinoxaline (163).
Displacement o f  the bromine from 157 was accomplished using sodium formate in a 
hexamethylphosphoramide (HMPA) solution, 178 to give the formate ester (161) in 86% 
yield after recrystallisation. This compound was characterised by its C = 0 stretch in the 
IR spectrum at 1720 and 1700 cm'1, and its and 13C NMR aldehyde signals at 6 8.24 
and 160.2, respectively.
Initial attempts to methanolyse the ester linkage, utilising the starting material itself as a 
basic catalyst, resulted in a reaction which was too slow to be o f  practical value. Hence, 
1 drop o f  concentrated ammonia solution was added to a methanolic solution o f  the ester 
(161). This rapidly brought about the required transformation in near quantitative yield 
(99%), generating a product which required no purification. The IR spectrum showed no 
C =0 stretch, but strong OH stretches at 3410 and 3236 cm*1 were observed. Similarly, 
the !H and 13C NMR spectra showed the hydroxymethyl signals, at 5 4.96 and 161.0, 
respectively.
Attempts to prepare the alcohol (162) based on direct nucleophilic displacement o f  the 
halide groupings from bis(bromomethyl) compound (157) were less successful. This was 
attempted with either acetone/water/sodium bicarbonate heated at reflux for 18 hours, or 
acetone/water/sodium hydroxide at room temperature for 30 minutes. In both cases the 
TLC and XH NMR spectra showed signs o f formation o f the required product. However,
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impurities were also present, which proved to be difficult to remove. Hence this method 
was abandoned.
Several methods were utilised in an attempt to transform the alcohol (162) into its 
bis(chloromethyl) derivative (163), including thionyl chloride, PPhs/CCU and 
CHCh/benzyltriethylammonium chloride/50% sodium hydroxide solution. The first 
method employed used thionyl chloride. This was the least successful o f  the three 
methods attempted, with only a black tar being isolated, which showed no signs o f  the 
required product. The second method, which used PPhs/CCU, appeared to be slightly 
more successful, but gave poor yields (<5%), did not go to completion, and generated 
several impurities as well as a compound which showed NMR signals consistent with 
the required product. Only when the phase transfer method was employed, was a 
practical, but still low (33%), crude yield achieved. However, two products (probably 
resulting from mono- and bis-chlorination) were produced, and some unreacted starting 
material remained. Since 2,3-bis(chloromethyl)quinoxaline (163) could not be readily 
produced in acceptable yield and purity, synthesis o f  this compound was abandoned.
4.5.3 Synthesis of carbamates and their N-oxides
As 2,3-bis(hydroxymethyl)quinoxaline (162) had already been formed it was a relatively 
simple matter to convert it into its carbamate derivatives (164a+b), by the previously 
documented procedures. These carbamates were fully characterised before being 
transformed into their mono- (165a+b) and di-A-oxides (166a+b) using w-CPBA, to 
give the required products in moderate to good yield. The difficulty in obtaining a 50:50 
mixture o f  the mono- and di-A-oxide products (165a+b and 166a+b) in the reaction 
mixture prior to workup, was seen for both carbamate derivatives. These showed a 
predominance o f  the mono-A-oxides (165a+b) over their di-A-oxide counterparts 
(166a+b). The mono-A-oxides (165a+b) have different properties from the di-A-oxides 
(166a+b) which allowed easy separation and characterisation. Such properties include 
the reduced R f values o f  the di-A-oxides (166a+b), and their greater symmetry, which 
considerably simplifies their NMR spectra when compared to their mono-A-oxide 
counterparts (165a+b).
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5. S yn th esis  of B en zen e  a n d  
T h io phene  De r iva tives
5.1 Mono-bioreducible agents
5.1.1 Background
Previous studies on 3-nitrothiophene-5-carboxamides56 have shown that these 
compounds have some selective toxicity towards hypoxic cells. The small selectivity that 
these drugs express could be solely due to the toxic species which are directly associated 
with nitro group reduction (e.g. nitroso free radicals and the hydroxylamine), and not 
due to the influence that a newly formed amine group would have on any side chain 
present in these compounds. Such a theory is based on the assumption that the side 
chains act as too poor leaving groups to be labile even after the drug has been reduced.
With this in mind, and the previously shown selectivity which these systems have 
exhibited to nitro group reduction, it was decided to investigate two series o f  derivatives 
which incorporated carbamate functionality in their pendant arms. These compounds are 
susceptible to alkylation at the carbon next to the aromatic moiety.
An outline o f the synthetic steps utilised to generate the target compounds is shown in 
Scheme 29. All the steps outlined were well proven and reliable, having given products 
with high yields and purities when utilised with other starting materials.
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Scheme 29 -  Synthetic route to benzene- and thiophene-containing carbamates.
5.1.2 Synthesis of benzyl alcohol derivatives
Due to the greater stability o f a carbocyclic aromatic compound over a compound which
incorporates a thiophene ring, initial studies were conducted on the
dimethoxybenzaldehydes (167) and (168). Reduction o f the benzaldehyde which does
not contain a nitro group (167) with sodium borohydride in methanol gave the required
alcohol (169) as an oil (95% yield) which required no purification. The nitro derivative
(168) proved to be more resistant to reduction, with some starting material remaining
even after employing the above reaction conditions for an extended period o f time. To
bring about complete reduction, the aldehyde was treated with sodium borohydride in a
solution o f ethanol at 75 °C for lV6 h. This extended reaction time and elevated
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temperature led to the formation o f several impurities, some o f  which may have 
contained reduced nitro species. These impurities were readily removed by 
crystallisation, to give the required product (170) in 67% yield.
Neither o f  the alcohols generated (169 and 170) showed signs o f  contamination with 
starting material, or other impurities in any o f their spectra. They did however show 
signals consistent with a compound containing a methylene alcohol such as: NMR
signals at 5 3.52 (OH, 169), 4.41 (CH2, 169) and 4.79 (CH2, 170); 13C NMR signals at 
8  64.3 (CH2, 169) and 60.4 (CH2, 170); and IR signals at 3840 and 3440 cm ' 1 (OH, 
170), 1365 and 1265 cm' 1 (OH, 170) and 3498 cm' 1 (OH, 169). Evidence that the nitro 
group in 168 was not reduced during the transformation into 170 was obtained from the
1 13 •H and C NMR spectra o f the product, which showed relatively small changes in 
chemical shifts in the aromatic region o f  the spectra. A large change in the shifts would 
be expected if an amino group had been formed resulting in a greatly altered electron 
distribution within the ring. Furthermore, the IR spectrum showed the presence o f  a nitro 
group which absorbed at 1320 cm' 1 in the reduced product (170).
Formation o f the isopropylcarbamates, (171a) and (172a), was carried out using a 
standard procedure. However, although the nitrobenzyl alcohol (170) gave its 
isopropylcarbamate (172a) cleanly, reaction o f the non-nitro derivative (169) with 
isopropyl isocyanate gave two products. Since only one spot was visible on TLC it is 
reasonable to assume that one o f the two compounds was either not readily visualised, or 
that the R f values o f  the two products are similar. The ]H NMR spectrum o f  the mixture 
showed an additional set o f doublets corresponding to an isopropyl group. Otherwise, 
the spectrum showed only peaks associated with the required product. From this it can 
be assumed that the impurity is derived from the isopropyl isocyanate, and may be the 
isopropylcarbamic acid. This impurity was not isolated, since the best means o f  purifying 
the reaction mixture was crystallisation from methanol. This gave the required carbamate 
(171a), which showed high purity by microanalysis and spectroscopic means.
Synthesis o f the phenylcarbamates (171b and 172b) o f  the benzyl alcohols (169 and 
170), also gave impurities. The product mixtures obtained from these reactions were 
purified by crystallisation. Care had to be taken when crystallising 172b to ensure that 
crystals formed, and not a powder. To this end a slow recrystallisation from a three 
solvent system was effectively employed.
87
5.1.3 Synthesis of thiophene derivatives
Both the non-nitro thiophene aldehyde (173) and nitrothiophene aldehyde (174), were 
very sensitive to heat during the reduction process and associated workup. Degradation 
o f  the reaction mixture to a brown tar occurred if the temperature o f  the system 
exceeded 0 °C. For this reason the reduction was performed whilst external cooling was 
applied via an ice/salt bath. During the workup diethyl ether was used to extract the 
product from the aqueous mixture. This was then evaporated at room temperature to 
reduce further any impurity formation. Diethyl ether was chosen as the extraction solvent 
since it is more readily evaporated at lower temperatures than ethyl acetate. Even taking 
these precautions, some impurities did form. The crude samples o f  both alcohols, (175) 
and (176), required purification by distillation to remove the brown impurities which 
were produced during their formation. To minimise the amount o f  product degradation 
which occurred during the distillation, and so reduce further impurity formation, this 
operation was carried out at the lowest possible pressure and temperature.
The care taken to minimise impurity formation led to a good yield (85%) o f the non- 
nitro alcohol (175). However, the more electrophilic nitrothiophene system was so 
unstable that even when great care was taken to minimise adverse reactions, only a 41% 
yield o f  the product (176) was isolated after distillation. Analysis o f  both products 
showed no signs o f any remaining unreacted aldehyde, either in the lowfield region o f the 
*H or 13C NMR spectra, or by C =0 stretching in the IR spectrum. Additionally, signals 
were detected, in all o f the spectra, which were consistent with the required 
transformation having occurred. Several IR absorptions were observed which can be 
attributed to stretching o f the thiophene ring system. Assignment o f  these absorbancies 
was made with reference to the literature, 179 and are detailed in Figure 30.
Transformation o f  the alcohols (175 and 176) formed into their isopropylcarbamates, 
(177a and 178a), by the usual means, gave products which contained small amounts o f  
several impurities. These impurities were removed by crystallisation from methanol to 
give the pure products (177a and 178a). A factor which might have caused problems 
was the low melting point o f the non-nitro thiophene carbamate (177a). This was below 
the boiling point o f the methanol used to crystallise it and could have resulted in the 
oiling out o f  the carbamate (177a) during recrystallisation. However, when care was 
taken during crystallisation this did not occur and a crystalline product was isolated.
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Wavenumbers o f the various IR absorbancies o f  a 2-substituted thiophene (cm'1). 
*Bands not identified but their positions were approximated from other data.
Figure 30 -  Interpretation o f thiophene IR absorbancies (from lit.179).
The phenylcarbamates (177b and 178b) were also produced by the usual means. As with 
the isopropylcarbamates (177a and 178a) small amounts o f impurities were formed. Due 
to the highly absorbent nature o f the benzene ring to UV light, these impurities were 
much more readily visualised by TLC than the impurities produced during the formation 
o f  the isopropylcarbamates (177a and 178a). This allowed purification to be carried out 
by chromatographic methods.
5.1.4 Synthesis of amino derivatives
In the series o f heterocyclic A-oxides previously produced, the reduced form o f  the drug 
was also synthesised, so that its biological activity could be compared with that o f its 
respective prodrug under hypoxic conditions. From this data it was hoped that it would
be possible to determine whether reduction o f  the N-oxide occurred under hypoxic 
conditions. Within the nitroaromatic series o f compounds synthesised, we produced the 
nitroaromatic prodrugs, and controls which have no nitro grouping but are otherwise 
similar. Although the biological testing o f these compounds should give us enough data 
to determine whether the prodrugs operate as hypoxia selective drugs, without a variant 
o f  the activated prodrug to test, it would not be possible to say that any selective toxicity 
observed arose via formation o f  the aminoaromatic drug. To give a fuller picture o f the 
method by which the nitroaromatic prodrugs previously synthesised exert their toxicity, it 
was decided to attempt a synthesis o f the amino variant o f each prodrug.
Since the aminoaromatics that would be required for this synthesis were not readily 
available it was decided to attempt to synthesise them by reduction o f their nitro 
derivatives. However, the stability o f the carbamate linkage to reduction limits the scope 
o f  this method and in many cases reduction o f the nitroaromatic prior to carbamate 
linkage was the preferred route. Ail those methods attempted are shown in Scheme 30.
Initially experiments were based on modifying the nitrothiophene pathway (Scheme 29—  
compounds 174 -»  176 —> 178), with reduction o f the nitro group attempted at both the 
alcohol and carbamate stages. The Zinin reduction has been shown to be a highly 
selective method o f reducing aromatic nitro compounds to their respective amino 
derivatives utilising sulfide as the reducing agent. A comprehensive review180 gave 
examples o f  several successful reactions on compounds which had similar functionality to 
the starting material, 5-hydroxymethyl-2-nitrothiophene (176), and detailed several 
possible methods by which the reduction could be carried out. When one o f  these 
processes was attempted on 5-hydroxymethyl-2-nitrothiophene (176) only baseline 
material was isolated as a black tar. Since this tar was not readily soluble it could not be 
easily purified or identified. This method was abandoned.
90
OH
176
"mT6 h /h " 6 .......
Raney Nickel/ 
MeOH
H?N
OH
Raney Nickel/ 
OCONH MeOH"...........
Ammonium Formate/ 
MeOH/5%"Pd/C *
(NH2)2/Graphite/ 
MeOH.........................*
X
S.M.
S.M.
OCH OCH
OCH OCH
5% Pd/C/H2/
MeOH
OHOH
180170
OCH
OCH
5% Pd/C/H2/
MeOH
OCONH
172a
X
Scheme 30 -  Attempted formation o f aminoaromatic compounds.
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Alternative methods o f amine formation include catalytic reduction. Since platinum 
catalysed reduction frequently requires elevated pressures, the more active catalyst 
Raney nickel was employed. This catalyst was freshly prepared using standard 
methods181 prior to the reaction so as to ensure maximum catalytic activity. When this 
reaction was attempted on 5-hydroxymethyl-2-nitrothiophene (176) a brown oil was 
isolated. This oil showed only one compound by TLC which was more polar than the 
starting material. However, this product could not be purified since it could only be 
removed from a silica column by flushing through with methanol, and it decomposed 
when distillation was attempted. The crude product gave a NMR spectrum which was 
consistent with formation o f  the reduced product (179). The peaks associated with 
resonance o f the ring protons were both moved downfield, from 5 6.82 (4-H) and 7.63 
(3-H), to 5 6.7 (4-H) and 6.1 (3-H). This change in chemical shift, between the reduced 
and non-reduced forms o f the compound, is particularly large due to the close proximity 
o f  the adjacent nitrogen containing group which has undergone a change from strongly 
electron withdrawing to strongly electron donating.
Since difficulties were encountered in handling the product o f this reduction, it was 
decided to try the Raney nickel reduction on the carbamate (178a) rather than the 
alcohol (176). The compound so generated should be crystalline and so more readily 
purified. When Raney nickel reduction o f the carbamate (178a) was attempted, complete 
decomposition o f  the starting material occurred within 30 minutes with no isolatable 
products being formed.
Other methods o f  reduction which were attempted included catalytic reduction using 
ammonium formate as a hydrogen transfer reagent. This method has been shown to be 
effective in reducing both nitroaromatic and nitroaliphatic compounds to their amino
• 1 S'} •
derivatives, when catalytic methods using hydrogen gas have failed. When this process 
was attempted on 5-hydroxymethyl-2-nitrothiophene isopropylcarbamate (178a), no 
reaction was observed even after 24 hours with the reaction yielding only starting 
material. An alternative system used in transfer hydrogenation, with nitroaromatic 
compounds, uses a graphite catalyst and hydrazine hydrate as a hydrogen source. When 
used together these reagents were reported to operate as a selective reduction system, 
giving quantitative yields within two hours.183 However, when applied to 5-
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hydroxymethyl-2-nitrothiophene isopropylcarbamate (178a), only starting material, 
contaminated with some impurities, was isolated.
Palladium catalysed reduction on the nitrobenzyl alcohol (170) gave interesting results, 
with the product initially being isolated as a colourless solid, which turned black within 
seconds on standing. A rapid NMR analysis o f the product showed that the ring 
protons had shifted their resonant frequency from 5 7.16 (6 -H) and 7.57 (3-H) to 5 6.5 
(6 -H) and 6.2 (3-H). These results were consistent with the required product (180) being 
formed, but due to the product’s instability further characterisation was not possible. The 
instability o f  the product (180) is not surprising given that the aromatic ring in this 
compound contains three strongly electron donating groups and a benzylic hydroxyl 
group which under these conditions has the potential to act as a leaving group.
When palladium catalysed reduction was attempted on 5-hydroxymethyl-l,2-dimethoxy-
4-nitrobenzene isopropylcarbamate (172a) in an attempt to produce a more stable and 
easily purified compound, four products and some baseline material were produced. 
Since the four products appeared to be generated in roughly equal amounts, no attempt 
was made to separate them and determine whether the required aniline derivative had 
been formed.
The poor stability o f  aminothiophenes has been well documented.184 However, they have 
been reported to be stable when in the form o f their stannic chloride salts. The formation 
o f this salt can be carried out concurrently with nitro group reduction, so avoiding any 
degradation o f  the product.185 However, this process was not attempted, since it would 
not be possible to determine whether any toxicity which these compounds expressed was 
due to the nitrothiophene, or the presence o f the stannic chloride. Due to the difficulty in 
synthesising the reduced nitroaromatics and nitrothiophenes in a stable form this reaction 
route was abandoned.
5.2 Bis-bioreducible agents
5.2.1 Background
Previous work on bioreducible compounds has shown the advantages o f having 
complementary functionality, that is one part o f the molecule undergoing reduction
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which in turn facilitates a toxic event in another part o f the molecule. Extending this 
theory we could include two such complementary pairings within one molecule. Thus if 
the probability o f  reduction o f  one o f the functional groups in a hypoxic cell is six times 
greater than that o f  reduction in an oxic cell, it follows that the probability o f  reduction 
o f  both groups independently in a hypoxic cell is 36 times that o f  reduction in an oxic 
cell. However, if the two toxic events both involve alkylation o f DNA then they cannot 
be treated as being completely separate, since the first event will fix the molecule to the 
D N A  so ensuring that the second functionality is in close vicinity to the DNA. This 
should result in the second binding event being a more rapid procedure.
5.2,2 Retrosynthesis to fused thiophenes
Using the above reasoning a series o f  compounds, based on dimeric versions o f  the 
nitrothiophenes which had previously been synthesised, were prepared. The target 
compound (181) had to be designed in such a way as to ensure that reduction o f any one 
o f  the nitro groups did not facilitate activation o f both pendant arms. This dictated the 
relative position o f  the ring fusion to the nitro group on each thiophene as being 2,4. 
Other substitution patterns such as the more readily synthesised 2,5-compound (182) 
would allow activation o f both arms with reduction o f either nitro group. Even when the 
leaving groups are placed so as to avoid this phenomenon, as with compound 183, the 
reduction o f one nitro group will effect the reduction potential o f the second group (see 
Figure 31).
NO
181
> N = 0
182 0 ©
>N==0
183
O©
Figure 31 -  Fused thiophene ring systems.
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The leaving groups in a compound such as 181 could be carbamates or halides. These 
groups could be formed in the usual way from a diol (184). Applying retrosynthetic 
methodology to this compound gives the dialdehyde (185) as a suitable starting material 
(see Scheme 31). Generation o f  this dialdehyde could best be afforded in two steps via a 
bis(dichloromethyl) derivative (186), which could be formed from the fused 
bis(nitrothiophene) (187). A similar two step methodology has been shown to be 
successful in adding a formate group to 2-nitrothiophene (192). This generated the 3- 
formylated derivative in 74% yield.186
An alternative synthetic approach is to generate the fused 3,3-bithiophene (188), by 
connecting two 3-bromothiophene (189) units. This approach is desirable since it would 
result in production o f the fused thiophene (188), a known compound which can be 
synthesised by a well documented procedure.187 However it is also known that nitration 
o f  this compound gives a mixture o f isomers, none o f which is that required. 188
The desired substitution pattern cannot be guaranteed unless it is in place prior to the 
ring fusion. This would require the synthesis o f 3-bromo-5-nitrothiophene (190). This is 
a documented compound, however its synthesis from the expensive dibromothiophene
(191) is low yielding. 189 Hence an alternative route to this compound was sought.
Initial attempts at forming 3-bromo-5-nitrothiophene (190) relied on the bromination o f  
2-nitrothiophene (192). It was hoped that the 2,5-directing effect o f the sulfur in the ring 
would be outweighed by the strongly we/a-directing nitro group, so leading to 
regioselective substitution. When this was attempted on 2-nitrothiophene (192) using 
molecular bromine and an iron trichloride catalyst, a mixture o f three products was 
formed. Although these were not separated, the ]H NMR spectrum o f the crude product 
was consistent with the formation o f  a mixture o f the two disubstituted nitrothiophenes, 
2,3-dibromo-5-nitrothiophene (191) and 3,4-dibromo-5-nitrothiophene (193), as well as 
the required 3-bromo-5-nitrothiophene (190). These results are consistent with initial 
formation o f  the required product early on in the reaction. However, due to the similar 
reactivity o f 3-bromo-5-nitrothiophene (190) compared to 2-nitrothiophene (192), the 
newly formed 3-bromo-5-nitrothiophene (190) reacted readily with bromine at either o f  
its remaining unsubstituted positions, to generate a mixture o f  dibrominated products.
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Scheme 31 -  Retrosynthetic analysis o f a possible route to the fused thiophene (181).
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In an attempt to reduce the amount o f dibromination, the same reaction was carried out 
but in a dilute solution o f  dichloromethane (see Scheme 32). This reaction was stopped 
before completion and the products were carefully separated to yield sufficient material
showed the main product to be 2,3-dibromo-5-nitrothiophene (191). 3,4-Dibromo-5- 
nitrothiophene (193) was also isolated in a slightly lower yield, as well as small amounts 
o f  the required 3-bromo-5-nitrothiophene (190) and the previously undetected 2-bromo-
5-nitrothiophene (194). A small amount o f unreacted starting material was also 
recovered. Because separation o f the product mixture could only be accomplished by 
preparative TLC, the method outlined above was not considered to be a viable route for 
formation o f  the large amounts o f 3-bromo-5-nitrothiophene (190) which would be 
required for a multi-stage synthesis.
to carry out a tentative identification o f each fraction using NMR spectroscopy. This
191
+
193
FeCl3/Br/DCM
190
+
194
Scheme 32 -  Bromination products o f  2-nitrothiophene (192).
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Pervious studies on 2-nitrothiophene are consistent with the above result, 190 with 
electrophilic aromatic substitution leading primarily to 4-substitution in preference to 3- 
substitution. Furthermore, the same study reported that if bromination o f 2- 
thiophenecarboxaldehyde was carried out in the presence o f aluminium trichloride, only
4-nitro-2-thiophenecarboxaldehyde was isolated in an excellent yield. The high 
regioselectivity that this reaction exhibited was thought to derive from interactions 
between the Lewis acid and the aldehyde carbonyl. This generated a more electron 
deficient aldehyde and so enhanced its weta-directing effects. When a similar procedure 
was attempted using 2-nitrothiophene (192) a mixture o f 2,3-dibromo-5-nitrothiophene
(191), 3,4 -dibromo-5-nitrothiophene (193), and 2-bromo-5-nitrothiophene (194) was 
isolated in a poor yield. Carrying out the reaction using either glacial acetic acid, or 
chloroform did not increase the selectivity o f this reaction, and both reaction systems left 
a considerable amount o f  starting material, even after an extended reaction time.
The brominating agent N-bromosuccinimide was also utilised in an attempt to bring 
about the required transformation. However, as with the methods previously employed, 
this led to the formation o f several products well before the reaction had gone to 
completion. Given the difficulty which was encountered in brominating 2-nitrothiophene
(192), and the problem o f producing significant amounts o f 3-bromo-5-nitrothiophene 
(190) by the literature proceedure, 189 this route was abandoned.
An alternative route to the required alcohol (184) was devised from readily available 
starting materials and is shown in Scheme 33. The first step in this synthesis is the 
Knoevenagel condensation between two moles o f ethyl cyanoacetate (195) and one mole 
o f  2,3-butanedione (196), to give a conjugated diester (197). It should then be possible 
to generate the thiophene rings by closing the adduct formed (197) using the Gewald 
thiophene synthesis. 191 Ester reduction o f this bisthiophene (198) could then be carried 
out using lithium borohydride175 to give a diol (199). Oxidation o f the diamine using 
standard peracid conditions192 should then give the target compound (184), which could 
be converted into several different derivatives.
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Scheme 33 -  Proposed synthetic pathway to the thiophene dimer (184).
The first step in the planned synthetic route was a Knoevenagel condensation reaction 
between two molecules o f ethyl cyanoacetate (195) and one molecule o f  2,3-butanedione 
(196), to form the required conjugated species (197). This reaction was initially 
attempted in an ethanolic solution with a catalytic amount o f piperidine. However, even 
after heating this mixture at reflux, a lot o f starting material remained. Although 
aldehydes will undergo Knoevenagel reactions readily under the above reaction 
conditions, ketones are considerably less reactive and frequently require more forcing 
conditions. One means o f  enhancing the reactivity o f ketones in Knoevenagel reactions is 
by using a strong Lewis acid. Experiments have shown that titanium tetrachloride can 
perform this role, leading to the successful reaction o f ketones at room temperature or
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below .193 When this method was applied to the above starting materials, a brown liquid 
was formed. The !H NMR spectrum of this liquid was consistent with the formation o f  a
mono-adduct (2 0 0 ), such as that shown in Scheme 34. Since the mixture formed had 
impurities which could not be readily removed the products o f this reaction were not 
fully characterised. The required bis(Knoevenagel) product was not detected, even when 
the reaction was continued for much longer than suggested in the literature. Extended 
reaction time only lead to a greater amount o f impurities being formed, so this route was 
abandoned.
195 195
O
TiCl/THF/DCM/ 
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200
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Scheme 34 -  Products generated after first Knoevenagel reaction.
6. S y n th e s is  of Co m p o u n d s  fo r
ADEPT
6.1 Specifier and spacer subunits
6.1.1 Background
A glutamate fragment was chosen as a suitable specifier for the ADEPT system, due to 
the availability o f a suitable antibody-enzyme conjugate capable o f breaking amide bonds 
adjacent to glutamate.144 It was intended to link this glutamate through an aromatic 
spacer group to the required drug, so as to allow the antibody to act on the specifier unit 
without steric restrictions caused by the drug portion o f the molecule. 154 To produce a 
better compound for ADEPT than had been synthesised previously, the above system 
would need to be combined with an inactive prodrug that would release a highly active 
free drug.144 Such a situation would arise if hydrolysis o f the glutamate resulted in release 
o f  a free electron pair which could assist in drug activation, or further breakdown o f  the 
compound.
Applying these criteria resulted in the proposed design (201) shown in Scheme 35. This 
required a urea linkage between the glutamate specifier and the aromatic spacer. Upon 
cleavage o f  the glutamic acid (202 ), electrons should be donated from the resulting 
carbamate (203) to assist in cleavage o f the drug. To permit fragmentation o f  the drug 
and spacer subunits it was planned to connected them via a carbamate linkage. Such a 
compound would release two moles o f carbon dioxide per mole o f prodrug broken 
down. This would result in a large entropy gain in the system and so should facilitate 
breakdown. The breakdown products would then be the aromatic spacer section (204) 
(which might itself be toxic) and the final drug which would have an electron rich amine 
group on it. Should a mustard be chosen as the active agent, this could result in a highly 
toxic drug being released.
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Scheme 35 -  ADEPT synthetic target (2 0 1 ) and a proposed method for its breakdown.
6.1.2 Retro-synthetic analysis
The apparent disconnection points in the planned compound (2 0 1 ) are at the urea linkage 
with the glutamate portion and at the carbonate linkage with the drug. A general 
methodology was sought which could be utilised to produce either the urea linkage 
between the spacer and specifier subunits, or the carbamate linkage between the spacer 
and drug subunits. One possible method o f doing this is outlined in Scheme 36 and 
requires reaction between either a chloroformamide (205), or isocyanate (206) and a 
nucleophile. Carrying out such a reaction using an alcohol as the nucleophile would 
result in production o f  a carbamate (207), whilst use o f an amine as the nucleophile 
would give a urea (208).
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Scheme 36 -  Formation o f a carbamate (207) or urea (208) from the same starting
material.
Applying these principles to the retrosynthetic analysis o f the target (201) would give a 
drug fragment, a spacer fragment (209) and glutamic acid (20 2 ) (see Scheme 37).
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Scheme 37 -  Retrosynthetic analysis o f the target (201).
6.1,3 Synthesis of the specifier section
One possible synthesis o f the protected glutamic acid is given in Scheme 38. This 
synthesis was attempted with W-benzyloxycarbonyl-L-glutamic (210) as the starting 
material, which was protected to give its ditertiarybutyl ester (2 1 1 ). Carrying out this
concentrated sulfuric acid as a catalyst) gave variable yields. Investigation revealed the 
yield, concentration o f  sulfuric acid and reaction time to be closely linked. When a 
relatively large volume o f concentrated sulfuric acid (0.3 ml) was used, the reaction 
occurred within four days, but a large amount o f poly(isobutylene) was formed. Due to 
the high molecular weight and polarity o f  the product, attempted distillation o f the crude 
mixture was unsuccessful, hence chromatographic purification was employed to give the 
diester (211) in 62% yield. Reducing the volume o f concentrated sulfuric acid to four 
drops, decreased the amount o f  polymeric impurities and increased the purified yield to 
92%. The only penalty was a considerably longer reaction time (15 days).
showed the presence o f  two tertiarybutyl groups in magnetically distinct environments. 
Further evidence to support the structure o f the product come from the accurate mass 
spectrum which detected the protonated molecular ion. The lack o f  starting material was 
supported by the absence o f  OH stretching and bending modes in the IR spectrum as
reaction using standard procedures194 (a closed system containing isobutylene and using
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Scheme 38 -  Synthesis o f the protected glutamic acid (2 1 2 ).
The diester (211) was identified by its }H and 13C NMR spectra, both o f  which showed 
strong signals associated with the tertiary butyl group. The JH NMR integrals were 
consistent with formation o f  a diester, and the 13C NMR spectrum gave signals which
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well as the absence o f  any signals attributable to the starting material in either o f  the 
NM R spectra. Further confirmation for formation o f  the required product was gained 
from accurate microanalytical data.
Removal o f  the benzyloxycarbonyl (Cbz) protecting group from 211 was attempted 
using the well proven method o f  hydrogenolysis.195 Use o f  a palladium on carbon 
catalyst in a methanolic solution o f  the protected amine (21 1 ) under a hydrogen 
atmosphere, resulted in generation o f the free amine (212). After chromatographic 
purification the isolated yield was poor (37%), hence the procedure was modified by 
changing the solvent from methanol to ethanol. This significantly increased the amount o f  
crude product isolated and reduced impurity formation. These impurities were removed 
by distillation to give the free amine (212) as a colourless oil (58%). Confirmation that 
the product had undergone hydrogenolysis came from the !H and 13C NMR spectra, both 
o f  which showed no downfield signals which could be associated with an aromatic 
functionality. Similarly, the signals associated with the aromatic ring in the IR spectrum 
o f 211, such as ArH stretching and aromatic ring modes, were also absent.
6.1.4 Attempted synthesis of the amine spacer section
Synthesis o f  the spacer section o f the compound was attempted using 4-aminobenzyl 
alcohol (180) as the starting material (see Scheme 39). To permit linkage o f  the 
previously synthesised glutamate fragment (2 1 2 ) it was necessary to leave only one 
nucleophilic group on the spacer section. Selective protection o f  alcohols in the presence 
o f  amines can be readily accomplished using silyl protecting groups.196 Since this 
protecting group would have to survive basic conditions later in the reaction scheme, the 
more readily cleaved silyl ethers, such as trimethylsilyl, were discounted due to their 
instability under such conditions.197 Attempted generation o f  the more stable 
triisopropylsilyl (TIPS) ether (213) using TIPS triflate and lutidine, 198 gave a mixture o f  
at least seven products which could not be readily separated. Hence an alternative 
tertiarybutyldimethylsilyl (TBDMS) ether was prepared using standard conditions.199 
This was accomplished by treating 4-aminobenzyl alcohol (209) with TBDMSC1 and 
imidazole in a solution o f  distilled dichloromethane. The crude product o f  this reaction 
was purified by distillation to give the protected spacer (214) in excellent yield (94%) 
and with a high purity. Interesting spectroscopic features observed in the and 13C 
NMR spectra o f  this product include the highfield shift exhibited by the methyl group
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directly attached to silicon. As expected these peaks are located close to 5 0. 
Additionally a S i-0  stretch was clearly observed in the product’s IR spectrum. This 
helped to confirm that silylation had occurred at the alcohol and not the amine. Further 
evidence for the location o f  silylation came from the chemical shifts o f  the aromatic ring 
protons. These occur in the region that would be expected for a 4-substituted aniline 
compound.
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Scheme 39 -  Synthesis o f  the protected spacer section (214).
6.1.5 Coupling of the specifier and spacer sections
It should then have been possible to couple these two fragments via an activated species. 
Such species are generally prepared from an amine (215) and phosgene (216) by the 
route shown in Scheme 40.200 This initially forms a chloroformamide (217) and an amine 
hydrochloride salt (218). Upon heating the chloroformamide (217) to -5 0  °C, it expels 
hydrogen chloride to give the isocyanate (219). Use o f  this procedure is limited by the 
high temperature (-100  °C) required to transform the amine hydrochloride (218) into its 
isocyanate (219). If thionyl chloride (220) is added to the reaction mixture it results in 
formation o f  a N-sulfinylamine (221) and the amine hydrochloride (218). However, 
transformation o f  the amine hydrochloride (218) into its /V-sulfinylamine (221) can be 
accomplished at room temperature. Finally, transformation o f  the /V-sulfinylamine (221)
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into its isocyanate (219) is accomplished using phosgene (216). This procedure has the 
advantage o f  not requiring high temperatures. However, it still suffers from the 
requirement to use highly toxic phosgene gas (216).
2  RNH2 + COCl2 -------- —  ► RNHCOC1 + RNH2 . HC1
215 216 217 218
—
50 °C
100 °C —►
RNHCOC1----------------------- ------- ----------------- ► RNCO + HC1
217 219
RNH2 .HC1 + COCl2  -► RNCO + 3 HC1
218 216 219
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215 220 221 218
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Scheme 40 -  Isocyanate formation from amides.
The use o f  phosgene can be avoided altogether by utilising triphosgene, 
bis(trichloromethyl)carbonate (222). This phosgene substitute has been successfully 
employed to transform amines into isocyanates in high yield.201 Modifying this procedure 
by adding a large excess o f  triethylamine to the mixture should result in removal o f  the 
HC1 produced as triethylamine hydrochloride. This should eliminate the need, which 
would otherwise be required, to use high temperatures to convert the amine 
hydrochloride (218) into its chloroformamide (217).
The chloroformamide and subsequently its isocyanate could theoretically be generated 
from either the spacer (214) or the protected glutamate (212), since they both possess a 
free amine. One o f  the methods which was employed in an attempt to join these two 
compounds is shown in Scheme 41.
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Scheme 41 -  Attempted coupling o f  an activated glutamate with the protected spacer
(214).
Initially formation o f  the chloroformamide (223) and/or isocyanate (224) o f  the 
glutamate fragment was attempted. When the TLC indicated complete removal o f  the 
starting material, forming only one visible product after staining, the protected spacer 
unit (214) was added. N o attempts to isolate this product were made and it was reacted 
in situ in an attempt to form the coupled product (225) in a one pot reaction. However, 
even after several days o f  heating at reflux, most o f  the active species remained
108
unreacted. The only products detected were traces o f  several impurities. One noteworthy 
point was that even after this extensive period o f  heating at reflux, the product from the 
reaction between the protected spacer group (214) and triphosgene (222) did not 
decompose or change its structure. Since chloroformamides break down readily on 
heating to form their isocyanates, it can be assumed that the activated species was 
already in the form o f  the isocyanate when the protected glutamic acid (2 1 2 ) was added. 
Attempting the coupling starting with the isocyanate (226) o f  the spacer unit (214) and 
then adding the protected glutamate (212) (see Scheme 42) gave similar results.
OTBDMS
DCM/Triphosgene/NEt3 
 ►
OTBDMS
N.
226
OTBDMS
NHHN
225
Scheme 42 -  Attempted coupling o f  the activated spacer (226) with the glutamate (2 1 2 ).
The much harsher approach o f  forming a lithiated amine (227) and adding this to the 
isocyanate o f  the spacer unit (226) was also unsuccessful, since the lithiated amine (227) 
spontaneously decomposed even at -78° C. One o f  the many reactions occurring may
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have been displacement o f  one o f the ester groupings by the nitrogen centred anion, with 
the resulting formation o f  a lactam (228) (see Scheme 43).
€ 0 2*Bu BuLi/DCM
Scheme 43 -  Possible decomposition route o f  the lithiated amine (227).
Two possible reasons to explain the failure o f  the coupling between the spacer (214) and 
the glutamate (212) portions were considered. Firstly, both the aromatic nitrogen o f  the 
spacer unit (214) and the amine o f  the glutamate section (212) are relatively poor 
nucleophiles. Secondly, the bulky tertiarybutyl protecting group on the glutamate 
fragment (2 1 2 ) may lead to steric hindrance and reduce the probability o f  the two 
fragments coming close enough together to react. In an attempt to test this hypothesis a 
coupling between diethylamine (229) and the isocyanate o f  the protected spacer (226) 
was attempted. This successfully gave the product (230) shown in Scheme 44, without 
using forcing conditions. The formation o f a urea (230) can be clearly observed in the 
13C NMR spectrum which gives a signal at 5 165.2, consistent with a carbonyl carbon in 
a urea. Furthermore, the IR spectrum shows a carbonyl stretch at 1740 cm'1. This 
combined with an accurate mass measurement provided sufficient data to confirm that 
the coupling o f  the protected spacer (226) with diethylamine (229) had occurred 
successfully.
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Scheme 44 -  Formation o f  a diethylcarbamate (230)
This reaction proved the viability o f  joining the activated spacer (226) and an amine to 
form a urea. The diethylamine (229) used was both less sterically bulky and more 
nucleophilic than the tertiarybutyl protected glutamic acid (212). The most readily 
alterable o f  these characteristics possessed by the protected glutamic acid (2 1 2 ) is its 
steric bulk, which could be considerably reduced by using an alternative protecting 
group. A  phenyl ester was considered as a suitable alternative since it is less sterically 
bulky than the tertiarybutyl group and proven methods exist for its formation and 
removal from amino acids.202
Esterification o f  the Cbz-protected glutamic acid (210 ), was carried out successfully in a 
solution o f  dichloromethane using the coupling agent dicyclohexylcarbodiimide (DCC) 
(231). This coupling agent initially reacts with the carboxylic acid (210) to form a 
reactive intermediate (232) which is shown in Scheme 45. This is susceptible to attack by 
phenol (233) to give dicyclohexylurea (DCU) (234), and the monoester (235). Further 
esterification then gives the required diester (236). Using this methodology gave 
complete esterification when a slight excess o f the coupling agent was used. However, 
although the DCU (234) formed was easily removed by filtration, the highly soluble DCC 
(231) could not be separated from the products. In an attempt to convert all o f  the DCC 
(231) into DCU (234) excess acetic acid and methanol were added to the reaction 
mixture after the required coupling was complete. Despite this precaution, some DCC 
(234) remained after workup. This was evident from the NMR spectrum which 
showed a broad section o f  peaks centred on 5 1.5. Removal o f  the DCC (231) was 
successfully accomplished by chromatography to give a compound (236) which showed
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ester carbonyl stretching as well as stretching associated with the carbamate carbonyl 
(1784, 1774, 1756 and 1700 cm'1). Similar evidence was seen in the C -0  stretching 
frequency range which showed stretches associated with both the ester and carbamate 
groupings. After the structure o f  the protected glutamic acid (236) was further confirmed 
by accurate mass spectroscopy and microanalysis, a sample o f  it was deprotected (see 
Scheme 46) to generate the free base (237). This lacked the complexity in its IR 
spectrum associated with the C =0 and C -0  regions, as well as having much simplified 
and 13C NMR spectra.
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N = C = N
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Scheme 45 -  DCC (231) mediated esterification.
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Scheme 46 -  Hydrogenolysis to generate the glutamate free base (237).
When the protected spacer unit (214) was reacted with triphosgene (2 2 2 ), TLC indicated 
that a single new species had been formed. However, this failed to react with the 
glutamate diester (237). Addition o f  either dibutyltin diacetate, 
hexamethylphosphoramide, or 4-dimethylaminopyridine, combined with extended 
reaction times and/or elevated temperature did not bring about the reaction. Since 
severely forcing conditions did not induce the required reaction, an alternative target 
structure (238) was devised (see Figure 32). This molecule incorporated a carbamate 
linkage between the spacer and specifier regions, This should allow it to operate by a 
similar method to that expected o f  the target which contains a urea linkage (225) and 
should be easier to form.
o  c o 2h
Figure 32 -  Structure o f  the target molecule (238) which incorporates a carbamate
linkage.
The starting material for the synthesis o f  the previous spacer was 4-aminobenzyl alcohol 
(209). Due to this molecule having chemically distinct nucleophilic sites, selective 
protection o f  either one o f  them was readily possible. For the new spacer we require 4- 
hydroxybenzyl alcohol (239) as the starting material. This presented problems since its 
two nucleophilic sites were both centred on oxygen atoms. Working on the assumption 
that the primary aliphatic alcohol is the most nucleophilic site in the molecule, it was 
decided to attempt to protect this site selectively. Initial attempts were made to form the
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TBDMS ether (240), however this appeared to give the diprotected product (241) (see 
Scheme 47). This assumption is based on the *H NMR spectrum which showed twice as 
many highfield signals as those which would be produced by a compound which was 
mono-protected. One o f  the reasons for di-protection being favoured could be because 
the diol (239) was highly insoluble in the solvent used. Once it did react to form the 
mono TBDMS ether (240) this product was much more soluble so the concentration o f  
mono-ether (240) in the solution was greater than that o f  the diol (239), and hence di­
protection was favoured. Use o f  different protecting groups, in the form o f  either the 
tetrahydropyranyl ether or ethyl ester, as well as using different solvents failed to solve 
this problem.
,OH TBDMS ^.0 TBDMS
TBDMSC1/
Imidazole
TBDMSCl/
Imidazole
OH
239
OH
240
OTBDMS
241
Scheme 47 -  Formation o f mono- and di-protected TBDMS ethers.
Since selective alcohol protection had proved problematic, it was decided to attempt 
direct reaction between the isocyanate o f  the protected glutamic acid (224) and 4- 
hydroxybenzyl alcohol (239) (see Scheme 48). In an attempt to enhance the 
nucleophilicity o f  the phenol, a large excess o f triethylamine was added. This should 
selectively deprotonate the phenol (pKa -1 0 ) over the primary aliphatic alcohol (pKa 
-16). Since the resulting phenoxide (242) would be a better nucleophile than the 
aliphatic alcohol, reaction with the isocyanate (224) is most likely to occur at this 
phenolic site, so giving the required product (243). When this reaction was attempted on 
a small scale (<0.6 g) acceptable yields o f  between 55 and 62% were achieved. However, 
when working on a multi-gram scale the yield decreased dramatically (3.2 g, 7%). 
Attempts to remove the scale dependence o f  this reaction by carrying out the reaction at 
reduced temperature and lower concentrations did not lead to an increase in yield. 
Hence, several small scale reactions were carried out to obtain an acceptable amount o f  
the combined spacer-specifier (243). As with the urea-linked compound (230) previously 
synthesised, positive identification o f  the compound was carried out. The additional
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carbonyl, inserted via reaction with triphosgene, was observed in the 13C NMR (5 >170) 
spectrum as well as in the characteristic carbamate C =0 IR stretch at 1732 cm’1. All the 
other characterisation methods employed confirmed both the identity and purity o f  the 
product formed.
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239
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Scheme 48 -  Formation o f  the protected spacer-specifier (243).
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6.2 Formation of the drug subunit
6.2.1 Background
It was thought preferable to utilise a compound which we had previously synthesised as 
the drug subunit in a compound suitable for use in ADEPT, since its biological toxicity 
profile was well established. Ideally any drug candidate should be linked in a way which 
inactivates it as long as it is part o f the larger prodrug, and releases an active form o f  the 
drug upon prodrug breakdown. For this to occur the link between spacer and drug 
would have to be made at a part o f  the drug which is central to its effectiveness. An ideal 
candidate for such a compound would be an aminothiophene, which could be attached to 
the spacer via a carbamate linkage. Since the toxicity o f  this compound is fundamentally 
linked to its amino moiety the prodrug should be inactive. However, this approach is 
limited by the difficulty o f  generating stable aminothiophenes.
There are two possible strategies which could be employed in designing a drug suitable 
for use in an ADEPT system. The drug could either be the activated form o f  one o f the 
bioreducible drugs previously synthesised, or it could be a prodrug which then requires 
both the ADEPT process and bioreduction to become toxic. The heteroaromatic 
molecules so far synthesised did not appear to undergo bioreduction, possibly due to 
their excessively negative reduction potentials. If we could generate a species which had 
an amino group attached to its heterocyclic ring then this might in itself modify the 
compound’s reduction potential to a point where that compound’s activation within 
hypoxic cells became possible. Additionally, it would provide a nucleophilic site through 
which a molecule suitable for ADEPT could be linked. Given such parameters, a 
compound such as 244 (shown in Figure 33) was considered to be a suitable target, 
either as its free base or A-oxide.
OCONH
Figure 33 -  Target compound (244) suitable for fusion to the spacer-specifier (243).
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6.2.2 Nitration of a preformed heterocycle
To reduce the number o f  steps required to synthesise the target (244), direct nitration o f  
the previously synthesised compound (145a) was considered the preferred route. Mixed 
acid nitration on quinoline itself has been shown to give a mixture o f  the 5- and 8- 
nitrated products, in roughly equal amounts.203 However, the conditions required to 
bring about such a reaction are much more forcing than those used to nitrate an 
equivalent carbocyclic compound.204 It was thought that nitration on the carbocyclic ring 
would alter the reduction potential o f  the compound less than heteroaromatic nitration. 
Since part o f  the objectives o f  synthesising a nitrated quinoline (244) was to produce a 
compound with an altered reduction potential, and given the susceptibility o f  the 
carbamate functionality o f  the 2-quinolinecarbamate (145a) to the severely acidic 
conditions required to bring about this reaction, mixed acid nitration was ruled out as a 
method o f  forming the target (244).
Work on quinoline A-oxide (245) has shown that mixed acid nitration gives the 4-, 5- 
and 8 -substituted isomers (246, 247 and 248 respectively) .205 The orientation o f  this 
substitution can be controlled by altering the acidity o f  the reaction medium. Scheme 49 
shows that the ratio o f  the 4-nitrated product (246) increases at higher pH, since at that 
pH, protonation o f  the A-oxide is reduced. The resulting N-oxide will have an enhanced 
nucleophilic character at its 4-position. Since it is nitration at the 4-position that we wish 
to encourage, and given that our starting compound is susceptible to acidic conditions, a 
nitrating agent with a considerably lower acidity was required. One possible candidate is 
nitronium tetrafluoroborate, which has been shown to nitrate quinoline at room 
temperature or below in a sulfolane solution.206 When this process was performed on the 
quinoline free base (145a), the required product (249) was not observed (see Scheme 
50). Even after increased reaction time and/or bringing the system to reflux, only starting 
material could be isolated. However, this system did lead to reaction o f  the quinoline N- 
oxide (148a). Analysis o f  the product, a brown tar which could not be readily purified, 
showed that the carbamate functionality had survived these reaction conditions, but no 
signals corresponding to the CH2 adjacent to the heterocyclic ring were observed. Due to 
the degree o f  impurity in the product and the complexity o f  the aromatic region o f the 
spectra, this compound could not be positively identified.
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Scheme 49 -  Distribution o f isomers produced by nitration o f quinoline A-oxide (245).
NO2BF4/ 
Sulfolane ^
OCONHOCONH 249145a
Scheme 50 -  Attempted nitration o f  2-hydroxymethylqinoline isopropylcarbamate
(145a).
An alternative approach would be to nitrate selectively the 3-position o f  the heterocyclic 
ring o f  compound (148a), using the conditions laid out by Ochiai and Kaneko.207 The 
rationale behind their reaction is shown in Scheme 51.
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Scheme 51 -  Nitration o f quinoline iV-oxide (245).
In the first step benzoyl chloroformate and silver nitrate react in situ, forming benzoyl 
nitrate (250). This nitrates the oxygen o f  quinoline jV-oxide (245) to form a species (251) 
which is attacked by the released benzoate (252). This sets up a new species (253), in 
which the most nucleophilic site is at the 3-position, which can then attack benzoyl 
nitrate giving an unstable intermediate (254). This intermediate loses a proton and expels 
benzoyl nitrate to give 3-nitroquinoline iV-oxide (255).
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When these reaction conditions were applied to 2-hydroxymethylquinoline 
isopropylcarbamate A-oxide (148a), colourless crystals were isolated. However, none o f  
the spectra were consistent with the required product, and although HPLC indicated that 
only a single product had formed, extensive investigation failed to identify the product.
6.2.3 Heterocyclic ring synthesis
Since selective nitration o f the heterocyclic ring had proved difficult, it was decided to 
attempt a synthesis o f  a quinoline skeleton which contained the required substitution 
pattern. A  wide variety o f  literature procedures exists for the synthesis o f  4-substituted 
quinolines. Since the 4-substituted carbamate (147a) is almost as active as the 2 - 
substituted derivative (145a), its amino derivative (256) was defined as a target (see 
Figure 34).
OCONH
Figure 34 -  Structure o f  the 2-amino substituted target (256).
The planned route shown in Scheme 52 involved the hydrolysis o f  isatin (257) to form 
potassium isatogenate (258). Self-condensation o f  the other starting material, 
nitromethane (259), should lead to the formation o f  methazonic acid (260). Reacting 
these two products together in a convergent synthesis should give a quinoline skeleton 
(261) with the correct substitution pattern. This Pfitzinger synthesis o f  quinoline has 
been thoroughly reviewed,208 as a means o f  synthesising 3-A-substituted quinolines. The 
compound formed (261) could then undergo reduction o f its acid group; carbamate 
formation through the resulting alcohol; and finally reduction o f  the nitro group to give 
the target compound (256).
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Scheme 52 -  Method for the attempted condensation o f potassium isatogenate (258)
and methazonic acid (260).
Hydrolysis o f  isatin (257) was attempted using an equimolar amount o f  20% potassium 
hydroxide solution at 40 °C or below. This literature method209 failed to give any 
significant degree o f  hydrolysis even after a three day reaction . It had been previously 
noted that increasing the reaction temperature, or the concentration o f  potassium 
hydroxide led to the formation o f  side products,209 and this was confirmed 
experimentally. In an attempt to form the required product, various combinations o f  
different solvent systems (methanol:water) and an alternative base (sodium hydroxide) 
were employed, to no effect.
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Synthesis o f  methazonic acid (260) proved equally problematic. The literature 
method,210 which required condensation o f nitromethane (259) in excess sodium 
hydroxide solution at 45-50 °C, failed to give the reported crystals on acidification o f  the 
reaction mixture. Extraction o f  this mixture with diethyl ether gave an orange oil which 
consisted o f  several different products. Attempted chromatographic purification led to 
degradation o f  the product. The instability o f  the product had previously been noted, 
with decomposition o f  even pure product occurring within 3 three days at 0 °C. 
Investigating the reaction revealed that at any temperature lower than 45 °C the reaction 
failed to occur, whilst above 50 °C, many impurities were formed. Due to the exothermic 
nature o f  the reaction, once it had been initiated at 45 °C the reaction mixture heated 
rapidly and even with great care it was not possible to keep the temperature within the 
narrow specified range. Therefore, it was not possible to produce the product in a pure 
form.
Other reports had indicated that the condensation o f nitromethane, hydrolysis o f  isatin, 
and coupling o f  the resulting products could all be carried out in a one pot reaction.211 
When this method was attempted, starting materials were recovered. Increasing the 
reaction time or temperature from that reported only led to the formation o f  several 
impurities. Since formation o f  both o f  the starting materials for the synthesis o f  target 
material (261), and one pot synthesis o f the target compound all proved problematic, an 
alternative strategy was considered.
Champaigne and Hutchinson reported212 that the reaction between isatin (257) and 
malononitrile gave a 2,3,4-trisubstituted quinoline (265). This presumably occurred, as 
shown in Scheme 53, by reaction o f malononitrile with sodium isatogenate (262), which 
should be formed by hydrolysis o f  isatin, to give the Knoevenagel product (263). Ring 
closure could then occur giving 264, which upon tautomerisation would give the 
reported product, sodium 2-amino-3-cyanoquinoline-4-carboxylate (265). This 
compound could then be transformed into the desired product (256) using a combination
• * 213o f  the steps previously outlined as well as decyanation using literature methods. 
However, since the initial coupling to form sodium 2-amino-3-cyanoquinoline-4- 
carboxylate (265) could not be reproduced this route was abandoned.
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Scheme 53 -  Planned synthetic route to a 2-aminoquinoline (256).
6.2.4 Direct coupling
An alternative site on the drug for linkage to the spacer-specifier section (243), could be 
through either the nitrogen o f  a quinoline free base or through the oxygen o f  its A-oxide. 
Suitable candidates for such drugs are shown in Figure 35 and include the quinoline free 
base 145a and its A-oxide 148a. Considerable precedence exists for forming such 
adducts and both jV-alkylation214 and O-alkylation215 have been carried out. To achieve 
this coupling a highly reactive electrophile, such as an alkyl iodide is required. The 
protected spacer-specifier (243) previously prepared could be transformed into its alkyl 
iodide using trimethylsilyl chloride and sodium iodide.216 Due to the difficulty in 
generating large quantities o f  the spacer-specifier (243), a test system was set up using 
benzyl alcohol (266). This was transformed into benzyl iodide (267) as described in the
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literature (see Scheme 54) .216 The conditions were not optimised and hence only a 55% 
yield was achieved, with 35% o f  the starting material being recovered after the reaction. 
The product was identified spectroscopically by its high field °C  NMR CH2 signal at 5 
5.48, as well as by detection o f  the molecular ion by mass spectrometry.
OCONH
V --V 53  
1
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145a 148a
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Figure 35 -  Structure o f  potential drug subunits.
TMSCl/Nal/
CH3CN/Et3NX X  X X
266 267
Schem e 54 -  Iodination using trimethylsilyl chloride and sodium iodide.
Attempted reaction o f  benzyl iodide with the drug (145a), either in dichloromethane or 
acetonitrile was very slow, and bringing the system to reflux resulted in a large number 
o f  degradation products being formed. It was thought that part o f  the reason for the poor 
reactivity o f  the drug (145a) was due to the steric effects o f  having a ring fusion and an 
alkyl substituent a  to the nitrogen which was required to act as a nucleophile. In an 
attempt to reduce this steric hindrance, an alternative drug (147a) was tried, which had 
its alkyl substituent at the 4-position. However, this compound behaved in a similar 
manner to the 2 -substituted analogue.
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Initial attempts to couple quinoline-based compounds to the spacer-specifier (243) were 
via an alkyl iodide, a method which has literature precedence. Since these were 
unsuccessful, an attempt was made to react the chloroformate (268) o f  the spacer- 
specifier (243), with the drug (147a) to form a coupled product (269) (see Scheme 55).
OCONH
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Scheme 55 -  Attempted formation o f  the target compound 269.
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Application o f  triphosgene to a basic solution o f  the alcohol (243) gave a compound 
which was thought to be a chloroformate (268). The product was not isolated and the 
quinoline (147a) was added directly, to generate a mixture o f  starting material and three 
new products. These products could not be separated by crystallisation, and adhered to 
silica or alumina columns, so this route was taken no further.
6.2.5 Coupling via a hydroxy quinoline
As mentioned previously, to achieve the maximum therapeutic benefit from a drug 
designed for use in ADEPT, the drug should be linked to the spacer-specifier fragment in 
such a way as to inactivate it. Since initial attempts to create such an adduct had failed, 
an alternative approach was tried. This relied on linking the drug fragment to the spacer- 
specifier fragment by any convenient means. It was hoped that the final compound would 
be too bulky to be transported into cells, and that even if  it were, the additional steric 
bulk would inhibit any interactions it would have with biological material. With this in 
mind and using readily available starting materials, the route outlined in Scheme 56 was 
planned.
Reduction o f  4-hydroxyquinoline-2-carboxylic acid hydrate (270) could either be carried 
out in one step, or via its ester (271). Initially the most direct route, borane reduction o f  
the acid (270), was attempted. This resulted in a residue from which the inorganic 
material could not be fully removed. A considerable quantity o f  boric acid was present in 
all extracts o f  this residue, and isolation o f  the organic components was difficult. Given 
the poor solubility in organic solvents that would be expected o f  the alcohol (272) 
produced, and the high temperature extractions with polar solvents, such as methanol, 
that were used in attempts to extract it, the persistence o f  borane derived impurities in 
the extract is not surprising.
Using lithium aluminium hydride as a reducing agent was more successful since the 
workup led to selective extraction o f the organics from the residue using pyridine. These 
organic materials were purified by crystallisation from methanol to give 4-hydroxy-2- 
hydroxymethylquinoline (272) in a very poor yield (6%). The poor yield could either be 
due to a breakdown o f  the product under the harsh reaction conditions employed, or it 
could be due to an inability to extract it from the inorganic materials which made up the 
reaction residue.
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Scheme 56 -  Proposed route to a prodrug suitable for use in ADEPT.
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Due to the difficulties listed above, the alternative two step route was attempted, 
whereby transformation o f  the acid group in 270 to a more readily reducible ester group, 
should result in a compound which could be reduced under milder conditions. This 
should minimise the degree o f  product degradation during the reduction. Transformation 
o f  the acid (270) into its ester (271) was best accomplished by stirring the acid in a 
solution o f  methanol, which had a stream o f  hydrogen chloride gas passed through it. 
This method gave a higher yield (59%) and purity than either the use o f  a concentrated 
sulfuric acid catalyst (13% after purification); 1,3-diisopropylcarbodiimide (231) as a 
coupling agent (34% with impurities); or 1,3-dicyclohexylcarbodiimide as a coupling 
agent (26% with impurities).
Several different strategies were planned, but time did not permit further investigation. 
However an outline o f  the remaining steps would involve reduction o f  the ester (271) to 
its alcohol, possibly using lithium borohydride,175 to give the diol (272). Carbamate 
generation from this diol, would give a mixture o f  products, but by ensuring that the 
reaction was carried out under neutral conditions the primary alcohol should be more 
reactive than the phenol, so ensuring that the major product was the desired carbamate 
(273).
Should carbamate formation from the diol (272) not produce the required product (273) 
then it might be necessary to protect the phenol, possibly as its TBDMS ether (274). 
Subsequent carbamate formation at the only remaining free alcohol should give a more 
soluble product (275), than the equivalent non-TBDMS protected alcohol (272). This 
should facilitate separation o f  the organic compounds from the inorganic residue formed 
during reduction. The carbamate group could then be generated from the only available 
alcohol. On deprotection this should give the desired product (273). Coupling could then 
occur between this compound and the chloroformate o f  the spacer-specifier (268) 
forming a compound which only requires removal o f  the tertiarybutyl protecting groups, 
to give a compound (276) suitable for use in ADEPT.
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7. B io lo g ic al  and  
E lec tr o c h e m ic a l  Ev a lu a tio n s
7.1 Introduction
7.1.1 General (electrochemical)
Cyclic voltamagrams (CVs) were taken on a Lloyd PL3 plotter using a EG&G Parc 
model 175 universal programmer, model 173 potentiostat/galvanostat and model 176 
current follower to generate and monitor the signal. Each compound was dissolved in a 
solution o f  DMSO which contained tetraethylammonium tetrafluoroborate (0.1 M) as an 
electrolyte. The CVs were measured using a 0.5 cm2 gold electrode, with reference to a 
standard sodium calomel electrode. All measurements were carried out by Andrew Glidle 
(Department o f  Electronic and Electrical Engineering, Glasgow University).
7.1.2 General (biological)
Testing was carried out at the CRC Beatson Laboratories, Department o f  Medical 
Oncology, University o f  Glasgow.
IC50 values were determined by myself under the supervision o f  Dr. Jane Plumb. These 
values were determined using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) based cytotoxicity assay. This is a microtitration assay which utilises a 
colour change produced by the action o f living cells on MTT. In this way the absorbance 
o f  a MTT treated culture is directly proportional to the number o f  living cells present. 
Employing this method to cells which had been exposed to varying concentrations o f  the 
drug, and comparing the absorbances produced after treatment with MTT with that o f  a 
control, allowed the IC50 value o f  each drug to be calculated.
The oxic:hypoxic screening was carried out by either Martin Gerritsen or myself as 
specified in the text. Results from this assay are not directly comparable with those o f  the 
MTT based assay since the drug exposure period was limited to three hours. Initial
129
screening o f  each o f  the compounds was carried out under both oxic and hypoxic 
conditions, at one concentration only (1 mM). This allowed identification o f  those 
compounds which were active and potentially selective. The IC50 values o f  these 
compounds were then determined, in both oxic and hypoxic conditions, by repeating the 
above test procedure but using four, five-fold dilutions o f  each compound and plotting 
the results on a graph. The IC50 value o f  each compound was taken to be the 
concentration o f  that compound which resulted in a reduction in the number o f  cells 
present to 50% o f  that o f  the control.
7.1.3 Cell lines
Previous work has shown that the obligate two-electron reduction enzyme, DT- 
diaphorase, is overexpressed in certain cell lines.76 This enzyme has the ability to activate 
several bioreducible prodrugs, such as E 0 9  (80),217 leading to an increase in the 
concentration o f  released drug and hence increased cell kill. The heterocyclic 7V-oxides 
synthesised were expected to express a similar mode o f  toxicity to SR 4233 (53), and as 
such produce a toxic event via a one-electron reduction process. Studies have shown 
that SR 4233 (53) can be effectively reduced by DT-diaphorase to its two-, four- and 
six-electron reduced products.77 Since this enzymatic reduction bypasses the toxic event, 
it is possible that cells which express high levels o f  DT-diaphorase would be resistant to 
treatment using SR 4233 (53) or its analogues.113 Hence, by carrying out biological 
evaluation on two cell lines which have differing levels o f  DT-diaphorase it was hoped to 
establish whether any toxic event involved in prodrug activation was mediated by a one- 
or two-electron reduction process.
The cell lines used were BE and HT29. These cell lines both originated from human 
tumours cells and are very similar, differing primarily in the DT-diaphorase each cell line 
produces. BE cells have been genetically altered to express a mutant form o f  DT- 
diaphorase with essentially no activity.218 The reductive process o f  these cells are 
primarily one-electron based.
7.1.4 MTT based cytotoxicity assay
Primary testing on prospective new anticancer agents is carried out in vitro using 
cytotoxicity tests. Clonogenic assays have been utilised for some time and use the plating 
efficiency, either on plastic or in agar, o f  a sample o f  cells which have been exposed to
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the compound under study. By comparing the number o f  colonies after drug exposure 
with that produced by a control it is possible to determine the toxicity o f  a compound. 
Although these assays are accurate and well proven they are slow and labour intensive. 
Microtitration assays are quicker to process and allow multiple tests o f  each compound 
to be carried out simultaneously, with minimal extra effort. This makes for a more 
reliable measure o f  toxicity which is less susceptible to error. The end point o f  a 
microtitration assay is an estimate o f  cell number. This can be achieved directly by cell 
counts or by indirect methods such as isotope incorporation.
A  well documented and reliable microtitration assay is based on the use o f  MTT as a cell 
viability measure.219 MTT is a yellow water soluble tetrazolium dye that is reduced by 
living, but not dead cells, to a purple formazan product that is insoluble in aqueous 
solutions. It should be noted that a number o f  factors can influence the reduction o f  
MTT.220 However, in the assay used, the same result has been achieved with a standard 
clonogenic assay.221
Cells in the exponential phase o f  growth were exposed to the cytotoxic drug o f  interest. 
The duration o f exposure is usually determined as the time required for maximal damage 
to occur but is also influenced by the stability o f  the drug. After removal o f  the drug the 
cells were allowed to proliferate for two to three doubling times in order to distinguish 
between cells which remain viable and are capable o f  proliferation and those which 
remain viable but cannot proliferate. Surviving cell numbers were then determined 
indirectly by MTT dye reduction. The amount o f  MTT-formazan produced was 
determined spectrophotometrically once solubilised in DMSO. It is important to note 
that the colour produced by MTT reduction is shown to be in the linear range o f  
dependence on the cell number, and that the colour produced is proportional to the time 
under MTT exposure.
7.1.5 Hypoxic cytotoxicity assay
The plastic which makes up multiwell tissue culture plates has been shown to contain 
oxygen which is released slowly into the surrounding environment at low oxygen 
concentrations.222 This makes these plates unsuitable for use in hypoxic screening. Since 
glass multiwell plates are not available, this problem was overcome by using glass petri 
dishes for those cultures which were to be incubated in a hypoxic environment. This
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limits the number o f  compounds tested in each experiment, and the number o f  
concentrations at which these compounds can be tested.
The exposure period o f  each cell line to hypoxic conditions was limited to three hours, as 
the cells would die, even without drug exposure, if  the absence o f  oxygen was prolonged 
beyond this time. The medium containing the drug was then removed and replaced with 
fresh medium. After two days, surviving cell numbers were counted directly using a 
Coulter counter, and this number was taken as a percentage o f  the controls.
7,1.6 The assay systems in use
An example o f  the results obtained from carrying out these test procedures on SR 4233
• • •(53) is shown in Table 3. Since BE cells are not capable o f  carrying out two-electron
reductions using the enzyme DT-diaphorase, and both cell lines showed similar toxicity
to SR4233 (53), it can be assumed that SR4233 (53) is not reduced to toxic species by
the two-electron reductase, DT-diaphorase.
Compound
Number
Structure
SR4233 (50) a00IN*© N©^kN NH2
Survival as percentage o f  control at 1 mM 
and I C 5 0  values |iM
Oxic
HT29 Cells
Hypoxic
580 7.8
IC 5 0
240
Oxic
BE Cells
Hypoxic
540 6.1
IC 5 0
180
Table 3 -  I C 5 0  values and oxic:hypoxic test results for SR4233 (53) derivatives.
7.1.7 Properties required by prodrugs
The prodrugs should have as low a toxicity as possible so that they do not lead to the 
damage o f  normal tissue prior to activation. When these compounds are exposed to 
tumour cells which are under hypoxic conditions they should be readily reduced. One 
possible mode o f  toxicity could be through toxic intermediates produced upon 
bioreduction o f  the prodrug. Alternatively, the stable reduction products could be toxic 
so leading to cell death.
132
7.2 Heterocyclic A/-oxides
7.27 Pyridine derivatives
Table 4 shows results from the biological screening o f the pyridine derivatives. Shaded 
areas indicate compounds which contain an A^-oxide.
Compound Structure Survival as percentage o f  control at 1 mM
Number and IC50 values
A HT29 Cells BE Cells
R R
R Equals Oxic Hypoxic IC 50 Oxic Hypoxic IC 50
103 OCONH7Pr 100 100 >2000 100 100 >2000
104 OCONHEt 100t 100 >2000 100 100 >2000
105 OCONHPh 47 42 130 87 68 210
107 O CO N H 'Pr 100 100 >2000 100 100 >2000
108 OCONHEt 100 100 >2000 100 100 >2000
109 OCONHPh 100 100 870 100 100 830
118 Cl of 0* 1.1 of of 1.4
117 Br of 0f 0.39 of of 0.78
119 I of 0f 0.18 of of 0.45
121 Cl o* 0f 3.4 of ot 3.7
120 Br of of 0.75 ot ot 2.0
122 I of of 0.49 of ot 0.68
Table 4 -  IC50 values and oxic:hypoxic test results for the pyridine derivatives.
t Tests carried out by Martin Gerritsen
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As expected, a general correlation can be seen between the results obtained for the 
oxic:hypoxic screening and the screening used to determine IC50 values. Each test 
showed that all the halogen-containing compounds are highly toxic. Results from the 
oxic: hypoxic screening showed that after a three hour exposure o f  the compound at a 
concentration o f  1 mM, under both oxic and hypoxic conditions, complete cell kill 
occurred. Likewise the initial screening used in an attempt to determine IC50 values, 
which was carried out at four different drug concentrations (1000 pM, 200 pM, 40 pM  
and 8 pM), showed complete cell kill after 24 h exposure even at the lowest 
concentration at which the compound was tested.
To determine accurately the IC50 values o f  these compounds, it was necessary to repeat 
the test using lower concentrations (5 pM, 1 pM, 0.2 pM and 0.04 pM). These tests 
showed the bis(halomethyl)pyridine compounds to be toxic in the micromolar and 
submicromolar ranges. A  correlation between the compound’s toxicity and the type o f  
halide it possesses can be clearly seen. Both the free bases (117, 118, and 119) and N- 
oxides (120, 121 and 122) showed an increasing toxicity from chloro- to iodo- 
substituted analogues. This can be correlated with the ability o f  these halide moieties to 
act as leaving groups, with the compound which contains the better leaving groups 
proving to be the most toxic. Graph 13 shows the data obtained from tests on the free 
bases (117,118 , and 119).
0.6 +
•  117
Q .
■119
0.0
Concentration (M)
Graph 13 -  Toxicity profiles o f  the 2,6-bis(halomethyl)pyridines 117, 118 and 119 to
BE cells.
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Although simple IC50 values gained from these data indicate that 2,6-
bis(chloromethyl)pyridine (118) is considerably less toxic than 2,6-
bis(bromomethyl)pyridine (117), this is only true at certain concentrations. However,
2,6-bis(iodomethyl)pyridine (119) is more toxic over a broad concentration range.
Comparing the toxicity o f  the halopyridine free bases with their A-oxides shows that the 
free bases are approximately twice as toxic as their iV-oxides. This is illustrated in Graph 
14 which shows the toxicity profiles for 2,6-bis(bromomethyl)pyridine (117) and its N- 
oxide (120). The high toxicity o f  the 2,6-bis(halomethyl)pyridine TV-oxides combined 
with the low differential toxicity they exhibit when compared to their free bases, 
precludes them for use as prodrugs, since they would be toxic even prior to activation.
0.6 +
Br
•  120
O© Br
0.0
Concentration (M)
Graph 14 -  Toxicity profiles o f 2,6-bis(bromomethyl)pyridine 7V-oxide (120) and its free
base (117) to BE cells.
The pyridine carbamates are much less toxic than their halopyridine analogues. Only the
2,6-bis(hydroxymethyl)pyridine bis(phenylcarbamate) (105) showed any toxicity at the 
concentrations used. Although its N-oxide (109) is non-toxic at the test concentrations, 
making it a potential prodrug, there is no indication o f  prodrug activation in hypoxic 
tumour cells.
More detailed oxic:hypoxic testing has been carried out on SR4233 (53) and the results 
o f this testing is shown in Graph 15.223 When these procedures were appplied to 2,6- 
bis(bromomethyl)pyridine iV-oxide (120) the results shown in Graph 16 were obatined. 
The results obtained for 2,6-bis(bromomethyl)pyridine JV-oxide (120) show that there is 
no appreciable difference in toxicity o f the compound under oxic verses hypoxic
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conditions in either cell line. For this reason 2,6-bis(bromomethyl)pyridine A^oxide (120) 
could not be used as a hypoxia activated anticancer prodrug. The I C 50 values determined 
using this assay under oxic conditions, in both cell lines, are similar to the the I C 50 values 
obtained from the MTT based cytotoxicity assay. The difference in the I C 50 values 
obtained in the two separate assays was probably due to the different exposure times 
used in each assay.
It would be desirable to test all the compounds using this method. However, due to the 
limited number o f  compounds which can be tested per experiment, such detailed testing 
was not feasible.
There was lack o f  any differential toxicity shown in the oxic:hypoxic screening between 
free base and A^oxide, when testing the pyridine derivatives on both o f  the cell lines. This 
indicates that reduction o f  the N-oxide is not occurring. These compounds would 
therefore not be suitable candidates for hypoxia selective prodrugs.
BE Cells100 -
Oxic
Hypoxic
ok .
C
HT29 Cells 
A Oxic 
A Hypoxic
80 -
8
o>o> „W 60 -  
cs0)
j§ 40 -
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|
05 20 -
Concentration (M)
Graph 15 -  Toxicity profiles o f  SR4233 (53) under hypoxic and oxic conditions.
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Graph 16 -  Toxicity profiles o f  2,6-bis(bromomethyl)pyridine A-oxide (120) under
hypoxic and oxic conditions.
7.2.2 Quinoline derivatives
Table 5 shows results from the biological screening o f  the quinoline derivatives. Shaded 
areas indicate compounds which contain an A-oxide. Numbers in square brackets 
indicate the position on the quinoline ring at which the substituent is attached.
All o f  the quinoline A-oxides showed little toxicity. The most toxic o f  these compounds 
is the 2-substituted isopropylcarbamate A-oxide (148a). The toxicity o f  both quinoline 
iV-oxides and their free bases appears to be dependent on the substitution pattern o f  the 
quinoline skeleton. Similar compounds to the 2-substituted isopropylcarbamates (145a 
and 148a) which have the isopropylcarbamate substituted at the 3- or 4-position o f  the 
quinoline ring (146a, 147a, 149a and 150a) are much less toxic. The opposite 
relationship between substitution pattern and toxicity was observed in the 
phenylcarbamates. The 3- and 4-substituted compounds (146b, 147b, 149b and 150b) 
were more toxic than the 2-substituted compounds (145b and 148b). These results may 
indicate that a specific mode o f  action exists for the 2-substituted compounds.
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Compound
Num ber
Structure Survival as percentage o f control at 1 mM 
and IC50 values jaM
N
HT29 Cells BE Cells
R  Equals
[Substituent position]
Oxic Hypoxic IC50 Oxic Hypoxic IC50
145a [2] OCONH7Pr 0* 0f 44 0+ 0t 55
146a [3] OCONH7Pr 40 35f 2000 40* 40* 2000
147a [4] OCONH7Pr 1* 5f 2000 0* 0* 1700
148a [2] OCQNHOPr 100* 100f 480 100* 100* 910
149a [3] OCONH7Pr 100* 100t >2000 100* 100* >2000
150a [4] OCONHOPr 100 too1 >2000 100+ O O -4- >2000
145b [2] OCONHPh 60 49t 130 100* 70* 200
146b [3] OCONHPh 43* 35f 100 20* 20* 160
147b [4] OCONHPh 28* 34f 79 20* 10* 130
148b [2] OCONHPh 100* 100 1400 100* 100* 1500
149b [3] OCONHPh 100 100f 1000 100* 100* 1300
150b 1 [4] OCONHPh 100* 100f 860 100* 100* 970
Table 5 -  IC50 values and oxic:hypoxic test results for the quinoline derivatives.
All the compounds tested showed similar toxicity towards both o f  the cell lines and none 
o f the N-oxides showed any selective activation under hypoxic conditions. This indicates 
that no reductive activation o f  the prodrugs is occurring. Additionally the difference in 
toxicity (IC50 values) between the free bases and their N-oxides (-1 0  times) is not great 
enough to  allow the A^oxides to be used as prodrugs, which rely for their activity on the
* Tests carried out by Martin Gerritsen
138
formation o f  toxic drugs after activation. This would not however preclude the A^-oxide 
prodrugs being used in a system where the reductive act itself generates toxic species. 
This is the mode o f action which has been found to occur in heterocyclic iV-oxides such 
as SR 4233 (53).
7.2.3 Quinoxaline derivatives
Table 6 shows results from the biological screening o f  the quinoxaline derivatives. 
Lightly shaded areas indicate compounds which contain a mono-A^-oxide. Darker shading 
indicates compounds which contain a di-A^-oxide.
Compound Structure Survival as percentage o f control at ImM
N umber and IC50 \values p.M
L r
^  N  ^
HT29 Cells BE Cells
R Equals Oxic Hypoxic IC50 Oxic Hypoxic IC50
157 Br 0 0 0.29 0 0 0.30
160 I 0 0 0.16 0 0 0.20
164a OCONH7Pr 80f 80+ 700 72f 18f 820
164b OCONHPh 8f 27 0f 0f 16
158 Br 0 0 0.37 0 0 0.40
165a OCONW Pr 100f 100+ >2000 100* 100f >2000
165b OCONHPh i t 130 0* o* 420
_ _ _
a
166a 
166b
i P i i B
OCONIEPr
OCONHPh
~~~~~~~........ .
100f
■ '■ ....... .
' 0
1001. ■ ..TA - _ >2^
860
0
100f
100+
' : " ' 
0
loot
100f
v 
: ?
■-
A
A
 
:
O
O
-
 
O 
O 
A
O
Table 6 -  IC50 values and oxic:hypoxic test results for the quinoxaline derivatives.
* Tests carried out by Martin Gerritsen
139
As with the bis(halomethyl)pyridine derivatives, the bis(halomethylquinoxaline) 
derivatives showed a high toxicity. Both 2,3-bis(bromomethyl)quinoxaline mono- and di- 
jV-oxide (158 and 159) are too toxic to act as prodrugs. 2,3- 
Bis(hydroxymethyl)quinoxaline bis(phenylcarbamate) di-A-oxide (166b) was less toxic 
than either its mono-A-oxide (165b) or free base (164b) (see Graph 17). In particular the 
toxicity ratio, as measured by IC50 values, for the di-A-oxide (166b):mono-JV-oxide 
(165b):free base (164b) was 1:5:32. If reduction o f  the di-TV-oxide (166b) to form its 
free base (164b) occurred in tumour cells under hypoxic conditions, then the di-A-oxide 
(166b) should be considerably more toxic under hypoxic as opposed to oxic conditions. 
However, this selectivity was not observed. The di-Af-oxide (166b) showed no selective 
toxicity to cells under hypoxic conditions. Similarly, reduction o f  the mono-A-oxide 
(165b) to its free base did not appear to occur, since no selective toxicity was shown by 
the mono-A-oxide (165b) to cells under hypoxic conditions.
cccOCONHOCONH N V ^'O C O N H  OCONHIO©
0.6 +
•  166b
■ 164b
0.0
Concentration (mM)
o ©
OCONH
OCONH
o©
164b 165b 166b
Graph 17 -  Toxicity profiles o f  2,3-bis(hydroxymethyl)quinoxaline 
bis(phenylcarbamate) (164b), its mono-TV-oxide (165b), and its di-JV-oxide (166b) for
BE cells.
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7.2.4 Electrochemical Investigation
Previous studies have shown that the selectivity o f  benzotriazine di-V-oxides is closely 
linked to their reduction potentials.81 These studies were carried out using a dropping 
mercury electrode. However, due to the practical limitations and toxicity involved in 
using this system in our work, the dropping mercury electrode was substituted with a 
gold electrode. Tests showed that this system gave similar values to those obtained using 
a dropping mercury electrode. Compounds which have reduction potentials in the range - 
0.2 to -0.4 V  can be reduced in hypoxic but not oxic cells.81 Compounds which have 
reduction potentials more negative than -0.4 V do not undergo biochemical reduction 
even in hypoxic cells. For compounds with reduction potentials more positive than - 
0.2 V, reduction occurs even in well oxygenated cells, reducing the selectivity o f  these 
compounds.
O f the compounds synthesised, the quinoxaline series appeared to show the greatest 
toxicity difference between their free bases and V-oxides. Therefore this series o f  
compounds was chosen as a model system to investigate the electrochemical behaviour 
o f  heterocyclic V-oxides.
The CVs o f  2,3-bis(hydroxymethyl)quinoxaline bis(isopropylcarbamate) (164a) and its 
mono- and di-V-oxides (165a and 166a) were taken at four different scan rates and are 
shown in Graph 18, Graph 19 and Graph 20.
Potential Difference (V)
-2.0 -1.5 -1.0 -0.5
Scan Rate 
(mV s'1)
100
Yax
164a
OCONH
OCONH 100
Graph 18 -  CVs o f  2,3-bis(hydroxymethyl)quinoxaline bis(isopropylcarbamate) (164a).
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Potential Difference (V) 
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(mV s'1)
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OCONH
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Graph 19 -  CVs o f  2,3-bis(hydroxymethyl)quinoxaline bis(isopropylcarbamate)
■2.0
mono-V-oxide (165a).
Potential Difference (V)
■1.5 -1.0 -0.5
Scan Rate 
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- 5 0  =
-  100
Graph 20 -  CVs o f  2,3-bis(hydroxymethyl)quinoxaline bis(isopropylcarbamate)
di-V-oxide (166a).
It is evident that each compound undergoes several reductions. The CVs show that none 
o f  the compounds tested undergoes reduction when the potential applied is less negative
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than -0.8 V, and this is well outwith the range which can be accomplished in biological 
systems. The CVs o f  the mono- and di-V-oxides (165a and 166a) show at least four 
separate reduction waves. The potentials at which these reductions occurred are much 
more negative than the reduction potentials quoted in the literature for quinoxaline V-
1*7*7
oxide (-0.52 to -0.68 V). This in turn is much less negative that the reduction potential 
quoted for pyridine V-oxide (-1.43 V).
In an attempt to determine the nature o f  the reductions occurring as the potential was 
applied, several IR spectra o f  each compound were taken during the reduction process. 
The changes in the IR spectra o f  the mono-V-oxide (164a) as a potential was applied are 
shown in Graph 21. Absorbance values greater than 0.00 indicate that as the compound 
is reduced, a new species is formed which absorbs at the frequency in question more 
strongly than the starting material. Similarly, peaks with negative absorbance values 
indicate loss o f  functionality from the starting material which originally absorbed in that 
region o f  the spectrum.
OCONH0.18
OCONH
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0.00
A
0.00
-0.02
-a 04
-0.08
-0.16
-0.18
-0 .20
1300 12001800 1600 11001700
Graph 21 -  Effect o f  the applied potential on the IR absorbancies o f  2,3- 
bis(hydroxymethyl)quinoxaline bis(isopropylcarbamate) mono-A-oxide (165a).
Expanding a portion o f  this spectra and plotting the results in three-dimensions gives 
Graph 22. This shows the changes in the IR spectra o f  2,3- 
bis(hydroxymethyl)quinoxaline bis(isopropylcarbamate) mono-A-oxide (165a) as the
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potential was varied from -1.1 V to -1.6 V. The y-axis shows the change in IR 
absorbance over the range in which the first two reduction waves were observed (use of 
dry DMSO in this experiment resulted in these reductions occurring at more negative 
potentials then those previously quoted).
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Graph 22 -  3-D plot o f the IR spectrum o f 2,3-bis(hydroxymethyl)quinoxaline 
bis(isopropylcarbamate) mono-V-oxide (165a) with varying potential.
The absorbance associated with the carbamate C = 0  stretch at 1720 cm*1 became smaller 
as each o f  the first two reduction waves was crossed, at -1.32 V and -1.60 V. This 
implies that these two waves represent separate reduction events for each o f the two 
carbamate moieties. Further supporting evidence comes from an increase in the IR 
absorbance at 1500 cm '1. Absorbancies at this wavenumber are consistent with a 
carboxylate moiety, such as that in a carbamic acid (277), which might be formed after 
electrochemical cleavage o f the carbamate moiety o f 2,3-bis(hydroxymethyl)quinoxaline 
bis(isopropylcarbamate) mono-V-oxide (165a) resulting in the formation o f  a conjugated 
species (278) (see Scheme 57).
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Scheme 57 -  Putative products from 2,3-bis(hydroxymethyl)quinoxaline 
bis(isopropylcarbamate) mono-V-oxide (165a) after the first two reduction events.
Similar analysis o f  the spectra o f the free base (164a) and di-JV-oxide (166a) show 
comparable electrochemical behaviour. The reduction o f  both carbamate moieties in the 
free base (164a) occurs at the same voltage, hence the CVs o f  this compound (Graph 18) 
show fewer distinct reduction waves than either the mono- or di-TV-oxide (165a or 
166a).
Analysis o f  the IR absorbance which occurs at 1250 cm-1 showed a more complicated 
pattern, with the reduction in absorbance at this wavenumber occurring as each o f  the 
four waves are crossed. The changes in the IR spectra as the first two reduction waves 
are crossed can be attributed to loss o f the C -0  stretch when the carbamate is cleaved. 
There is not sufficient information to make positive identification o f  the cause o f  the 
reduced absorbance at the more negative reduction potentials, although reduction o f  the 
JV-oxide is one possibility.
Although it was not possible to identify which reduction waves were associated with 
reduction o f  the V-oxide, it is possible to say that this reduction does not occur as the 
first two reduction waves are crossed. This suggests that the reduction potential o f  the 
V-oxide moiety in both the mono- and di-V-oxides (165a and 166a) in dry DMSO is at 
least -1.6 V  and possibly more.
Due to the poor solubility o f  the compounds under study it was not possible to repeat the 
experiments in aqueous medium. Although the reduction potentials o f  the compounds
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under examination will become less negative as water is added to the system, it is 
unlikely that the reduction potential will be moved to within the range required for 
bioreduction (-0.2 to -0.4 V).
7.2.5 Conclusion
All o f  the pyridine and quinoxaline halide derivatives showed a high toxicity, with IC50 
values in the micromolar range. This toxicity prohibits the use o f  these //-oxides as 
prodrugs, since they would act on all the cells in the body, even prior to activation. The 
toxic action o f  these compounds probably arises from nucleophilic attack by 
biomolecules directly on the halomethyl group, with expulsion o f  the halide, resulting in 
the formation o f  an adduct. Evidence to support this conclusion comes from the 
changing toxicity o f  such compounds as the halide is varied. Changing the halide for a 
different halide which acts as a better leaving group increases the toxicity o f  the 
compound.
None o f  the pyridine //-oxides showed any selective activation in hypoxic cells. Changing 
the structure o f  the heteroaromatic skeleton to either quinoline or quinoxaline did not 
lead to any selectivity. This behaviour was seen in both the carbamate and halomethyl 
derivatives synthesised. The electrochemical data indicate that reduction o f  the //-oxides 
would only occur at a potential well outwith that which can be facilitated within hypoxic 
cells. Because biochemical reduction o f the A-oxides was not possible, the toxicity 
differential which was seen between the toxic free bases and less toxic //-oxides could 
not be exploited. This toxicity differential could be exploited in future compounds by 
altering their structure in such a manner as to alter the resulting compound’s reduction 
potential. This might be achieved by creating a triazole ring or altering the electron 
demand in the ring system. Compounds with these structural features have been shown 
to have reduction potentials in the range necessary for hypoxia activated anticancer 
prodrugs.81
7.3 Benzene and thiophene derivatives
Table 7 shows results from the biological screening o f  the benzene and thiophene 
derivatives.
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Compound
Number
Structure Sui
I
Oxic
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an
IT29 CeUs 
Hypoxic
jrcentag 
d I C 5 0 1
IC50
;e o f  com 
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Oxic
trol at 1 m  
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BE Cells 
Hypoxic
M
IC50
173a
o c h 3
^ L ^ o c h 3
OCONH
1 0 0 2 1 2 0 0 1 0 0 1 0 0 60
173b
OCH3
J s s .°CH3
w
OCONH
1 0 0 1 0 0 1 2 0 0 76 1 0 0 2 0 0 0
174a
OCH3
J ^ O C a 3
- Y r
OCONH
1 0 0 1 0 0 810 1 0 0 1 0 0 750
174b
OCH3
i ^ O C H a
OCONH
55 1 0 0 630 84 75 4.6
179a r \  Y> V ^ O C O N H 47 94 94 1 0 0 1 0 0 280
179b Pn  T
J ^ ^ O C O N H
5 27 330 8 82 290
180a 49 63 420 18 21 330
180b 0r \  T
X  .OCONH
o 2n ^  ^ s t  ^
1 0 0 1 0 0 530 85 58 250
Table 7 -  IC50 values and oxic:hypoxic results for the benzene and thiophene derivatives.
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Several o f  the compounds tested seemed to show a selective toxicity under oxic 
conditions for both BE cells and HT29 cells. Although in some cases it is possible that 
this result could be due to the toxicity o f the reduced form o f  the compound being less 
than the oxygenated form, this appears unlikely. This trend is seen in compounds such as 
173a, 179a and 179b which do not contain any nitro groups or any other readily 
bioreducible moieties. Furthermore, the toxicity o f  reduced nitro species has been 
frequently shown to be greater than their non-reduced forms. It seems probable that the 
increased toxicity o f  these compounds under oxic conditions is a result o f  a bioprotective 
change in the tumour cells when they are under hypoxic conditions, such as a reduction 
in the rate that these cells progress through the cell cycle.
The results obtained in both the oxic:hypoxic screening and the IC50 tests show that 
versions o f  each compound containing and not containing nitro groups have similar 
toxicity. Graph 23 shows one example where the compound containing a nitro group, 5- 
hydroxymethyl-1,2-dimethoxy-4-nitrobenzene phenylcarbamate (174b), was slightly 
more toxic than its non-nitro counterpart, 4-hydroxymethyl-l,2-dimethoxybenzene 
phenylcarbamate (173b). However, by replacing the phenylcarbamate for an 
isopropylcarbamate the results are reversed, with the deriviative contiaing no nitro 
group (173a) showing a greater toxicity than the derivative containing the nitro group 
(174a).
In general the toxicity o f  the compounds under test varied slightly between the two cell 
lines used, some compounds being slightly more toxic to BE cells whilst others were 
slightly more toxic towards HT29 cells. Only 5-hydroxymethyl-1,2-dimethoxy-4- 
nitrobenzene phenylcarbamate (174b) showed any appreciable toxicity differential 
between the two cell lines. This compound was 136 times more toxic to BE cells than 
HT29 cells (see Graph 24). Since BE cells express a non-active form o f  DT-diaphorase, 
and as such can facilitate only one-electron reduction events, these results imply that 5- 
hydroxymethyl-l,2-dimethoxy-4-nitrobenzene phenylcarbamate (174b) undergoes one- 
electron reduction to generate a toxic species. This species is not generated if  the 
compound undergoes two-electron reduction, and so cells which contain high levels o f  
DT-diaphorase, such as HT29 cells, are resistant to the effects o f  5-hydroxymethyl-1,2- 
dimethoxy-4-nitrobenzene phenylcarbamate (174b).
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Although this compound has shown a pattern o f  activity which implies that it undergoes 
one-electron reduction to generate a toxic species, the oxic:hypoxic screening appears to 
shows that this reduction shows little hypoxia selectivity. It is possible that the apparent 
lack o f  selectivity could be due to the reduction potential o f  this compound being within 
the range necessary for biochemical reduction in oxic as well as hypoxic cells (<-0.2 V). 
Future work on this compound is required to determine accurately its hypoxic selectivity, 
as well as its reduction potential.
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Graph 23 -  Toxicity profiles o f 4-hydroxymethyl-l,2-dimethoxybenzene 
phenylcarbamate (173b) and 5-hydroxymethyl-l,2-dimethoxy-4-nitrobenzene 
phenylcarbamate (174b) to BE cells.
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Graph 24 -  Toxicity profiles o f  5-hydroxymethyl-l,2-dimethoxy-4-nitrobenzene
phenylcarbamate (174b).
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8. Exp e r im e n ta l
8.1 General
All melting points were measured on a Kofler hot-stage or Gallenkamp melting point 
apparatus and are uncorrected. Infra red spectra were obtained on a Perkin Elmer 580 or 
Perkin Elmer Paragon 1000 spectrophotometer in the form o f  KBr discs for solids and 
thin films or solutions for oils and liquids. Nuclear magnetic resonance spectra were 
recorded with a Bruker WP 200-SY or AM 200-SY spectrometer operating at 200 MHz 
(8h) and 50 MHz (5c) with reference to the solvent as an internal standard. Coupling 
constants are quoted in Hz. The multiplicities o f  the 13C NMR spectra were determined 
using DEPT spectra with pulse angles o f  90 and 135 °. Mass spectra were obtained with 
V G  updated A.E.I. MS 12 or 902 spectrometers. Elemental analyses were obtained with 
a Carlo-Erba 1106 elemental analyser.
TLC was carried out on either neutral aluminium oxide 60 F254 or Kieselgel 60 F254 plates 
o f  0.2 mm thickness obtained from Merck and were detected using U V light, or 
visualised using a vanillin based solution [vanillin (5 g) dissolved in ethanol (160 ml) and 
sulfuric acid (2 M, 40 ml)] which was developed by heating. Column chromatography 
was carried out using 70-230 mesh or 230-400 mesh silica gel.
Tetrahydrofuran was dried by distillation from sodium-benzophenone under nitrogen 
prior to use. Dichloromethane was dried by distillation from calcium hydride. DMF was 
dried by distillation from magnesium sulfate. Triethylamine was distilled from potassium 
hydroxide. Petroleum ether refers to the fraction with the boiling range 40-60 °C. 
Solvents were evaporated off under reduced pressure below 50 °C.
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8.2 Synthetic Methods
A - Isocyanate Production
A  solution o f  the alcohol, excess isocyanate and dibutyltin diacetate (2 drops) in 
dichloromethane was stirred at room temperature until TLC indicated that the reaction 
had gone to completion, after which time the volatiles were removed to give the crude 
product.
B - N-oxide Production
A solution o f  the free base and a slight excess o f  zwe/a-chloroperoxybenzoic acid (m- 
CPBA) in dichloromethane was stirred at room temperature until TLC indicated that the 
reaction had gone to completion. The reaction mixture was then washed with saturated 
sodium bicarbonate solution (3 portions), and the washings extracted with 
dichloromethane (2 portions). The combined organic fractions were then dried, filtered 
and concentrated to yield the crude product.
C - N-oxide Production
This procedure was employed only when the A-oxide produced was completely soluble 
in the reaction medium.
The reaction was performed as in procedure B, but the workup was accomplished by 
flushing the reaction mixture through a short (~4 cm) basic alumina pad and eluting with 
methanol (-4 0 0  ml). Evaporation o f  the volatiles gave the crude product.
D - N-oxide Production
This procedure was employed only when the iV-oxide produced was very sparingly 
soluble in the reaction medium.
The reaction was performed as in procedure B, but the workup was accomplished by 
filtering off the precipitate.
E - Reduction with Sodium Borohydride
The aldehyde was dissolved in methanol and the solution cooled by application o f  an ice 
bath. To the stirred reaction mixture, a solution o f  excess sodium borohydride 
( -4  equivalents) in methanol was added dropwise, over several minutes. The majority o f
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the methanol (90%) was then evaporated. Water and a few drops o f  saturated ammonia 
solution were added and the resulting mixture was extracted with ethyl acetate (3 
portions). The organic extracts were dried, filtered and concentrated to give the crude 
product.
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8.3 Experimental for Chapter 4
2.6-Bis(hydroxymethyl)pyridine mono(isopropylcarbamate) (102)
2.6-Bis(hydroxymethyl)pyridine bis(isopropylcarbamate) (103)
A  s a m p l e  o f  2 , 6 - b i s ( h y d r o x y m e t h y l ) p y r i d i n e  ( 1 0 1 )  ( 0 . 7 3 5 0  g, 5 . 2 5  m m o l )  w a s  t r e a t e d  
w i t h  i s o p r o p y l  i s o c y a n a t e  ( 1 . 2 7 5 0  g ,  1 4 . 9 8  m m o l )  i n  d i c h l o r o m e t h a n e  ( 5 0  m l )  b y  t h e  
m e t h o d  o u t l i n e d  i n  p r o c e d u r e  A  f o r  2  h .  T h i s  g a v e  a  c r u d e  p r o d u c t  ( 1 . 4 5 0 0  g ) ,  a  s m a l l  
s a m p l e  o f  w h i c h  ( 0 . 3 0 2 5  g )  w a s  p u r i f i e d  b y  d r y  c o l u m n  f l a s h  c h r o m a t o g r a p h y  [ S i 0 2 ,  
E t O A c / p e t .  e t h e r ]  t o  y i e l d  2 , 6 - b i s ( h y d r o x y m e t h y l ) p y r i d i n e  m o n o ( i s o p r o p y l c a r b a m a t e )  
( 1 0 2 )  ( 0 . 0 8 2 3  g ,  0 . 3 4  m m o l ,  3 1 %  [ y i e l d  b a s e d  o n  u s i n g  a l l  t h e  c r u d e  s a m p l e  f o r  
c h r o m a t o g r a p h y ] ) ,  a n d  2 , 6 - b i s ( h y d r o x y m e t h y l ) p y r i d i n e  b i s ( i s o p r o p y l c a r b a m a t e )  ( 1 0 3 )  
( 0 . 1 5 0 2  g ,  0 . 4 9  m m o l ,  4 4 % ) .
2 . 6 - B i s ( h y d r o x y m e t h y l ) p y r i d i n e  />-py 
m o n o ( i s o p r o p y l c a r b a m a t e )  ( 1 0 2 )  m . p .  2 4 8 -  
2 5 0  ° C  ( F o u n d :  M*, 2 2 4 . 1 1 4 3 .  C i i H i 6 0 3N 2  
r e q u i r e s  M, 2 2 4 . 1 1 6 1 ) ;  R f  0 . 4 1  [ S K > 2,  E t O A c ] ;
V i M x / c m '1 ( K B r )  3 2 9 0  ( O H  a n d  N H ) ,  3 0 1 0  ( A r H ) ,  H N C O O  O H
2 9 7 0  a n d  2 9 3 0  ( C H 3  a n d  C H 2 ) ,  2 8 6 0  ( C H ) ,  1 7 1 0  a n d  1 7 0 0  ( C = 0 ) ,  1 6 1 0 ,  1 5 5 0  a n d  1 4 5 0  
( A t ) ,  1 3 2 0  ( O H  a n d  C - 0  [ O C O N ] ) ,  1 0 8 0  ( C - 0  [ C H 2 O H ] ) ;  5 h  (2 0 0  M H z ,  C D C 1 3)  1 . 0 9  
(6  H ,  d ,  J  7 . 0 ,  C H 3 ) ,  3 . 8 0  ( 1  H ,  m ,  C / / ( C H 3 ) 2) ,  4 . 0 2  ( 1  H ,  b s ,  N H ) ,  4 . 6 2  ( 2  H ,  s ,  
C / / 2 O H ) ,  5 . 1 1  ( 2  H ,  s ,  CH2OCO), 7 . 1 8  ( 2  H ,  d ,  J  7 . 4 ,  m - P y - H ) ,  7 . 5 3  ( 1  H ,  t ,  J  7 . 4 ,  p- 
P y - H ) ;  5 c  ( 5 0  M H z ,  C D C 1 3 )  2 3 . 5  ( C H 3) ,  4 4 . 2  ( C H ,  C H ( C H 3 ) 2 ) ,  6 3 . 3  ( C H 2 ,  C H 2 O H ) ,
66.8 ( C H 2 ,  C H 2 O C O ) ,  1 2 0 . 2  ( C H ,  m - P y ) ,  1 3 7 . 0  ( C H ,  p - P y ) ,  1 5 4 . 9 0  ( C ,  o - P y ) ,  1 5 9 . 9 0  
( C ,  C O ) ;  m/z ( A / ,  0 . 8 % ) ,  1 6 6  ( 4 7 . 2 ,  - N H ' P r ) ,  1 3 8  ( 3 6 . 1 ,  - C O N H ' P r ) ,  1 2 2  ( 7 6 . 2 ,  -  
O C O N H ' P r ) ,  1 2 1  ( 7 1 . 0 ,  - O C O N H ' P r - H ) ,  1 0 5  ( 9 . 6 ,  - O C O N H ' P r - O H ) .
2 . 6 - B i s ( h y d r o x y m e t h y l ) p y r i d i n e  
b i s ( i s o p r o p y l c a r b a m a t e )  ( 1 0 3 )  m . p .  1 3 7 -  
1 3 9  ° C  ( F o u n d :  C ,  5 8 . 2 0 ;  H ,  7 . 4 9 ;  N ,  1 3 . 4 9 % ;
A f  3 0 9 . 1 6 8 3 .  C13H23N 3O4 r e q u i r e s  C ,  5 8 . 2 2 ;
H ,  7 . 5 1 ;  N ,  1 3 . 5 8 % ;  My 3 0 9 . 1 6 8 8 ) ;  R f  0 . 6 7
O C O N HH N C O O
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[S i0 2, EtOAc]; Vmax/cm*1 (KBr) 3305 (NH), 3060 (ArH), 2980 and 2940 (CH3 and CH2), 
2880 (CH), 1720 and 1690 (C =0), 1545 (Ar); 6 h  (200 MHz, CDC13) 1.1 (12 H, d, J  6.5, 
CH3), 3.8 (2 H, m, C//(CH3)2), 4.8 (2 H, bs, NH), 5.2 (4 H, s, CH2), 7.2 (2 H, d, J  7.7, 
m-Py-H), 7.7 (1 H, t, J  7.7, p-Py-H); 6C (50 MHz, CDCI3) 23.0 (CH3), 43.2 (CH, 
CH(CH3)2), 6 6 .8  (CH2), 120.5 (CH, m-Py), 137.4 (CH, p-Py), 155.2 (C, o-Py), 156.3 
(C, CO); m/z 310 (A7H+, 1.2%), 309 (0.3, A /) , 251 (55.7, -NH'Pr), 224 (30.1, - 
CONH'Pr +H), 223 (6.0, -CONHPr), 208 (53.2, -OCONH'Pr +H), 105.0562 (105.0579,
9.9, -2xOCONH'Pr).
2.6-Bis(hydroxymethyl)pyridine bis(isopropylcarbamate) (103)
Procedure A  was employed, using 2,6-bis(hydroxymethyI)pyridine (101) (0.7350 g,
5.28 mmol), isopropyl isocyanate (1.700 g, 20.00 mmol) and dichloromethane (50 ml), 
to yield a crude product (1.834 g) after 17 h. Crystallisation from dichloromethane/pet. 
ether gave colourless needles (1.513 g, 4.90 mmol, 93%), analysis o f  which was 
consistent with a reference sample.
2.6-Bis(hydroxymethyl)pyridine bis(ethylcarbamate) (104)
Procedure A  was employed using 2,6- 
bis(hydroxymethyl)pyridine (101) (0.7392 g,
5.32 mmol), ethyl isocyanate (1.5106 g,
21.28 mmol) and dichloromethane (50 ml).
HNCOO OCONH
After 18 h the crude product generated was
isolated and crystallised from dichloromethane/pet. ether to give colourless needles 
(1.4178 g, 5.05 mmol, 95%), m.p. 129-131 °C (Found: C, 55.25; H, 6.82; N, 15.04%; 
A /,  281.1375. C rsH isN ^  requires C, 55.52; H, 6.76; N, 14.95%; M, 281.1375); R f 
0.59 [S i0 2, EtOAc]; v ^ /c m ' 1 (KBr) 3360 (NH), 3060 (ArH), 2975 and 2940 (CH3 and 
CH2), 1720 and 1690 (C =0), 1600 and 1530 (Ar); 8h (200 MHz, CDC13) 1.08 (6  H, t, J
9.9, CH3), 3.17 (4 H, m, C //2CH3), 5.02 (2 H, bs, NH), 5.12 (4H, s, CH2Py), 7.19 (2 H, 
d, J  7.7, m-Py-H), 7.61 (1 H, t, J  7.7, p-Py-H); 8c (50 MHz, CDC13) 15.0 (CH3), 35.8 
(CH2, C H ^H s), 66.7 (CH2, CH2Py), 120.2 (CH, m-Py), 137.2 (CH, p-Py), 155.9 (C, o- 
Py), 156.2 (C, CO); m/z 282 (A/H+, 0.8%), 281 (0.1, A /) ,  266 (0.1, -CH3), 237 (8 .1, 
-NHEt), 210 (13.8, -CONHEt +H), 194 (53.3, -OCONHEt +H).
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2.6-Bis(hydroxymethyl)pyridine bis(phenylcarbamate) (105)
Procedure A  was employed using 2,6- 
bis(hydroxymethyl)pyridine (101) (0.735 g,
5.25 mmol), phenyl isocyanate (2.38 g,
20.0 mmol) and dichloromethane (50 ml).
The crude product (2.566 g), formed after 
17 h, was crystallised from acetone/hexane 
4.94 mmol, 94%), m.p. 155-157 °C (Found: C, 66.84; H, 5.11; N, 11.12%. C21H 19N 3O4 
requires C, 66.84; H, 5.04; N, 11.14%); R f 0.84 [S i02, EtOAc]; W c m ' 1 (KBr) 3320 
(NH), 3030 (ArH), 2940 (CH2), 1700 (C =0), 1500 (Ar), 750 and 650 (5 adjacent H on 
an aromatic ring); 8h (200 MHz, ^-acetone) 5.24 (4 H, s, CH2), 7.01 (2 H, m, /?-Ar-H), 
7.20 (4 H, m, ro-Ar-H), 7.39 (2 H, d, J7 .8 , m-Py-H), 7.56 (4 H, m, o-Ar-H), 7.66 (1 H, 
t, J  7.8,/7-Py-H), 8.10 (1 H, bs, NH), 8.91 (1 H, bs, NH); 6C (50 MHz, ^-acetone) 67.3 
(CH2), 119.1 and 119.4 (CH, o-Ar), 121.0 and 123.6 (CH, /?-Ar), 122.8 (CH, /w-Py), 
129.5 and 129.6 (CH, /w-Ar), 138.5 (CH, p-Py), 140.0 and 140.1 (C, s-Ar), 154.2 (C, o- 
Py), 157.3 (C, CO); m/z 137 (0.2, -2xCONHPh), 119 (26.7, CONPh), 77 (20.6, Ph).
2.6-Bis(hydroxymethyl)pyridine bis(4-nitrophenylcarbamate) (106)
A solution o f  2,6-
bis(hydroxymethyl)pyridine (101) (0.2418 g,
1.74 mmol), 4-nitrophenyl isocyanate 
(1.1401 g, 6.952 mmol) and dibutyltin 
diacetate (2 drops) in dichloromethane 
(50 ml) was stirred for 18 h. The yellow 
precipitate produced (0.7940 g) was filtered 
off and recrystallised from DMSO/water to give yellow needles (0.5264 g, 1.13 mmol, 
65%), m.p. 244-246 °C, R f 0.66 [S i02, EtOAc]; W e n t '1 (KBr), 3420 (NH), 3080 
(ArH), 2920 (CH2), 1740 and 1730 (C =0), 1600 and 1650 (Ar), 1500 and 1330 (N 0 2), 
850 (2 adjacent H on an aromatic ring); 5h (200 MHz, dk-DMSO) 5.29 (4 H, s, CH2), 
7.44 (2H, d, J 7 .7 , /w-Py-H), 7.68 (4H, m, o-Ar-H ), 7.92 (1 H, t, J  7.7, /?-Py-H), 8.18 (4 
H, m, m-Ar-H), 10.58 (2 H, bs, NH); 5C (50 MHz, ri^-DMSO) 66.7 (CH2), 117.7 (CH, 
o-Ar), 121.1 (CH, w-Py), 125.1 (CH, m-Ar), 138.1 (CH, p-Py), 141.8 (C,/?-Ar), 145.5 
(C, 5-Ar), 152.9 (C, o-Py), 155.6 (C, CO); m/z 137 (1.4, -2><C0NHPhN02), 122 (1.7,
N 0 2 N O ,
N
flNCOO OCONH
£Ar p * y  p-Az
/ \
• m-Ar 
X  o - A i  x  |
m-Py ^
*  o-Py v
N
■ m-Ar 
°-Ar x
HNCOO OCONH
to gave colourless needles (1.862 g,
o © OCONHHNCOO
P hN 02), 106 (32.6, PhNO), 92 (22.6, PhNH), 90 (100.0, ArN). Small additional peaks 
were noted in both o f  the NMR spectra []6c 117.94 (CH, o-Ar), 125.15 (CH, w-Ar), 
141.57 (C, p -Ar), 145.71 (C, s-Ar) and 151.92, (C, C =0)], these are described in 
Chapter 3 and were assigned to 4-nitrophenylcarbamic acid.
2.6-Bis(hydroxymethyl)pyridine bis(isopropylcarbamate) N-oxide (107)
Procedure B was used with
2 .6-bi s(hy droxymethyl)pyridine 
bis(isopropylcarbamate) (103) (0.100 g,
0.32 mmol), w-CPBA (0.084 g, 0.49 mmol) 
and dichloromethane (2 ml), to produce the 
crude product (0.054 g), within 17 h. Crystallisation from dichloromethane/pet. ether 
gave colourless needles (0.042 g, 0.14 mmol, 43%), m.p. 160-162 °C (Found: C, 55.22;
H, 7.05; N, 12.85%; M+, 325.1636. C13H23N 3O5 requires C, 55.38; H, 7.08; N, 12.92%; 
M, 325.1638); R f 0.32 [S i02> EtOAc]; W e n t 1 (KBr) 3300 (NH), 3060 (ArH), 2980 
and 2940 (CH, and CH2), 2880 (CH), 1720 and 1680 (C =0), 1300 (C-O), 1225 (N+- 0 ‘); 
8 h  (200 MHz, CDCI3) 1.15 (12 H  d, J 6 .5 , CH3), 3.81 (2 H, m, CH(CH3)2), 4.99 (2 H, 
d, J  6.0, NH), 5.31 (4 H, s, CH2), 7.25 (3 H  s, m-Py-H and p-Py-H); 6c (50 MHz, 
CDC13) 22.9 (CH3), 43.3 (CH, O ^C H j^), 60.4 (CH2), 122.3 (CH, m-Py), 125.2 (CH, 
p-Py), 147.6 (C, o-Py), 154.7 (C, CO); m/z 325 (AT, 0.2), 251 (1.2, -NH'Pr -O), 240 
(1.3, -CONH'Pr +H), 239 (0.2, -CONH'Pr), 224 (3.3, -CONH'Pr -O +H) 223 (5.4, - 
CONH'Pr -O), 209 (1.5, -CH2OCONH,Pr), 182 (2.6, -CONH'Pr -NH'Pr +H), 166 (6.0, - 
CONH'Pr -NH'Pr -O) 154 (3.2, -2><CONH'Pr +H).
2.6-Bis(hydroxymethyl)pyridine bis(ethylcarbamate) N-oxide (108)
Using procedure B with a 5 h reaction time,
2.6-bis(hydroxymethyl)pyridine 
bis(ethylcarbamate) (104) (0.7130 g,
2.54 mmol), m-CPBA (0.4441 g, 2.57 mmol)
and dichloromethane (50 ml), a crude product HNCOO 0 0  OCONH  
(0.7440 g) was produced. Crystallisation from ethanol gave colourless needles (0.5106 g,
I.72 mmol, 68%), m.p. 162-164 °C (Found: C, 52.49; H, 6.52; N , 14.02%; A /,  
297.1316. Ci3Hi9N30 5 requires C, 52.52; H  6.39; N, 14.14%; A/, 297.1325); R f 0.13 
[S i0 2, EtOAc]; W c m ' 1 (KBr) 3305 (NH), 3040 (ArH), 2980 and 2960 (CH3 and CH2),
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1725 and 1700 (C =0), 1530 (Ar), 1240 (bf-CT); 6 h  (2 0 0  MHz, CDCfe) 1.11 (6  H, t, J  
7.7, CH3), 3.20 (4 H, d, J 7.7, C //2CH3), 5.06 (2 H, bs, NH), 5.30 (4 H, s, CH2Py), 7.24 
(3 H, s, m-Py-H and p-Py-H); 8C (50 MHz, CDC13) 15.0 (CH3), 35.9 (CH2, CH2CH3), 
60.4 (CH2, CHiPy), 122.1 (CH, m-Py), 125.2 (CH, p-Py), 147.5 (C, o-Py), 155.4 (C, 
CO); m/z 298 (A t  [ l x I3C], 0.1), 297 (0.2, A t), 253 (0.1, -NHEt), 237 (0.3, -NHEt -O), 
226 (2.9, -CONHEt +H), 225 (0.2, -CONHEt), 210 (2.5, -CONHEt -O +H), 209 (3 .8 , - 
CONHEt -O), 194 (3.8, -OCONHEt -O +H), 137 (67.0, -OCONHEt -CONHEt -O), 
121 (41.0, -OCONHEt -CONHEt -2x0 ).
HNCOO OCONH
2.6-Bis(hydroxymethyl)pyridine bis(phenylcarbamate) N-oxide (109)
Procedure D was employed using
2 .6 -bis(hydroxymethyl)pyridine 
bis(phenylcarbamate) (105) (0.7327 g,
1.94 mmol), m-CPBA (0.3404 g, 1.97 mmol) 
and dichloromethane (50 ml). After 72 h the 
precipitate produced (0.6438 g) was filtered off and a sample (0.2512 g, 0.64 mmol) was 
recrystallised from methanol to yield large colourless needles (0.1446 g, 0.37 mmol, 48% 
[yield based on using all the crude sample for recrystallisation]), m.p. 204-205 °C 
(Found: C, 64.31; H, 4.61; N, 10.51%. C2iH19N 30 5  requires C, 64.12; H, 4.83; N, 
10.68%); R f 0.65 [S i02, EtOAc]; v ^ /c m "1 (KBr) 3350 and 3180 (NH), 3040 and 3020 
(ArH), 2950 (CH2), 1740 and 1720 (C =0), 1220 (hT-O-), 750 and 690 (5 adjacent H on 
an aromatic ring); 5H (200 MHz, ^ D M S O ) 5.30 (4 H, s, CH2), 7.01 (2 H, m, p-Ar-H),
7.29 (4 H, m, m-Ar-H), 7.51 (7 H, m, o-Ar-H, m-Py-H and p-Py-H), 10.00 (2 H, bs, 
NH); 8c (50 MHz, <&-DMSO) 60.2 (CH2), 118.3 (CH, o-Ar), 122.7 (CH, p-Ar), 123.0 
(CH, m-Py), 125.2 (CH, p-Py), 128.9 (CH, /w-Ar), 138.8 (C, 5-Ar), 146.6 (CH, o-Py),
152.8 (C, CO); m/z 274 (0.1, -CONHPh +H), 182 (0.1, -CONHPh -NHPh +H), 154 
(0.2, -2xCONHPh +H), 92 (5.7, -2xCH2OCONHPh) .
2,6-Bis(bromomethyl)pyridine (117)
Hydrobromic Acid: A modified version o f the procedure carried 
out by Baker et al165 was performed on a sample o f  2,6- 
bis(hydroxymethyl)pyridine (101) (0.4562 g, 3.28 mmol) which 
was heated at reflux in concentrated hydrobromic acid (46-48%, 
5 ml) for 3 h, then cooled by application o f an ice salt bath.
BrBr
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Saturated sodium hydroxide solution was then added dropwise with swirling until the 
solution was basic, at which point the precipitate was collected by filtration to give a pale 
pink powder (0.6130 g). Crystallisation from pet. ether gave colourless platelets 
(0.4008 g, 1.51 mmol, 46%), m.p. 83.6-84.5 °C (lit.165 84-89°C) (Found: C, 31.83; H, 
2.43; N, 5.10; Br, 60.38%; b f  [2x81Br] 266.8893. C7H7NBr2 requires C, 31.73; H, 2.66; 
N, 5.29; Br, 60.32%; M  266.8907); R f 0.86 [S i02, EtOAc]; W c m ' 1 (KBr) 3070 and 
3020 (ArH), 2970 and 2920 (CH2), 1595, 1570 and 1460 (Ar), 600 (CBr); 5H (200 
MHz, CDC13) 4.50 (4 H, s, CH2), 7.28 (2 H, d, 7 7 .7 , /n-Py-H), 7.66 (1 H, t, 7 7 .7 , p-Py- 
H); 6C (50 MHz, CDCI3) 33.4 (CH2), 122.7 (CH, w-Py), 138.0 (CH, p-Py), 156.5 (C, 0 - 
Py); m/z 267 (AC [2x81Br], 11.3), 266 (1.4, AC [lx^C , lx 81Br, l x ^ r ] ) ,  265 (23.9, AC 
[ lx 81Br, l x ^ r ] ) ,  105 (33.9, -2xBr), 91 (1.4, -C H ^r-B r).
Phosphorus tribromide: A solution o f  2,6-bis(hydroxymethyl)pyridine (101) (0.2524 g, 
1.81 mmol) in dichloromethane (10 ml) was cooled by application o f  an ice/salt bath and 
a solution o f  phosphorus tribromide (0.2579 g, 4.65 mmol) in dichloromethane (5 ml) 
was added to it dropwise, over the period o f 1 h. The resulting mixture was left to warm 
to room temperature and stirred for a further 18 h. The reaction mixture was then cooled 
in an ice/salt bath and the remaining phosphorus tribromide was decomposed by addition 
o f  ice water (10 ml) and then saturated sodium bicarbonate solution (40 ml). The two 
phases were separated and the aqueous phase was extracted with ethyl acetate 
(2 x 50 ml). Combining the organic phases, drying, filtering and concentration gave the 
required product as a white solid (0.1236 g, 0.46 mmol, 26%), analysis o f  which was 
consistent with a reference sample.
Triphenylphosphine and molecular bromine: A solution o f  triphenylphosphine 
(1.4659 g, 5.59 mmol) in dry acetonitrile (15 ml) was cooled by application o f  an ice/salt 
bath. To this, sufficient molecular bromine (1.047 g, 6.55 mmol) in dry acetonitrile 
(5 ml) was added until the reaction mixture just started to turn yellow. At this point a 
solution o f  2,6-bis(hydroxymethyl)pyridine (101) (0.3875 g, 2.78 mmol) in dry 
acetonitrile (5 ml) was added dropwise, and the system was allowed to reach room 
temperature. After IV2 h o f  stirring the precipitate was filtered o ff and dissolved in 
saturated sodium bicarbonate solution (50 ml). This solution was filtered and the filtrate 
was extracted with ethyl acetate (3 x 50  ml). The combined organic fractions were dried,
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filtered and concentrated to give a white solid (0.1415 g, 0.53 mmol, 19%), analysis o f  
which was consistent with a reference sample.
2.6-Bis(chloromethyl)pyridine (118)
A  modified version o f  the procedure carried out by Baker et a l165 
was performed on a solution o f  2,6-bis(hydroxymethyl)pyridine 
(101) (0.9621 g, 6.93 mmol), in thionyl chloride (14 ml) which 
was warmed to 50 °C for 4 h. After cooling, the solution was 
added to toluene (200 ml), and the precipitated hydrochloride 
salt (1.1700 g) was collected by filtration. The salt was neutralised by addition o f  
saturated sodium bicarbonate solution (30 ml) and then extracted with dichloromethane 
(3 x 30 ml). The organic extracts were dried, filtered and concentrated to give the crude 
product as a free base (0.9277 g). Crystallisation from petroleum ether yielded colourless 
needles (0.8721 g, 4.95 mmol, 71%), m.p. 73.6-74.5 °C (lit.165 72-74°C) (Found: C, 
47.55; H, 3.94; N, 7.80; Cl, 40.05%; K t  [2x37C1], 178.9900. C7H7NC12 requires C, 
47.76; H, 4.04; N, 7.96; Cl, 40.28%; A/, 178.9896); R f 0.72 [S i0 2, EtOAc]; W c m ' 1 
(KBr) 3080 and 3020 (ArH), 2970 and 2860 (CH2) 1595, 1580 and 1460 (Ar), 680 
(CC1); 8h (200 MHz, CDC13) 4.61 (4 H, s, CH2), 7.36 (2 H, d, J  7.7, m-Py-H), 7.69 (1 
H, t, J  7.7,p-Py-H); 6C (50 MHz, CDCI3) 46.3 (CH2), 122.0 (CH, w-Py), 138.0 (CH, p- 
Py), 156.1 (C, o-Py); m/z 179 {h/C [2x37C1], 10.4), 178 (5.1, A /  [lx^ C , lx 37Cl,
1 x35Cl]), 177 (61.9, A /  [ lx 37Cl, lx 35Cl]), 176 (8.2, A /  [lx^ C , 2 x35C1]), 175 (100.0, A /  
[2x35C1]), 143 (1.7, -Cl [ lx DC, lx 37Cl]), 142 (17.2, -Cl [ lx 37Cl]), 140 (57.3, -Cl 
[ lx 35Cl]), 128 (1.0, -CH2C1 [1x37C1]), 126 (4.1, -CH2C1 [ lx 35Cl]), 91 (3.9, -CH2C1 -Cl).
2.6-Dimethylpyridine (133)
A  solution o f  2,6-bis(hydroxymethyl)pyridine (101) (0.1588 g, 1.14 mmol) in hydriodic 
acid (54-56%) was heated at reflux for 21 h. The mixture was evaporated to dryness and 
the residue was taken up in a mixture o f  dichloromethane (20 ml) and water. The two 
phases were then separated and the aqueous phase was extracted with dichloromethane 
(2 x 20 ml). Combining the organic fractions, drying, filtration and concentration gave a 
crude product (0.0223 g), which was purified by flash column chromatography [S i02, 
EtOAc/pet. ether] to give a yellow oil (0.0155 g, 0.14 mmol, 12%), R f 0.47 [S i02, 
EtOAc]. Analysis o f  this compound was consistent with a reference sample o f  the named 
compound.
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2,6-Bis(iodomethyl)pyridine (119)
A solution o f  2,6-bis(chloromethyl)pyridine (101) (0.6825 g,
3.55 mmol) and sodium iodide (1.0725 g, 7.16 mmol) in acetone 
(30 ml) was placed in a flask, which was shielded from light, and 
heated to reflux for 24 h. The sodium chloride precipitate 
produced was filtered off and the volatiles removed from the 
filtrate to yield a white solid, the NMR spectrum o f  which showed it to contain some 
starting material. Hence, the solid was redissolved in acetone (30 ml), a further portion 
o f  sodium iodide (1.0351 g, 6.91 mmol) was added and heating at reflux was continued 
for a further 24 h. After this time filtration o f  the precipitate and concentration o f  the 
filtrate gave an orange solid, which was dissolved in dichloromethane (15 ml) and passed 
through a short Florisil (60-100 mesh) pad to yield an orange solid (1.2465 g). 
Crystallisation from dichloromethane/pet. ether gave the required product as pale yellow  
rhombic crystals (0.8217 g, 2.30 mmol, 65%), m.p. 80.5-81.0 °C (Found: C, 23.36; H,
1.88; N, 3.77; I, 70.73%; A /,  358.8667. C7H7NI2 requires C, 23.42; H, 1.97; N , 3.90; I,
70.71%; M  358.8671); R f 0.47 [S i02> EtOAc/pet. ether, 1:4]; W c m ' 1 (KBr) 3060 and 
3020 (ArH), 2995 and 2980 (CH2), 1590, 1570 and 1460 (Ar), 568 (Cl); 8H (200 MHz, 
CDCb) 4.48 (4 H, s, CH2), 7.25 (2 H, d, J l . l ,  m-Py-H), 7.58 (1 H, t, J 7  7, />-Py-H); 5C 
(50 MHz, CDCb) 6.0 (CH2), 121.7 (CH, m-Py), 139.9 (CH, p-Py), 158.1 (C, o-Py); m/z 
360 (M* [lx^ C ], 1.6), 359 (23.3, A /) , 233 (28.2, -1), 105 (52.2, -2x1).
O © BrBr
2,6-Bts(bromomethyl)pyridine N-oxide (120)
A  round-bottomed flask was charge with 2,6- 
bis(bromomethyl)pyridine (117) (0.2597 g, 0.98 mmol), m- 
CPBA (0.3427 g, 1.99 mmol) and dichloromethane (30 ml).
This solution was heated at reflux for 24 h and then washed 
with saturated sodium bicarbonate solution (3 x 30ml), which 
was back extracted with dichloromethane (2 x 30 ml). The combined organic extracts 
were dried, filtered and concentrated to give a yellow solid (0.3107 g), which was 
triturated with pet. ether (3 x 40 ml). The residue was then dissolved in ethyl acetate and 
passed through a short alumina pad. Further elution o f  the pad with ethyl acetate 
(2 x 20 ml), followed by concentration o f the combined fractions gave a pale yellow  
solid (0.1206 g, 0.43 mmol, 44%), m.p. 153.4-154.8 °C (Found: C, 29.93; H, 2.50; N,
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4.80; Br, 56.92%, A /,  282.8842. C7H7NOBr2 requires C, 29.93; H, 2.51; N, 4.99; Br, 
56.88%; M, 282.8856); R f 0.25 [S i02, EtOAc/pet. ether, 1:4]; Vmax/cm’1 (KBr) 3105 
(NH), 3070 and 3030 (ArH), 2960 (CH2), 1580 and 1425 (Ar), 1250 (InT-CT), 585 
(CBr); 8 h  (200 MHz, CDC13) 4.82 (4 H, s, CH2), 7.37 ( l H , t , 7  7.8, /?-Py-H), 7.94 (2 H, 
d, J  7.8, zw-Py-H); 6C (50 MHz, CDC13) 27.0 (CH2), 124.6 (CH, p-Py), 127.5 (CH, m- 
Py), 147.4 (C, o-Py); m/z 284 {h/t [ l x 13C, 2x81Br], 3.0), 283 (38.3, b /t  [2x81Br]), 280 
(3.6, M + [lx^ C , 2x79Br]), 279 (41.3, M+ P x ^ r ] ) ,  172 (5.0, -CH2Br -O [ lx 81Br]), 170 
(5.2, -CH2Br -O [ lx ^ r ] ) ,  91 (60.2, -CH2Br -O -Br).
2.6-Bis(chloromethyl)pyridine N-oxide (121)
2.6-Bis(chloromethyl)pyridine (118) (0.5282 g, 3.00 mmol), m- 
CPBA (1.1543 g, 6.69 mmol) and dichloromethane (30 ml) 
were stirred in a round-bottomed flask. Further portions o f  m- 
CPBA (0.1119 g, 0.65 mmol; 0.2533 g, 1.47 mmol; 0.4216 g,
2.44 mmol) were successively added at 20, 48 and 72 h, 
respectively. After a total reaction time o f  120 h the mixture was washed with saturated 
sodium bicarbonate solution (3 x 40 ml), and poured through an alumina column. The 
column was eluted with successive small portions o f  dichloromethane (2 0  x 30 ml). 
Those fractions which contained only the required product were combined and the 
volatiles removed. This gave the required product as a yellow solid (0.3737 g,
1.95 mmol, 65%), m.p. 110.0-110.9 °C (Found: C, 43.51; H, 3.79; N, 7.02; Cl, 36.73%; 
AT* [2x37C1], 194.9821. C7H7NOCI2 requires C. 43.78; H, 3.67; N, 7.27; Cl, 36.92%; AT, 
194.9846); R f 0.45 [AI2O3, EtOAc]; W c m ' 1 (KBr) 3120, 3080 and 3020 (ArH), 2960 
(CH2), 1590, 1430, 1420 and 1400 (Ar), 1260 (Nt-0 ')> 665 (CC1); 5h (200 MHz, 
CDCb), 4.78 (4 H, s, CH2), 7.28 (1 H, t, J  7.9, p-Py-H), 7.55 (2 H, d, J  7.9, m-Py-H), 
5c (50 MHz, CDCb) 39.7, (CH2), 124.8 (CH, m-Py), 125.0 (CH, p-Py), 147.2 (C, o-Py); 
m/z 195 (AT* [2x37C1], 9.0), 193 (56.5, A /  [ lx 37Cl, lx 35Cl]), 191 (81.5, AT" [2x35Cl]), 
158 (28.8, -Cl [ lx 37Cl]), 156 (0.2, -Cl [ lx 35Cl]).
0 0
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2,6-Bis(iodomethyl)pyridine N-oxide (122)
A  flask was charged with 2,6-bis(iodomethyl)pyridine (119)
(0.3161 g, 1.65 mmol), sodium iodide (0.8549 g, 5.70 mmol) and 
Analar acetone (25 ml). Light was excluded and the mixture was 
stirred for 18 h. The precipitate was filtered off* and silica was 
added to  the filtrate. Evaporation o f  the volatiles gave a solid 
which was subjected to gravity column chromatography [S i02, EtOAc/pet. ether, 1:2 ]. 
As the ratio o f  the solvent mixture was gradually increased to 1:1 the required product 
was obtained as a straw coloured solid (0.5523 g, 1.47 mmol, 89%), m.p. 116.1-
118.0 °C (Found A /,  374.8650. C7H7N0C12 requires M, 374.8621); R f 0.19 [S i02, 
EtOAc/pet. ether, 1:2]; W o n 1 (KBr) 3060 and 3034 (ArH), 2966 and 2924 (CH2), 
1485 (Ar), 1253 (IST-Cr), 529 (Cl); 5h (200 MHz, CDC13) 4.54 (4 H, s, CH2), 7.05 (1 H, 
t, J 7.8,/?-Py-H), 7.38 (2 H, d, J 7.8, m-Py-H); 6C (50 MHz, CDC13) -3.55 (CH2), 124.7 
and 124.8 (CH), 149.3 (C); m/z 375 (A /, 1.1), 248 (11.7, -I), 121 (42.3, -2><I), 105 
(45.7, -2 x1 -O), 91 (98.5, -CH2I -I -O).
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2-Hydroxymethylquinoline (142)
Procedure E was followed with 2- 
quinolinecarboxaldehyde (139) (1.008 g, 6.41 mmol) and 6 
sodium borohydride (0.5267 g, 13.86 mmol) in Analar 1 
methanol (170 ml). After workup this yielded a yellow 
solid (0.9987 g) which was dissolved in 
dichloromethane/acetone, 10 ml: 1 ml, filtered through a Celite pad and crystallised by the 
addition o f  hexane, to give colourless platelets (0.9276 g, 5.83 mmol, 91%), m.p. 6 8 - 
69 °C (Found: C, 75.23; H, 5.66; N, 8.97%; A /,  159.0672. C10H9NO requires C, 75.45; 
H, 5.70; N , 8.80%; M, 159.0684); R f 0.61 [S i02, EtOAc]; W c m ' 1 (KBr) 3220 (OH), 
3050 (ArH), 2980 and 2890 (CH2), 1600, 1565, 1510 and 1430 (Ar), 1320 (OH), 1080 
(CO), 840 (2 adjacent H on an aromatic ring), 750 (4 adjacent H on an aromatic ring); Sh 
(200 MHz, CDC13) 4.75 (1 H, bs, OH), 4.91 (2 H, s, CH2), 7.26 (1 H, d, J  8.4, 3-H), 
7.50 (1 H, ddd, J  6-H-7-H 8.2, J  frH-5-H 8.1 and J  g h -s -h  1-1, 6 _H), 7.69 (1 H, ddd, J  7 - h - 8 - h
8 .6 , J  7-h -6-h  8 .2  and J  7-h -s-h  1. 6 , 7-H), 7.76 (1 H, dm, 7 8 .1 , 5-H), 7.90 ( 1H, d, J  vn-w
8 .6 , 8 -H), 8.11  (1 H, d, 7 8 .4 , 4-H); 6c (50 MHz, CDCI3) 64.13 (CH2), 118.32 (CH, C- 
3), 126.24, 127.59, 128.49 and 129.71 (CH, C-5, C-6 , C-7 and C-8), 127.45 (C, C-4a),
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136.74 (CH, C-4), 146.65 (C, C-8a), 159.05 (C, C-2); m/z 160 (7.6, A t  [lx^ C ]), (77.1, 
A t),  158 (74.0, -H), 128 (46.3, -CH2OH).
3-Hydroxymethylquinoline (143)
Procedure E was followed using 3- 
quinolinecarboxaldehyde (140) (1.008 g, 6.41 mmol) 
and sodium borohydride (0.5267 g, 13.86 mmol) in 
methanol (170 ml). The normal workup followed by 
recrystallisation from dichloromethane/hexane gave colourless needles (1.2856 g,
8.09 mmol, 84%), m.p. 81.2-81.9 °C (Found: C, 75.62; H, 5.57; N , 8.91%; A /,  
159.0673. C10H9NO requires C, 75.45; H, 5.70; N, 8.80%; M  159.0685); R f 0.46 [S i0 2, 
EtOAc]; W c m 1 (KBr) 3140 (OH), 3005 (ArH), 2920 and 2850 (CH2), 1575, 1500 
and 1450 (Ar), 1330 and 1060 (OH), 785 (isolated H on an aromatic ring), 725 (4 
adjacent H on an aromatic ring); Sh (2 0 0  MHz, CDCI3) 4.82 (2 H, s, CH2), 5.26 (1 H, bs, 
OH), 7.45 (1 H, ddd, «/<s*-7-h 8.3, J  6-h -s-h  8.1 and J  6-h -s-h  1.1, 6-H), 7.60 (1 H, ddd, J  7-
8.4, J  7-H-6-H 8.3 and J  7-«-5-h  1.5, 7-H), 7.67 (1 H, dd, J  s-h -6-h  8.1 and J  5-H-7-H 1.5,
5-H), 7.98 (1 H, d, J  8.4, 8-H), 8.03 (1 H, d, J  2.2, 4-H), 8.72 (1 H, d, J  2.2, 2-H); 6C 
(50 MHz, CDCI3) 62.2 (CH2), 126.8, 127.7, 128.4 and 129.3 (C-5, C-6, C-7 and C-8),
127.8 (C, C-4a), 133.87, (CH, C-4), 134.19 (C, C-3), 146.88 (C, C-8a), 149.85 (CH, C- 
2); m/z 160 (9.8, b /t  [ l x BC]), 159 (83.7, A /) , 158 (39.7, -H), 142 (8.6, -OH), 128 
(12.5, -CH2OH).
4-Hydroxymethylquinoline (144)
Reduction o f  4-quinolinecarboxaldehyde (141) (1.5283 g,
9.72 mmol) with sodium borohydride (0.8006 g, 7.91 mmol) in f
methanol (150 ml) was accomplished using procedure E to give 
the crude product (1.3929 g), which was crystallised from | 
dichloromethane/acetone/hexane to give pale yellow rhombic 
crystals (1.2136 g, 7.63 mmol, 78%), m.p. 102-103 °C (Found:
C, 75.29; H, 5.68; N, 8.77%; A /, 159.0673. C10H9NO requires C, 75.45; H, 5.70; N, 
8.80%; M, 159.0684); R f 0.27 [S i02, EtOAc]; v ^ /c m 1 (KBr) 3140 (OH), 3060 (ArH), 
2990 and 2940 (CH2), 1590, 1570, 1510 and 1440 (Ar), 1090 (OH), 1250 (CO), 850 (2 
adjacent H on an aromatic ring), 760 (4 adjacent H on an aromatic ring); Sh (200 MHz, 
CDCI3) 5.19 (2 H, s, CH2), 5.46 (1 H, bs, OH), 7.47 (1 H, ddd, J  W t-7-H 8.4, J  6-H -5-H 8.3
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and J 6«^ h  1.1, 6-H), 7.51 (1 H, d, J 4.4, 3-H), 7.63 (1 H, ddd, 8.5, J 7# ^ h 8.4
a n d y 7* -5f l  1.3, 7-H), 7.87 (1 H, dd, J  8.3, 1.3, 5-H), 8.02 (1 H, dd, J  *«_
t*  8.5 a n d 7 s« -« i 1.1, 8-H), 8.65 (1 H, d, J 4 .4 , 2-H); 6C (50 MHz, CDCfe) 60.9 (CH2),
118.0 (CH, C-3), 122.8, 126.6, 129.30, and 129.3 (CH, C-5, C-6, C-7 and C-8), 125.9 
(C, C-4), 147.12 and 147.5 (C, C-4 and C-8a), 145.0 (CH, C-2); m/z 160 (K t  [ l x l3C], 
9.8), 159 (86.2, A /) ,  158 (3 1 .7 ,-H), 142 (4 .7 ,-OH), 128 (1 1 .5 ,-CH2OH).
2-Hydroxymethylquinoline isopropylcarbamate (145a)
A  solution o f  2-hydroxymethylquinoline (142)
(0.1057 g, 0.67 mmol), isopropyl isocyanate 
(0.1222 g, 1.436 mmol) and dibutyltin diacetate 
(2 drops) in dichloromethane (12 ml) was stirred 
for 24 h, after which time the reaction had not gone 
to completion, hence a further portion o f isopropyl isocyanate was added (0.5723 g,
6.72 mmol). The volatiles were removed after a total reaction time o f  48 h to yield a pale 
yellow solid (0.2188 g), which was purified using flash column chromatography [S i0 2, 
EtOAc/pet. ether] to yield an impurity (0.0270 g) R f 0.52 [S i0 2, EtOAc], and the 
required product as a yellow solid (0.1425 g, 5.84 mmol, 88%), m.p. 100-102 °C 
(Found: C, 66.68; H, 6.55; N, 11.47%; A /,  244.1195. C14H 16N2O2 requires C, 68.83; H,
6.60; N, 11.47%: M, 224.1212); R f 0.75 [S i02, EtOAc]; v ^ /c m '1 (KBr) 3320 (NH),
3050 (ArH), 2990 and 2920 (CH3 and CH2), 2860 (CH), 1680 and 1620 (C =0), 1600, 
1540, 1500 and 1460 (Ar), 1270 and 1260 (C-O), 840 (2 adjacent H on an aromatic 
ring), 770 (4 adjacent H on an aromatic ring); 8h (200 MHz, C D C I 3 )  1.18 (6 H, d, J  6.5, 
CH2), 3.88 (1 H, m, CH(CH3)2), 4.86 (1 H, bs, NH), 5.38 (2 H, s, CH2), 7.47 (1 H, d, J
8.5, 3-H), 7.52 (1 H, ddd, J en -w  8.3, 7  m m * 8.1 and 1.3, 6-H), 7.71, 1 H, ddd,
J  7-H-8-H 8.6, J 7 - h - 6 - h 8 . 3  and J  7-H -5-H1-3, 7-H), 7.80 (1H, dd, J  5-H-6-H 8.1 and J  5-H-7-H 1.3,
5-H), 8.08 (1 H, dm, J  wt-7-H 8.6, 8-H), 8.15 (1 H, d, J  8.5, 4-H); 5C (50 MHz, CDC13) 
22.94 (CH3), 43.23 (CH, CH(CH3)2), 67.40 (CH2), 119.34 (CH, 3-Qu), 126.44, 127.51,
129.09 and 129.62 (CH, C-5, C-6, C-7 and C-8), 127.42 (C, C-4a), 136.76 (CH, C-4), 
147.58 (C, C-8a), 155.24 (C, C-2), 157.03 (C, CO); m/z 244 (0.7, A /) ,  158 (28.8, - 
CONrfPr), 142 (24.1, -OCONHTr), 128 (10.9, -CH2OCONH/Pr).
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2-Hydroxymethylquinoline phenylcarbamate (145b)
A  flask was charged with 2- 
hydroxymethylquinoline (142) (0.4733 g,
2.98 mmol), phenyl isocyanate (0.3747 g,
3.15 mmol), dibutyltin diacetate (2 drops) and 
dichloromethane (25 ml). After 48 h o f stirring the 
reaction was incomplete, hence a further portion o f  phenyl isocyanate (0.1526 g,
1.28 mmol) was added and stirring continued until a total o f  96 h had passed. The 
volatiles were then removed to give a solid which was purified by flash column 
chromatography [S i02, CH2Cl2/hexane] to give, initially, a white solid (0.0045 g) R f 0.86 
[S i0 2, CH2CI2] and with increasing polarity a further impurity as a yellow oil (0.0803 g) 
R f 0.37 [S i0 2, CH2CI2]. The required product was obtained on further elution 
[CHCI3/CH2CI2] as a peach solid (0.8019 g) which was crystallised from ethyl 
acetate/hexane to give pale peach needles (0.7046 g, 2.53 mmol, 85%) which were 
recrystallised from methanol to give colourless needles (0.5826 g, 2.10 mmol, 57% ), 
m.p. 125.6-126.9 °C (Found: C, 73.27; H, 5.18; N, 10.21%; A /,  278.1037. C17H 14N 2O2 
requires C, 73.36; H, 5.07; N, 10.06%; M, 278.1055); R f 0.59 [S i0 2, EtOAc]; W c m ' 1 
(KBr) 3240 and 3120 (NH), 3060 and 3020 (ArH), 2960 and 2920 (CH2), 1720 and 
1620 (C =0), 1600, 1550, 1500 and 1450 (Ar), 1060 (C-O), 820 (2 adjacent H on an 
aromatic ring), 780 (4 adjacent H on an aromatic ring), 710 and 690 (5 adjacent H on an 
aromatic ring); 8h (200 MHz, d^acetone) 5.43 (2 H, s, CH2), 7.05 (1 H, m, p-Ai-W),
7.31 (2 H, m, /w-Ar-H), 7.60 (4 H, m, o-Ar-H, 3-H and 6-H), 7.75 (1 H, ddd, J  7-h-8-h
8.4, J  7 - h - 6 - h 8 . 4  and J  7.H-5-H 1.4, 7-H), 7.93 (1 H, dd, J  8.4 and J  5.H-7-H 1.4, 5-H),
8.02 (1 H, dm, J  8.4, 8-H), 8.32 (1 H, d, J  8.6, 4-H), 8.94 (1 H, bs, NH); 6C (50 MHz, 
</<s-acetone) 68.0 (CH2), 119.2 and 119.4 (CH, 0 -Ar), 112.0 (CH, 3-Qu), 123.6 (CH,/?- 
Ar), 127.3, 128.6, 129.6 and 130.4 (CH, C-5, C-6, C-7 and C-8), 128.4 (C, C-4a), 129.5 
(CH, /w-Ar), 137.6 (CH, C-4), 140.0 (C, s-Ar), 148.5 (C, C-8a), 154.2 (C, C-2), 158.0 
(C, CO); m/z 278 (8.4, A /) , 142 (24.5, -OCONHPh), 125 (26.6, -CH2OCONHPh).
3-Hydroxymethylquinottne isopropylcarbamate (146a)
A  mixture o f  3-hydroxymethylquinoline (143)
(0.5957 g, 3.75 mmol), isopropyl isocyanate 
(0.4964 g, 5.83 mmol) and dichloromethane
'OCONH
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(25 ml) were reacted by the method outlined in procedure A, for 24 h, to give a crude 
product (0.9S21 g). This was flushed through a short silica plug which was further eluted 
with ethyl acetate (200 ml). The combined organic eluate was concentrated and the solid 
produced was crystallised from dichloromethane/pet. ether to give pale yellow needles 
(0.7939 g, 3.25 mmol, 86%), which were recrystallised from ethanol to give the named 
product as colourless needles (0.4836 g, 1.74 mmol, 46%), m.p. 104.1-105.3 °C (Found: 
C, 68.82; H, 6.65; N, 11.45%; A/*, 244.1199. C w H ieN A  requires C, 68.83; H, 6.60; N,
11.47%; M, 244.1212); R f 0.60 [S i02, EtOAc]; W c m ' 1 (KBr) 3220 (NH), 3030 
(ArH), 2990 and 2960 (CH3 and CH2), 2870 (CH), 1720 and 1620 (C =0), 1550, 1500 
and 1450 (Ar), 1250 (C-O), 795 (isolated H on an aromatic ring), 745 (4 adjacent H on 
an aromatic ring); 5h (200 MHz, CDCI3) 1.16 (6  H, d, J  6.5, CH3), 3.84 (1 H, m, 
CH(CH3)2), 4.96 (1 H, bs, NH), 5.26 (2 H, s, CH2), 7.53 (1 H, ddd, -/mm-h 7.9, Jmm-h
7.9 and J  1.0, 6 -H), 7.70 (1 H, ddd, J  7-h-mi 7.9, J  7-11^7-117 .9  and J 1-71-5-111.5, 7-H),
7.75 (1 H, d, J 7 .9 , 5-H), 8.09 (1 H, d, J1.9, 8 -H), 8.12 (1 H, d, J  1.7, 4-H), 8.90 (1 H, 
d, J  1.7, 2-H); 5C (50 MHz, CDC13) 22.9 (CH3), 43.2 (CH, CH(CH3)2), 63.9 (CH2),
126.8, 127.8, 129.2 and 129.6 (CH, C-5, C-6 , C-7 and C-8), 127.6 (C, C-4a), 129.5 (C, 
C-3), 135.3 (CH, C-4), 147.7 (C, C-8a), 150.6 (CH, C-2), 155.2 (C, CO); m/z 245 (M* 
[lx^ C ], 2.5), 244 (18.6, A /) , 186 (1.5, -NH'Pr), 158 (21.6, -CONH'Pr), 128 (6 .6 , - 
CH2OCONH'Pr).
‘OCONH
3-Hydroxymethylquinoline phenylcarbamate (146b)
Application o f  procedure A  with 3- 
hydroxymethylquionline (143) (0.5888 g,
3.68 mmol), phenyl isocyanate (0.5535 g,
4.65 mmol) and dichloromethane (25 ml) 
yielded a crude product, which was purified by 
flash column chromatography [SiC>2, EtOAc/pet. ether] to yield a yellow solid 
(0.8787 g). Crystallisation from methanol gave colourless needles (0.7204 g, 2.59 mmol, 
70%), m.p. 154.5-155.3 °C (Found: C, 73.20; H, 5.06; N, 9.98%; h f  278.1068. 
C 1 7 H 1 4 N 2 O 2  requires C, 73.36; H, 5.07; N, 10.06%; M, 278.1056); R f 0.61 [S i02, 
EtOAc]; Vmax/cm"1 (KBr) 3240, 3190 and 3130 (NH), 3070, 3020 and 3010 (ArH), 2980 
and 2960 (CH2), 1730 and 1620 (C =0), 1600, 1550 and 1500 (Ar), 1250 and 1220  (C- 
O), 845 and 790 (isolated H on an aromatic ring), 760 and 690 (5 adjacent H on an
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aromatic ring), 750 (4 adjacent H on an aromatic ring); 6h (200 MHz, afe-acetone) 5.40 
(1 H, s, CH2), 7.01 (1 H, tt, J p in riilA  and 1.2,p-Ar-H), 7.29 (2 H, m, m-Ar-
H), 7.59 (3 H, m, o-Ar-H and 6-H), 7.75 (1 H, ddd, J  7-h -s-h  8 .3 , J  74t-6-H  8.5 and J  7-H-5-H
1.6, 7-H), 7.94 (1 H, dd, J  84^-7-h 8.3 and J  8-H-6-H 1.4, 8-H), 8.06 (1 H, m, 5-H), 8.32 (1  
H, m, 4-H), 8.90 (1 H, bs, NH), 8.98 (1 H, d, J  2.2, 2-H); 6C (50 MHz, ^ a c e to n e ) 64.7 
(CH2), 119.2 (CH, o-Ar), 123.6 (CH,/?-Ar), 127.7, 128.9, 130.0 and 130.3 (CH, C-5, C- 
6, C-7 and C-8), 128.7 (C, C-4a), 129.6 (CH, m-Ar), 130.8 (C, C-3), 135.8 (CH, C-4),
140.0 (C, s-Ar), 148.8 (C, C-8a), 151.7 (CH, C-2), 154.5 (C, CO); m/z 279 (M* [ l x 13C], 
2.5), 278 (13.2, A /) , 142 (100.0, -OCONHPh), 128 (8.3, -CH2OCONHPh).
OCONH
4-Hydroxymethylquinoline isopropylcarbamate (147a)
4-Hydroxymethylquinoline (144) (0.6611 g, 4.15 mmol) 
and isopropyl isocyanate (0.5137 g, 6.07 mmol) in 
dichloromethane (25 ml) was reacted for 48 h and 
worked up as outlined in procedure A to give a yellow  
solid (0.8081 g). Crystallisation from 
dichloromethane/hexane, followed by recrystallisation 
from ethanol gave colourless platelets (0.4569 g,
I.87 mmol, 45%), m.p. 105.3-106.2 °C (Found A /,  244.1194. Ci4Hi6N20 2 requires M, 
244.1213); R f 0.60 [S i02, EtOAc]; v ^ /c m -1 (KBr) 3310 (NH), 3060 (ArH), 2980 and 
2940 (CH3 and CH2), 1690 and 1615 (C =0), 1600, 1540, 1510 and 1450 (Ar), 1265 and 
1255 (C-O), 845 (2 adjacent H on an aromatic ring), 760 (4 adjacent H on an aromatic 
ring); (Found: C, 68.88; H, 6.55; N, 11.47. Ci4Hi6N20 2 requires C, 68.83; H, 6.60; N,
II.47); 5h (200 MHz, CDCI3) 1.18 (6 H, d, J 6 .5 , CH3), 3.87 (1 H, m, Ctf(CH3)2), 4.96 
(1 H, bs, NH), 5.57 (2 H, s, CH2), 7.39 (1 H, d, J 4 .4 , 3-H), 7.57 (1 H, ddd, Je^ t h  8.3, 
J  « i-5.h 8.1 and J  ^ h-s-h 1.3, 6-H), 7.71 (1 H, ddd, J  7-h-wi 8.5, J  7 4 t-6 «  8.3 and J  7-H-5-H
1.5, 7-H), 7.75 (1 H, dd, J 8.1, J  m -w  1.5, 5-H), 8.14 (1 H, dd, J  &«-7-h 8.5 and J
1.3, 8-H), 8.87 (1 H, d, J 4 .4 , 2-H); 5C (50 MHz, CDC13) 22.9 (CH3), 43.3 (CH, 
CH(CH3)2), 62.6 (CH2), 119.4 (CH, C-3), 123.0, 126.8, 129.3 and 130.1 (CH, C-5, C-6, 
C-7 and C-8), 125.9 (C, C-4a), 141.8 (C, C-4), 148.0 (C, C-8a), 150.2 (CH, C-2), 155.0 
(C, CO); m/z 244 (A /, 6.8), 158 (15.1, -CONHPh), 142 (47.0, -OCONHPh), 128 (4.8, - 
CH2OCONHPh).
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4-Hydroxymethylquinoline phenylcarbamate (147b)
Reaction o f  4-hydroxymethylquinoline (144) (0.5884 g,
3.70 mmol) and phenyl isocyanate (0.7115 g,
5.98 mmol) in dichloromethane (25 ml) by procedure 
A, followed by purification by flash column 
chromatography [Si0 2 , EtOAc/pet. ether] gave a white 
powder (0.9720 g). This was crystallised from methanol 
to give colourless needles (0.7777 g, 2.80 mmol, 75%), 
m.p. 161.4-162.1 °C (Found: C, 73.15; H, 5.00; N,
10.04%; A /,  278.1069. C17H 14N 2O2 requires C, 73.15;
H, 5.07; N, 10.06%; M, 278.1055); R f 0.61 [S i02, EtOAc]; W c m ' 1 (KBr) 3240, 3190 
and 3130 (NH), 3070, 3060, 3040 and 3010 (ArH), 1730 and 1615 (C =0), 1600, 1550, 
1500 and 1440 (Ar), 1245 and 1220 (C-O), 850 (2 adjacent H on an aromatic ring), 770 
(4 adjacent H on an aromatic ring), 755 and 690 (5 adjacent H on an aromatic ring); 5h 
(200 MHz, ^ a ce to n e) 5.73 (2 H, s, CH2), 7.04 (1 H, tt, J p^mn 7.4 J pa-on 1.2, p-Ar- 
H), 7.32 (2 H, m, /w-Ar-H), 7.60 (2 H, m, o-Ar-H and 3-H), 7.67 (1 H, ddd, 8.3,
J  64T-5-H 8 .6  and J  6-h -s-h  1.4, 6 -H), 7.80 (1 H, ddd, J  7 - h s h  8.4, J  7-h_6-h8.3  and J  7 ^ 5 -H
I.5, 7-H), 8.0 (2 H, m, 5-H and 8-H), 8.91 (1 H, d, 7 4 .4 , 2-H), 9.02 (1 H, bs, NH); 5C 
(50 MHz, ^ a ce to n e) 63.4 (CH2), 119.2 (CH, o-Ar), 120.5 (CH, C-3), 123.7 (CH, p- 
Ar), 124.4, 127.7, 130.1 and 131.0 (CH, C-5, C-6 , C-7 and C-8), 126.8 (C, C-4a), 129.7 
(CH, m-Ar), 134.0 (C, s-Ar), 142.8 (C, C-4), 149.2 (C, C-8a), 151.2 (CH, C-2), 154.0 
(C, CO); m/z 278 (A /, 2.0), 158 (28.8, -CONHPh), 128 (9.4, -CH2OCONHPh).
2-Hydroxymethylquinoline isopropylcarbamate N-oxide (148a)
A  solution o f  2-hydroxymethylquinoline 
isopropylcarbamate (145a) (0.4038 g, 1.65 mmol) 
and zm-CPBA  (0.2609 g, 1.51 mmol) in 
dichloromethane (25 ml) was stirred for 18 h, prior 
to the addition o f  a further portion o f tw-CPBA 
(0.0313 g, 0.18 mmol). After a total time o f  40 h the reaction mixture was put through a 
short (~4 cm) basic alumina pad, and flushed through with methanol (400 ml). Removal 
o f  the volatiles gave a yellow solid, which was recrystallised from 
dichloromethane/hexane to yield colourless rhombic crystals (0.4195 g, 1.61 mmol,
OCONHO©
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97%), m.p. 123.3-125.5 °C (Found: C, 64.73; H, 6.21; N, 10.60%; A / ,  260.1166. 
C m H isN A  requires C, 64.68; H, 6.20; N , 10.76%; M, 260.1161); R f 0.70 [A120 3, 
EtOAc]; Vmax/cm"1 (KBr) 3200 (NH), 3040 (ArH), 2970 and 2925 (CH3 and CH2), 2870
(CH), 1725 (C =0), 1570, 1530, 1520 and 1450 (Ar), 1250 (N*-CT and C-O), 850 (2  
adjacent H  on an aromatic ring), 775 (4 adjacent H on an aromatic ring); Sh (200 MHz, 
CDCI3) 1.20 (6  H, d, J 6 .6 , CH3), 3.87 (1 H, m, C//(CH3)2), 5.28 (1 H, bs, NH), 5.53 (2
H, s, CH2), 7.36 (1 H, d ,7 8 .7 , 3-H), 7.60 (1 H, ddd, 7mm«  8.3, 7  8.1  and 7  (a i 8-f 1
I.2, 6 -H), 7.69 (1 H, d, 7 8 .7 , 4-H), 7.70 (1 H, ddd, 7 ™ - ^  8 .6 , 7 7jm h  8.3 and7 7^ -5^
1.4, 7-H), 7.82 (1 H, d, 7 8 .1 , 5-H), 8.62 (1 H, d, 7 8 .6 , 8 -H); Sc (50 MHz, CDCI3) 22.9 
(CH3), 43.3 (CH, CH(CH3)2), 61.2 (CH2), 119.1 (CH, C-8  and C-3), 125.4 (CH, C-4),
128.0 (CH, C-5), 128.3 (CH, C-6 ), 129.2 (C, C-4a), 130.4 (CH, C-7), 141.2 (C, C-8 a),
144.6 (C, C-2), 154.8 (C, CO); m/z 261 (W  [ lx BC], 1.4), 260 (7.6, M*), 174 (9.7, - 
CONH'Pr), 158 (90.0, -OCONH'Pr), 128 (58.7, -CH2OCONH'Pr -O).
N
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2-Hydroxymethylquinoline phenylcarbamate N-oxide (148b)
A  solution o f  2-hydroxymethylquinoline 
phenylcarbamate (145b) (0.4241 g, 1.53 mmol) 
and /w-CPBA (0.2966 g, 1.72 mmol) in 
dichloromethane (25 ml) was stirred for 24 h 
before a further portion o f  m-CPBA (0.0216 g,
0.13 mmol) was added. After a total o f 72 h the system was cooled by application o f an 
ice salt bath. The white precipitate produced (0.3808 g) was filtered o ff and crystallised 
from ethanol to give colourless needles (0.2135 g, 0.73 mmol, 47%), m.p. 182.5- 
182.7 °C (decomp.) (Found: C, 69.13; H, 4.88; N, 9.40%; h f ,  294.1024. C17H 14N 2O3 
requires C, 69.38; H, 4.79; N, 9.52%; M, 294.1004), R f 0.51 [A120 3, EtOAc]; v ^ /c m ' 1 
(KBr) 3250, 3200 and 3130 (NH), 3070, 3050, 3030 and 3000 (ArH), 2960 and 2920 
(CH2), 1735 and 1610 (C =0), 1600, 1560, 1500 and 1450 (Ar), 1220  (N+-0 '), 1100 (C- 
O), 820 (2 adjacent H on an aromatic ring), 770 (4 adjacent H on an aromatic ring), 705 
and 690 (5 adjacent H on an aromatic ring); Sh (200 MHz, Ti-acetone), 5.53 (2 H, s, 
CH2), 7.04 (1 H, bt, 7 7 .4 , />-Ar-H), 7.32 (2 H, m, m-Ar-H), 7.56 (2 H, m, o-Ar-H), 7.60 
(1 H, d, 7 8 .9 , 3-H), 7.71 (1 H, m, 6 -H), 7.82 (1 H, ddd, J 7-ham 8.1, 7 7-h-<>h8.1 and 7 7. 
h - m i  1.6, 7-H), 7.90 (1 H, d, 7 8 .9 , 4-H), 8.03 (1 H, d, 7 7 .9 , 5-H), 8.64 (1  H, d, 7 8 .1 , 8 -  
H); Sc (50 MHz, Ts-DMSO) 60.9 (CH2), 118.3 (CH, o-Ar), 118.4 (CH, p-Ar), 119.6
170
(CH, C-8), 122.7 (CH, C-3), 124.9 (CH, C-4), 128.5 (CH, C-6 ), 128.7 (CH, C-5), 128.8 
(CH, m-Ar), 129.2 (C, C-4a), 130.6 (CH, C-7), 138.8 (C, s-Ar), 140.6 (C, C-8a), 143.6 
(C, C-2), 152.9 (C, CO); m/z 294 (A /, 2.5) 278 (1.3, -O), 202 (1.2, -NHPh), 186 (4.7, - 
NHPh -O), 174 (2.3, -CONHPh), 142 (1.2, -OCONHPh -O), 128 (56.6, - 
CHzOCONHPh -O).
‘OCONH
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3-Hydroxymethylquinottne isopropylcarbamate N-oxide (149a)
A  solution o f  3-hydroxymethylquinoline 
isopropylcarbamate (146a) (0.2952 g,
1.21 mmol) and tw-CPBA (0.2124 g,
1.23 mmol) in dichloromethane (25 ml) was 
stirred for 24 h. A  further portion o f  zw-CPBA 
(0.0216 g, 0.13 mmol) was then added to bring the reaction to completion in a total time 
o f  48 h. The solution was then passed through an alumina flash column and the 
impurities were removed by elution with dichloromethane (2 x 30 ml). The product was 
obtained by elution with methanol (3 x 50 ml), removal o f  the volatiles and crystallisation 
from dichloromethane/hexane to gave pale peach platelets (0.2458 g, 0.95 mmol, 79 %), 
m.p. 129.4-160.7 °C (Found: A /,  260.1154. C14H 16N 2O3 requires M, 260.1161); R f 0.41 
[AI2O3, EtOAc]; Vn^/cm'1 (KBr) 3220 and 3100 (NH), 3080 and 3020 (ArH), 2960 and 
2920 (CH3 and CH2), 2870 (CH), 1710 (C =0), 1580, 1540, 1500 and 1450 (Ar), 1270 
and 1250 (C-O), 1220 (N*-O'), 775 (4 adjacent H on an aromatic ring); Sh (200 MHz, 
^ a ce to n e ) 1.18 (6 H, d, J6.7  CH3), 3.82 (1 H, m, Ctf(CH3)2), 5.09 (2 H, s, CH2), 5.57 
(1 H, bs, NH), 7.61 (1 H, dd, J  « t-7-H 8.5 and J  6- -^5-h 8.0, 6-H), 7.64 (1 H, s, 4-H), 7.74 
(1 H, ddd, J  7-h - s h  8.6, J  7-h - 6 «  8.5 and J  7-H-5-H 1.6, 7-H), 7.81 (1 H, bd, J  8.0, 5-H ), 
8.53 (1 H, s, 2-H), 8.68 (1 H, d, J 8 .6 , 8-H); 6c (50 MHz, 4s-acetone) 22.6 (CH3), 43.2 
(CH, CH(CH3)2), 62.9 (CH2), 119.5 (CH, C-8), 125.0 (CH, C-4), 128.1 (CH, C-5),
128.9 (CH, C-6), 129.8 (C, C-4a), 130.4 (CH, C-7), 130.9 (C, C-3), 135.4 (CH, C-2), 
140.71 (C, C-8a), 154.9 (C, CO); m/z 261 (A/* [ l x 13C], 11.5), 260 (72.6, A/*), 244 (5.5, 
-O), 174 (16.0, -CONH'Pr), 158 (100.0, -OCONH'Pr), 142 (46.2, -OCONH'Pr -O).
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3-Hydroxymethylquinoline phenylcarbamate N-oxide (149b)
The synthesis was carried out using 
procedure D  with 3-hydroxymethylquinoline 
phenylcarbamate (146b) (0.3244 g,
1.17 mmol) and tw-CPBA (0.2267 g,
1.31 mmol) in a solution o f  dichloromethane 
(25 ml). This yielded a white powder 
(0.3324 g), which upon crystallisation from methanol gave colourless needles (0.2203 g, 
0.75 mmol, 64%), m.p. 204.9-205.3 °C (Found: C, 69.19; H, 4.76; N , 9.25%; A t, 
294.1002. C17H 14N 2O3 requires C, 69.38; H, 4.79; N, 9.52%; M, 294.1004); R f 0.56 
[AI2O3, EtOAc]; Vnux/cm'1 (KBr) 3240, 3190 and 3130 (NH), 3080, 3040 and 3010 
(ArH), 2950 (CH2), 1725 and 1620 (C=0), 1600, 1560, 1500 and 1445 (Ar), 1230 (N+- 
O"), 1060 (C-O), 850 (isolated H on an aromatic ring), 770 and 695 (5 adjacent H on an 
aromatic ring), 760 (4 adjacent H on an aromatic ring); 8h (200 MHz, ^fe-DMSO) 5.27 (1
H, s, CH2), 7.00 (1 H, tt, JpH-mH 7.3 and Jp^-oa 1.2, /?-Ar-H), 7.28 (2 H, m, /w-Ar-H),
7.41 (2 H, dm, 7  8.8, o-Ar-H), 7.77 (2 H, m, 6-H and 7-H), 7.97 (1 H, m, 4-H),
8.08 (1 H, m, 5-H), 8.51 (1 H, m, 8-H), 8.70 (1 H, d, J  1.4, 2-H); 8C (50 MHz, d6- 
DMSO) 62.7 (CH2), 118.3 (CH, o-Ar), 118.8 (CH, /?-Ar), 122.6 (CH, C-8), 123.9 (CH, 
C-4), 128.7 (CH, C-6), 128.8 (CH, m-Ar), 129.1 (CH, C-5), 129.7 (C, C-3), 130.4 (CH, 
C-7), 131.2 (C, C-4a), 134.9 (CH, C-2), 138.9 (C, s-Ar), 140.2 (C, C-8a), 153.06 (C, 
CO); m/z 295 (A / [ l x uC], 2.2), 294 (10.6, A t), 278 (3.6, -O), 174 (4.0, -CONHPh), 
158 (26.4, -OCONHPh), 144 (2.5, -CH2OCONHPh), 142 (36.2, -OCONHPh -O), 128 
(16.7, -CH2OCONHPh -O).
4-Hydroxymethylquinoline isopropylcarbamate N-oxide (150a)
Application o f  procedure C with 4- 
hydroxymethylquinoline isopropylcarbamate (147a)
(0.2138 g, 0.88 mmol), ro-CPBA (0.2005 g,
I.16 mmol) and dichloromethane (20 ml), followed by 
crystallisation from dichloromethane/hexane, gave the 
product as yellow needles (0.1546 g, 0.60 mmol, 68%), 
m.p. 132.9-134.3 °C (Found: C, 64.52; H, 6.35; N,
10.17%; A t,  261.1179. Ci4Hi6N 20 3 requires C, 64.68; O©
OCONH
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H, 6.20; N , 10.74%; M, 260.1161); R f 0 .1 0  [AI2O3, EtOAc]; v ^ /c m ' 1 (KBr) 3220 
(NH), 3065 and 3040 (ArH), 2960 and 2920 (CH3 and CH2), 2960 (CH), 1710 (C =0), 
1665, 1540, 1515 and 1450 (Ar), 1270 and 1250 (C-O), 1210 (I'T-O’), 805 (2 adjacent 
H  on an aromatic ring), 770 (4 adjacent H  on an aromatic ring); 8 h  (200 MHz, CDCI3)
I.23 (6  H, d, J  6.4, CH3), 3.87 (1 H, m, Ctf(CH3)2), 5.39 (2 H, s, CH2), 6.17 (1 H, bs, 
NH), 7.01 (1 H, d, J  6.0, 3-H), 7.65 (2 H, m, 6 -H and 7-H), 7.94 (1 H, d, J  7.9, 5-H), 
8.34 (1 H, d, J  6.0, 2-H), 8.75 (1 H, d, J 8 .3 , 8-H); 8c (50 MHz, CDCI3), 22.8 (CH3),
43.2 (CH, CH(CH3) 2), 61.9 (CH2), 120.2 (CH, C-3 and C-8), 124.0 (CH, C-6), 128.2 
(C, C-4), 129.0 (CH, C-5), 130.2 (CH, C-7), 132.2 (C, C-4a), 134.8 (CH, C-2), 140.9 
(C, C-8a), 155.0 (C, CO); m/z 261 (A / [ l x 13C], 8.4), 260 (53.0, M*), 174 (10.9, - 
CONH'Pr) 142 (15.7, -OCONH'Pr -O), 128 (9.0, -CH2OCONH'Pr -O).
OCONH
4-Hydroxymethylquinoline phenylcarbamate N-oxide (150b)
A  solution o f  4-hydroxymethylquinoline 
phenylcarbamate (147b) (0.5176 g, 1.86 mmol) and 
zw-CPBA (0.3514 g, 2.04 mmol) in dichloromethane 
(25 ml) was stirred for 48 h. The white precipitate 
produced (0.2045 g) was filtered off, and the filtrate 
was flushed through a short ( -4  cm) basic alumina pad 
and eluted with methanol (-400  ml). Evaporation o f  
the volatiles gave a further sample o f  crude product 
(0.2126 g). The combined samples o f  crude product 
were then recrystallised from methanol, forming 
colourless needles (0.3964 g, 1.35 mmol, 72%), m.p. 204.9-205.3 °C (Found: C, 69.30; 
H, 4.85; N, 9.32%; A /,  294.1007. C17H 14N2O3 requires C, 69.38; H, 4.79; N, 9.52%; M, 
294.1005); R f 0.56 [A120 3, EtOAc]; W c m -1 (KBr) 3220, 3190 and 3130 (NH), 3060 
and 3010 (Ar), 2980 (CH2), 1730 and 1705 (C =0), 1595, 1550, 1500 and 1450 (Ar), 
1205 (N+-O'), 1050 (C-O), 845 (2 adjacent H on an aromatic ring), 755 (4 adjacent H on 
an aromatic ring), 690 (5 adjacent H on an aromatic ring); 5h (200 MHz, g^-DMSO)
5.59 (2 H, s, CH2), 6.99 (1 H, tt, 7.3 l.l,/?-A r-H ), 7.28 (2 H, m, zw-Ar-
H), 7.49 (2 H, m, o-Ar-H), 7.54 (1 H, d, J  6.3, 3-H), 7.83 (2 H, m, 6-H and 7-H), 8.19 
(1 H, m, 5-H), 8.61 (2 H, m, 2-H and 8-H); 6C (50 MHz, <&-DMSO), 62.1 (CH2), 118.2 
(CH, o-Ar), 119.5 (CH, /?-Ar), 121.9 (CH, C-3), 122.6 (CH, C-8), 125.0 (CH, C-6),
N
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128.2 (C, C-4), 128.8 (CH, m-Ar), 129.1 (CH, C-5), 130.3 (CH, C-7), 130.4 (C, C-4a),
134.6 (CH, C-2), 138.9 (C, s-Ar), 140.7 (C, C-8a), 153.0 (C, CO); m/z 295 (A / [ l x 13C], 
0.4), 294 (1.7, A /) , 278 (5.1, -O), 158 (35.5, -CONHPh -O), 142 (18.2, -OCONHPh - 
O), 128 (13.5, -CH2OCONHPh -O).
Dimethyl 2,3-pyrazinedicarboxylate (152)
A  stream o f  hydrogen chloride gas was passed through a stirred C 0 2CH3
solution o f  2,3-pyrazinedicarboxylic acid (151) (5.1640 g, S '
30.72 mmol) in methanol (200 ml), until the solution was U J .
saturated with hydrogen chloride. The solution was then purged C 0 2CH3
o f  HC1 by passing a stream o f  nitrogen through it, prior to evaporation o f  the volatiles to 
give a pink oil (5.4062 g), which solidified on cooling. This salt was neutralised by 
addition o f  saturated sodium bicarbonate solution (5 ml) and solid sodium bicarbonate 
(5 g). The excess bicarbonate was removed by filtration and the filtrate was extracted 
with chloroform (3 x 30 ml). The extract was dried, filtered and concentrated to give a 
pink oil (4.8601 g) which solidified in the refrigerator. Three recrystallisations from ethyl 
acetate yielded the pure product as colourless crystals (2.8941 g, 14.77 mmol, 48%), 
m.p. 56-57 °C (Found: C, 49.09; H, 4.04; N, 14.18%; A /,  196.0476. C g H g N ^  requires 
C, 48.97; H, 4.08; N, 14.28%; M, 196.0584); R f 0.56 [S i02, EtOAc]; v ^ /c m '1 (KBr) 
3005 (ArH), 2960 (CH3), 1740 (C=0), 1560 and 1530 (Ar); 6h (200 MHz, CDC13) 4.04 
(6 H, s, CH3), 8.79 (2 H, s, Py-H); 6C (50 MHz, CDC13) 53.5 (CH3), 144.8 (C, Py),
145.5 (CH), 164.6 (C, CO); m/z 197 (A / [ l x 13C], 3.5), 196 (33.3, A /) ,  166 (54.8, - 
OCH3 +H), 165 (75.5, -OCH3), 78 (14.4, -2xC 02CH3).
2.3-Bis(bromomethyl)quinoxaline mono-N-oxide (158) and
2.3-Bis(bromomethyl)quinoxaline di-N-oxide (159)
2.3-Bis(bromomethyl)quinoxaline (157) (0.4792 g, 1.50 mmol) was stirred in a solution 
o f  trifluoroacetic acid (3 ml) and hydrogen peroxide (30%, 0.5 ml, 4 mmol) for 5XA h, 
until the TLC showed most o f  the starting material to have reacted and an approximately 
equal amount o f  the mono- and di-A-oxides had formed. The mixture was then poured 
into ethyl acetate (20 ml) and washed with saturated sodium bicarbonate solution 
( 3 x 3 0  ml). Drying, filtration and concentration o f  the organic phase gave a yellow solid 
(0.5786 g), which was purified by pressure assisted gravity column chromatography 
[S i0 2, EtOAc/pet. ether, 1:3] to give: starting material (0.0222 g, 0.07 mmol, 5%[ki]) R f
174
0.50 [S i02, EtOAc/pet. ether, 1:3]; mono-iV-oxide (158) as a colourless solid (0.1958 g, 
0.59 mmol, 39%); and di-A-oxide (159) as a yellow solid (0.2138 g, 41%).
2,3 -Bis(bromomethyl)quinoxaline mono-A-oxide
(158), m.p. 168.4-169.6 °C (decomp.) (Found: h f  6 
[2x81Br], 333.8994. CioHgNiOBrj requires M, 7
333.8965); R f 0.28 [S i02, EtOAc/pet. ether. 1:3];
Vmax/cm' 1 (KBr) 3090 and 3040 (ArH), 2980 and 2920 
(CH2), 1600 and 1500 (Ar), 1340 (N'-O"), 770 (4 adjacent H on an aromatic ring), 640 
(CBr); 8h (2 0 0  MHz, CDCI3) 4.77 (2 H, s, 10-CH2), 5.02 (2  H, s, 9-CH2), 7.82 (2  H, m,
6 -H and 7-H), 8.08 (1 H, dd, J  7 .94 and J  s-h-7-h 1.05, 5-H), 8.54 (1 H, dd,
8.2 and J  1.5, 8-H); 8c (50 MHz, CDCI3) 20.9 (CH2, C-9), 30.2 (CH2, C -10),
119.2 (CH, C-8), 130.1, 130.9 and 132.2 (CH, C-5, C-6  and C-7), 136.3 (C, C-2), 138.5 
(C, C-8a), 143.3 (C, C-4a), 152.6 (C, C-3); m/z 334 (A t [2x81Br], 14.7), 330 (14.9, A t  
p x^ B r]), 172 (5.0, -2xBr), 156 (15.8, -2xBr -O), 142 (64.5, -CHzBr -Br -O).
2,3-Bis(bromomethyl)quinoxaline di-/V-oxide (159), 
m.p. 151.1-151.5 °C (decomp.) (Found: h/t [2x81Br],
349.8913. CioH8N 20 2 Br2 requires M, 349.8915); R f 
0.11 [S i02, EtOAc/pet. ether, 1:3]; Vmax/cm' 1 (KBr)
3080 and 3040 (ArH), 2920 and 2855 (CH2), 1570,
1540 and 1490 (Ar), 1350 (N*-O'), 770 (4 adjacent H q q
on an aromatic ring), 660 (CBr); Sh (200 MHz, dtf-DMSO) 5.07 (4 H, s, CH2), 8.03 (2 
H, bs, 6 -H and 7-H), 8.51 (2 H, bs, 5-H and 8 -H); 5C (50 MHz, d<s-DMSO) 23.1 (CH2),
120.0 (CH, C-5 and C-8), 133.0 (CH, C-6  and C-7), 136.9 (C, C-2 and C-3), 140.1 (C, 
C-4a and C-8a); m/z 350 (A t [2x81Br], 37.7), 348 (76.1, A t  [ lx 8IBr lx^B r]), 346 
(37.3, A t  px^ B r]), 188 (18.7, -2xBr), 172 (7.4, -2xBr -O).
2,3-Bis(iodomethyl)quinoxaline (160)
A solution o f  2,3-bis(bromomethyl)quinoxaline (157) (0.5098 g, 1.61 mmol) and sodium 
iodide (0.5592 g, 3.73 mmol) in acetone (20 ml) was stirred for 18 h. The precipitate 
was filtered off and washed with water. This yielded fine cream needles (0.4627 g,
1.12 mmol, 70%), m.p. 156.0-157.0 ° C (Found: C, 29.11; H, 1.83; N, 6.67; I, 61.78%; 
A /,  409.8770. C io H g ^  requires C, 29.30; H, 1.97; N, 6.83; I, 61.91%; 409.8780);
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R f 0.72 [SiC>2, EtOAc/pet. ether, 1:3]; Vmax/cm"1 (KBr) 3050 and 3020 (ArH), 1550, 
1480 and 1430 (Ar), 2960 and 2920 (CH2), 760 (4 adjacent H on an aromatic ring), 495
(Cl); 8h (200 MHz, ^ D M S O ) 4.00 (2 H, s, CH2), 7.80 (2 H, m, 6 -H and 7-H), 8.09 (2 
H, m, 5-H and 8 -H); 5C (50 MHz, ^ D M S O ) 4.00 (CH2), 128.40 (CH, C-5 and C-8), 
130.91, (CH, C-6  and C-7), 140.85 (C, C-4a and C-8a), 152.51 (C, C-2 and C-3); m/z 
411 (AC [lx^ C ], 1.4), 410 ( 12 .6 , AC), 284 ( 12 .8 , AC [lx^ C ]) -I), 283 ( 10 0 .0 , -I), 157 
(12.0, AC [lx^ C ] -2 x1), 156 (64.5, -2 x1), 142 (0 .2 , -CH2I -I).
2,3-Bis(formyloxymethyl)quinoxaline (161)
To a solution o f  sodium formate (0.7879 g,
11.59 mmol) in HMPA (5 ml), a solution o f  2,3- 
bis(bromomethyl)quinoxaline (157) (0.9314 g,
2.95 mmol) in HMPA (5 ml) was added dropwise, 
over a period o f  5 min. After 36 h o f stirring the mixture was added to ethyl acetate 
(30 ml). This solution was washed with water (3 x 20 ml), and then sodium thiosulfate 
solution (10%, 20 ml). The combined aqueous washings were then extracted with ethyl 
acetate (30 ml). The organic fractions were combined, dried, filtered and evaporated to 
give a peach solid (1.0320 g). Crystallisation from dichloromethane/hexane gave pale 
peach platelets (0.6222 g, 2.53 mmol, 86%), m.p. 100.6-101.5 °C (Found: C, 58.59; H, 
4.22; N, 11.46%; AC, 246.0649. C12H 10N2O4 requires C, 58.54; H, 4.09; N, 11.38%; M, 
246.0641); R f 0.16 [SiC>2, EtOAc/pet. ether, 1:3); Vmax/cm' 1 (KBr) 3060 and 3040 
(ArH), 2970 (CH2), 1720 and 1700 (C=0), 1560, 1480 and 1450 (Ar), 1175 (C-O), 780 
(4 adjacent H on an aromatic ring); 8h (200 MHz, CDCI3) 5.59 (4 H, s, CH2), 7.80 (2 H, 
m, 6 -H and 7-H), 8.10 (2 H, m, 5-H and 8-H), 8.24 (2 H, s, CHO); 8C (50 MHz, CDC13)
64.1 (CH2), 129.1 (CH, C-5 and C-8), 130.7 (CH, C-6  and C-7), 141.4 (C, C-4a and C- 
8a), 148.3 (C, C-2 and C-3), 160.2 (C, CO); m/z 247.0695 (247.0674, 5.2, IVT [ l x 13C]), 
246 (AC, 28.8), 217 (4.5, -CHO), 202  (80.0, -C 0 2), 189 ( 11 .6 , -2 xCHO), 174 ( 10 0 .0 , - 
CHO -C 02), 173 (41.0, -CHO -OCHO), 158 (86.7, -OCHO -C 0 2), 157 (15.9, 
2xOCHO).
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2.3-Bis(hydroxymethyl)quinoxaline (162)
2.3-Bis(formyloxymethyl)quinoxaline (161)
(6.0948 g, 24.75 mmol) and concentrated ammonia 
solution (1 drop) were added to methanol (100 ml).
This solution was stirred for 30 min, and the volatiles ^
were removed to give a pink solid (4.6836 g, 24.62 mmol, 99%), m.p. 158.6-160.2 °C 
(Found: C, 63.18; H, 5.44; N, 14.85%; A /,  190.0727. C10H 10N 2O2 requires C, 63.15; H, 
5.30; N, 14.73%; M, 190.0742); R f 0.16 [S i02, EtOAc]; W c m ’1 (KBr) 3410 and 3236 
(OH), 2959 and 2944 (CH2), 1495 (Ar), 1365 (OH), 1029 (CO), 768 (4 adjacent H on 
an aromatic ring); Sh (200 MHz, ^ D M S O ) 4.97 (4 H, d, J  5.9, CH2), 5.53 (2 H, t, J  
5.92, OH), 7.83 (2 H, m, 6-H and 7-H), 8.12 (2 H, m, 5-H and 8-H); 5C (50 MHz, d6- 
DMSO) 62.90 (CH2), 128.54 (CH, C-5 and C-8), 129.80 (CH, C-6 and C-7), 140.37 
(C, C-4a and C-8a), 155.06 (C, C-2 and C-3); m/z 191 (A / [ l x 13C], 4.6), 190 (43.1, 
A /) , 172 (75.6, -H -OH), 159 (11.9, -CH2OH), 142 (10.9, -CH2OH -OH).
OCONH
OCONH
2,3-Bis(hydroxymethyl)quinoxaline bis (isopropylcarbamate) (164a) 
Employment o f  procedure A with 2,3- 
bis(hydroxymethyl)quinoxaline (162) ^
(0.9546 g, 5.02 mmol), isopropyl isocyanate 
(1.3842 g, 16.26 mmol) and dichloromethane 
(30 ml) yielded the crude product (1.9318 g) 
after 24 h. Crystallisation from 
dichloromethane/hexane gave colourless rhombic crystals (1.6701 g, 4.63 mmol, 92%), 
m.p. 167.3-168.9 °C (Found: C, 59.75; H, 6.69; N, 15.58%; A /,  360.1795. C ig H ^ N ^  
requires C, 59.99; H, 6.71; N, 15.54%; M, 360.1797); R f 0.64 [S i02, EtOAc/pet. ether, 
1:2); Vmax/cm'1 (KBr) 3314 (NH), 3085 (ArH), 2990 and 2950 (CH2), 1690 (C =0), 1545 
(Ar), 1265 and 1099 (C-O), 764 (4 adjacent H on an aromatic ring); Sh (200 MHz, 
CDC13) 1.17 (12 H, d, J 6 .5 , CH3), 3.82 (2 H, m, Ctf(CH3)2), 5.10 (2 H, d, J 6 .9 , NH),
5.41 (4 H, s, CH2) 7.70 (2 H, m, 6-H and 7-H), 8.01 (2 H, m, 5-H and 8-H); Sc (50 
MHz, CDC13) 22.8 (CH3), 43.2 (CH, CH(CH3)2), 64.9 (CH2), 128.9 (CH, C-5 and C-8),
130.0 (CH, C-6 and C-7), 141.1 (C, C-4a and C-8a), 149.9 (C, C-2 and C-3), 154.9 (C, 
CO); m/z 360 (A /, 0.8), 275 (34.3, -CONtfPr +H), 259 (4.8, -OCONH'Pr +H), 190
177
(5.7, -2xC0NH'Pr +2xH), 174 (13.8, -OCONH'Pr -CONH'Pr +2xH), 172 (100.0, - 
OCONH'Pr -CONH'Pr), 144 (44.4, -CH2OCONH'Pr -OCONH'Pr +2xH).
2,3-Bis(hydroxymethyl)quinoxaline bis (isopropylcarbamate) (164b)
2,3 -Bis(hydroxymethyl)quinoxaline (162)
(1.0371 g, 5.42 mmol), phenyl isocyanate 
(1.5234 g, 12.79 mmol), dibutyltin diacetate 
(2  drops) and dichloromethane (150 ml) were 
placed in a flask equipped with an overhead 
stirrer and stirred vigorously for 2 d . The 
volatiles were then removed to give a pale 
orange solid (2.0725 g), which was 
crystallised from methanol (care being taken 
to keep the temperature above 0 °C or a gel formed) to give a white powder (1.2960 g). 
A  second crop was harvested from the mother liquors once the volume was reduced, by 
evaporation o f  half o f  the volatiles, at elevated temperature. This crop was combined 
with the first to give a white solid (1.6927 g, 3.96 mmol, 73%), m.p. 190.1-191.4 °C 
(Found: C, 67.05; H, 4.66; N, 13.55%; A /,  428.1471. C24H2DN4O4 requires C, 67.28; H, 
4.71; N, 13.08%; M, 428.1484); R f 0.58 [S i02 , EtOAc/pet. ether, 1:1); v ^ /c m -1 (KBr) 
3317 (NH), 3057 (ArH), 2973 and 2922 (CH2), 1703 (C =0), 1601, 1545 and 1447 (Ar), 
1250 and 1070 (C-O), 762 (4 and 5 adjacent H on an aromatic ring), 693 (5 adjacent H 
on an aromatic ring); 5h (200 MHz, ^-acetone) 5.65 (4 H, s, CH2), 6.98 (2 H, t, J
6 .8 ,p-Ar-H), 7.27 (4 H, m, m-Ar-H), 7.51 (4 H, d, 7 ^  8.3, o-Ar-H), 7.82 (2 H, m,
6 -H and 7-H), 8.06 (2 H, m, 5-H and 8-H), 9.97 (2 H, bs, NH); 5C (50 MHz, ^ a ceto n e)
64.21 (CH2), 118.6 (CH, o-Ar), 122.8 (CH, /?-Ar), 128.9 (CH, C-5 and C-8), 129.0 
(CH, m-Ar), 130.8 (CH, C-6  and C-7), 139.2 (C, 5-Ar), 140.7 (C, C-4a and C-8a), 150.4 
(C, C-2 and C-3), 153.3 (C, CO); m/z 428 (A /, 0.7), 309 (2.2, -CONHPh +H), 278 (0.8, 
-CH2OCONHPh), 217 (38.7, -CONHPh -NHPh +H), 190 (11.3, -2xCONHPh +2xH), 
173 (20.9, -OCONHPh -CONHPh +H), 172 (30.1, -OCONHPh -CONHPh), 157 (23.9, 
-2xOCONHPh +H), 143 (34.0, -CH2OCONHPh -OCONHPh +H), 142 (4.7, - 
CH2OCONHPh -OCONHPh), 129 (9.4, -2xCH2OCONHPh +H).
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2j3-Bis(hydroxymethyl)quinoxaline bis(isopropylcarbamate) mono-N- 
oxide (165a) and 2,3-Bis(hydroxymethyl)quinoxaline 
bis(isopropylcarbamate) di-N-oxide (166a)
A  solution o f  2,3-bis(hydroxymethyl)quinoxaline bis(isopropylcarbamate) (164a) 
(0.8012 g, 2.30 mmol) and zw-CPBA (0.8576 g, 4.97 mmol) in dichloromethane (75 ml) 
was stirred for 36 h until most o f the starting material had reacted to give a mixture o f  
mono- and di-N-oxide. This mixture was pre-adsorbed onto alumina and placed on a 
short alumina plug. Elution with ethyl acetate (2 x 250 ml) gave two fractions. The first 
contained small amounts o f  starting material which were removed by crystallisation, 
twice from dichloromethane/hexane. The second fraction was pure and only required 
concentration. Combining these two samples gave the mono-A-oxide (165a) as a white 
solid (0.4779 g, 1.27 mmol, 55 %). Further elution with methanol yielded the di-A-oxide 
(166a) as a white solid (0.2253 g, 0.57 mmol, 25%).
2 ,3 -Bis(hydroxymethyl)quinoxaline 
bis(isopropylcarbamate) mono-A-oxide 
(165a), m.p. 189.8-191.2 °C (Found: C,
57.44; H, 6.27; N, 14.78%; A /, 376.1733.
C18H24N 4O5 requires C, 57.44; H, 6.43; N,
14.88%; My 376.1747); R f 0.45 [A120 3,
EtOAc/pet. ether, 1:1); W c m "1 (KBr) 3326 (NH), 3057 (ArH), 2970 and 2930 (CH2), 
2876 (CH), 1694 (C=0), 1575, 1541 and 1493 (Ar), 1260 (hT-Cr), 1123 and 1087 (C- 
O), 772 (4 adjacent H on an aromatic ring); 8 h  (200 MHz, CDCI3) 1.15 (6  H, d, J  6.1, 
I4 -CH3 and lS-CHs), 1.18 (6  H, d, J  6.5, 21-CH3 and 22-CH3), 3.80 (2 H, m, 
Cff(CH3)2), 5.09 and 5.12 (2 H, bs, NH), 5.44 (2 H, s, 16-CH2), 5.55 (2 H, s, 9-CH2),
7.75 (2 H, m, 6-H and 7-H), 7.99 (1 H, m, 5-H), 8.48 (1 H, m, 8 -H); 6c  (50 MHz, 
CDCI3) 22.7 (CH3), 43.2 (CH, CH(CH3h), 56.8 (CH2, C-9), 65.1 (CH2, C-16), 118.9 
(CH, C-8), 129.8, 130.2 and 131.6 (CH, C-5, C-6 and C-7), 136.0 (C, C-2), 137.0 (C, 
C-8a), 143.7 (C, C-4a), 153.1 (C, C-3), 154.8 and 155.0 (C, CO); m/z 376 (A /, 0.7), 
274 (12.3, -OCONH'Pr), 188 (28.0, -CONH'Pr -OCONH'Pr), 172 (17.8, - 
2xOCONH'Pr).
OCONH
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2,3-Bis(hydroxymethyl)quinoxaline 
bis(isopropylcarbamate) di-A-oxide (166a), 
m.p. >360 °C (Found: C, 55.33; H, 5.94; N,
14.38%. C1&H24N 4O6 requires C, 55.09; H,
6.16; N, 14.28%); R f 0.17 [A120 3,
EtOAc/pet. ether, 1:1); Vmax/cm’1 (KBr) 3324 
(NH), 3059 (ArH), 2975 and 2932 (CH2), 2760 (CH), 1696 (C =0), 1543 and 1458 (Ar), 
1258 (N^-O"), 1123 and 1087 (C-O), 772 (4 adjacent H on an aromatic ring); 8h (200 
MHz, drDMSO) 1.04 (12 H, d, J  6.5, CH3), 3.57 (2 H, m, Gtf(CH3)2), 5.48 (4 H, s, 
CH2), 7.24 (2 H, bd, J  7.2, NH), 8.00 (2 H, m, 6 -H and 7-H), 8.50 (2 H, m, 5-H and 8 - 
H); 8C (50 MHz, ^ D M S O ) 22.5 (CH3), 42.6 (CH, CH(CH3)2), 69.8 (CH2), 120.0 (CH, 
C-5 and C-8), 132.7 (CH, C-6  and C-7), 137.2 (C, C-2 and C-3), 134.0 (C, C-4a and C- 
8a), 154.8 (C, CO); m/z 302 (A / -NH'Pr -2^ 0, 0.2), 290 (0.2, -OCONH'Pr -O), 275 
(0.7, -NH'Pr -'Pr -O), 274 (1.5, -CONH'Pr -2x0 ), 258 (0.3, -OCONH'Pr -2 x 0 ), 216 
(0.1, -OCONH'Pr -NH'Pr -O), 200 (0.1, -OCONH'Pr -NH'Pr -2 x 0 ), 156 (3.1, - 
2 x OCONH'Pr -2xQ).
2.3-Bis(hydroxymethyl)quinoxaline bis(phenylcarbamate) mono-N-oxide 
(165b) and 2,3-Bis(hydroxymethyl)quinoxaline bis (phenylcarbamate) di- 
N-oxide (166b)
2.3-Bis(hydroxymethyl)quinoxaline bis(phenylcarbamate) (164b) (0.9452 g, 2.21  mmol) 
and m-CPBA (1.1726 g, 6.79 mmol) were stirred in dichloromethane (250 ml) for 70 h. 
Neutral alumina was then added, the volatiles were removed and the remaining solid 
placed on an alumina column. Elution with ethyl acetate/pet. ether gave the mono-iV- 
oxide (165b) as a brown solid (0.5112 g, 1.15 mmol, 52%). Elutution with methanol 
yielded the di-JV-oxide (166b) as a yellow solid (0.2166 g, 0.47 mmol, 2 1 %).
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2.3-Bis(hydroxymethyl)quinoxaline 
bis(phenylcarbamate) mono-A-oxide (165b), 
m.p. 192.2-192.6 °C (decomp.) (Found: C,
64.75; H, 4.32; N, 12.33%. C24H2DN4O5 
requires C, 64.86; H, 4.54; N, 12.61%); R f 
0.64 [AI2O3, EtOAc/pet. ether, 2:1);
Vmax/cm"1 (KBr) 3341 (NH), 3135 and 3061 
(ArH), 2963 and 2926 (CH2), 1713 (C=0),
1601, 1547, 1501 and 1447 (Ar), 1242 (IST- 
O"), 1086 and 1069 (C-O), 761 (4 adjacent H on an aromatic ring), 748 and 690 (5 
adjacent H  on an aromatic ring); 5h (200 MHz, */<j-DMSO) 5.60 (2 H, s, 19-CH2), 5.63 
(2 H, s, 9-CH2), 6.95 (2 H, m, p-Ar-H), 7.23 (4 H, m, m-Ar-H), 7.43 (4 H, m, o-Ar-H), 
7.85 (2 H, m, 6-H and 7-H), 8.05 (1 H, m, 5-H), 8.42 (1 H, m, 8-H), 9.80 and 9.91 (2 H, 
bs, NH); 6c (50 MHz, ^ D M S O ) 56.9 (CH2, C-9), 64.4 (CH2, C-19), 118.6 (CH, o-Ar 
and C-8), 123.0 (CH, p-Ar), 129.0 (CH, /w-Ar), 129.9, 131.1 and 132.7 (CH, C-5, C-6 
and C-7), 135.7 (C, C-2), 136.7 (C, C-8a), 138.9 and 139.1 (C, s-Ar), 143.4 (C, C-4a),
153.3 and 153.5 (C, CO), 153.7 (C, C-3); m/z 336 (A / -NHPh, 1.7), 309 (1.6, - 
CONHPh +H), 308 (1.6, -CONHPh), 233 (10.1, -CONHPh -NHPh +H), 217 (13.9, - 
CONHPh -NHPh -O +H), 189 (20.8, -2*CONHPh -O +H), 188 (15.1, -OCONHPh - 
CONHPh -O +H), 172 (12.3, -OCONHPh -CONHPh -O), 159 (7.1, -CH2OCONHPh - 
CONHPh -O +H), 129 (20.7, -2*CH2OCONHPh -O +H).
2.3-Bis(hydroxymethyl)quinoxaline 
bis(phenylcarbamate) mono-A-oxide (166b), 
m.p. 193.6-194.2 °C (decomp.) (Found: C,
62.33; H, 4.30; N, 12.07%. Q24H20N4O6 
requires C, 62.61; H, 4.38; N, 12.17%); R f 
0.57 [Al20 3 , EtOAc/pet. ether, 2:1); Vmax/cm"
1 (KBr) 3324 (NH), 3136 and 3076 (ArH),
2963 and 2926 (CH2), 1709 (C =0), 1578,
1545, 1500 and 1447 (Ar), 1225 (N O ^ ,
1088 and 1030 (C-O), 790 (4 adjacent H on an aromatic ring), 758 and 692 (5 adjacent 
H on an aromatic ring); 5h (200 MHz, ^-DM SO ) 5.69 (4 H, s, CH2), 6.95 (2 H, tt, Jp-n- 
mfl 7.2 Jpj^oii 2.2, p-Ar-H), 7.22 (4 H, m, /w-Ar-H), 7.42 (4 H, dd, J  on-mK 7.3 J  oa-pa
00
OCONH
OCONH
oe
OCONH
OCONH
O©
181
2.2, o-Ar-H), 7.99 (2 H, m, 6 -H and 7-H), 8.52 (2 H, m, 5-H and 8-H), 9.81 (2 H, bs, 
NH); 5c (50 MHz, rfe-DMSO) 57.5 (CH2), 118.5 (CH, o-Ar), 120.1 (CH, C-5 and C-8),
122.7 (CH, p-Ar), 128.8 (CH, m-Ar), 132.9 (CH, C-6  and C-7), 137.3 and 139.7 (C, C- 
2, C-3, C-4a and C-8a), 138.8 (C, s-Ar), 153.1 (C, CO); m/z 325 (A / -CONHPh -O +H, 
0.3), 217 (1.5, -CONHPh -NHPh -2 x 0  +H), 205 (0.7, -2xCONHPh -O +H), 204 (1.2, - 
2xCONHPh -O), 201 (0.4, -OCONHPh -NHPh -2 x 0  +H), 189 (5.1, -2xCONHPh -2 x 0  
+H), 188 (7.2, -2xCONHPh -2x0), 172 (3.2, 2xOCONHPh -O), 158 (3.2, - 
CHjOCONHPh -OCONHPh -O), 142 (4.3, -CH2OCONHPh -OCONHPh -2 x 0 ).
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8.4 Experimental for Chapter 5
4-Hydroxymethyl-l,2-dimethoxybenzene (169)
3,4-Dimethoxybenzaldehyde (167) (0.5514 g, 3.32 mmol) was 
reduced with sodium borohydride (0.3636 g, 9.61 mmol) in 
methanol (25 ml), using general procedure E, to give a pale yellow  
oil (0.5321 g, 3.16 mmol, 95%), b.p. 245-248 °C (>1  mbar)
(Found: C, 64.08; H, 6.95%; A /,  168.0775. C9H12O3 requires C,
64.27; H, 7.19%;M, 168.0786); R f 0.39 [S i02, CHCI3]; v ^ /c m ' 1 
(thin film) 3480 and 3400 (OH), 3080 and 3000 (Ar), 2940 and 
2880 (CH2), 2840 (OCH3), 1610, 1595, 1515 and 1460 (Ar), 1325 and 1265 (OH), 
1240, 1155, 1140 and 1030 (CO), 860 (isolated H on an aromatic ring), 810 (2 adjacent
H on an aromatic ring); 5h (200 MHz, CDCI3) 3.52 (1 H, bs, OH), 3.70 and 3.71 (6  H, s,
CH3), 4.41 (2 H, s, CH2), 6.73 (3 H, m, Ar-H); 5C (50 MHz, CDCI3) 55.3 and 55.4 
(CH3), 64.3 (CH2), 110.0 (CH, C-3), 110.5 (CH, C-6 ), 118.9 (CH, C-5), 133.3 (C, C-4),
147.8 (C, C-2), 148.4 (C, C-l); m/z 169 Qvt [lx^C ], 9.9), 168 (100.0, A /) ,  153 (12.1, - 
CH3), 137 (18.7, -OCH3 or -CH2OH), 121 (6 .6 , -OH -2xCH3), 89 (3.1, -OH -2xOCH3).
5-Hydroxymethyl-l,2-dimethoxy-4-nitrobenzene (170)
Into a round-bottomed flask was placed 4,5-dimethoxy-2- 
nitrobenzaldehyde (168) (0.7598 g, 3.60 mmol), sodium 
borohydride (0.6123 g, 16.18 mmol) and ethanol (50 ml).
The mixture was warmed to 75 °C for VA h, the volume 
was then reduced to 10 ml and water (1 0  ml) was added.
This mixture was extracted with ethyl acetate (3 x 20 ml), OH
and this extract was was dried, filtered and concentrated to
give an orange solid (0.6720 g). Crystallisation from chloroform/hexane yielded the 
product as pale yellow needles (0.5126 g, 2.40 mmol, 67%), m.p. 144.4-145.6 °C 
(FoundA/*", 213.0636. C9Hi20 3 requiresM, 213.0637); R f 0.54 [S i02, CHCI3]; Vmax/cm' 1 
(KBr) 3498 (OH), 3100 and 3016 (ArH), 2980 and 2945 (CH2), 2848 (OCH3), 1582, 
1497 and 1464 (Ar), 1520 and 1320 (N 0 2), 1068 (C-O), 879 (isolated H  on an aromatic 
ring); 6H (200 MHz, ^-DM SO ) 3.82 and 3.88 (6  H, s, CH3), 4.79 (2 H, s, CH2), 5.63 (1
OCH
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H, bs, OH), 7.16 (1 H, s, 6 -H), 7.57 (1 H, s, 3-H); 6C (50 MHz, 4rD M SO ) 56.0 and
56.1 (CH3), 60.4 (CH2), 107.7 (CH, C-3), 109.4 (CH, C-6 ), 134.4 (C, C-5), 138.3 (C, 
C-4), 147.0 (C, C-2), 153.7 (C, C -l); m/z 214 (Af [ l x BC], 6.2), 213 (59.1, Af ) .
OCONH
4-Hydroxymethyl-l,2-dimethoxybenzene isopropylcarbamate (171a)
Reaction o f  4-hydroxymethyl-l,2-dimethoxybenzene (169)
(0.5321 g, 3.16 mmol) with isopropyl isocyanate (0.4921 g,
3.16 mmol) in dichloromethane (20 ml), by procedure A  for 18 h, 
gave a pale yellow oil (0.7706 g), which slowly solidified on 
standing. Crystallisation from methanol gave colourless rods 
(0.4659 g, 1.84 mmol, 58%), m.p. 62.5-64.0 °C (Found: C,
61.43; H, 7.60; N, 5.49%; A /,  253.1312. C13H 19NO4 requires C,
61.64; H, 7.55; N, 5.53%; M  253.1313); R f 0.48 [SiC>2, CHCI3]; 
v j c m ' 1 (KBr) 3360 and 3300 (NH), 3000 (ArH), 2960 and 2930 (CH3 and CH2), 2840 
(OCH3), 1710 and 1680 (C =0), 1590, 1510 and 1460 (Ar), 1150, 1140 and 1030 (C-O); 
SH (200 MHz, CDCI3) 1.02 (6  H, d, J 6 .7 , CH(C//3)2), 3.77 (1 H, m, Ctf(CH3)2), 3.78 (6  
H, s, OCH3), 4.69 (1 H, bs, NH), 4.96 (2 H, s, CH2), 6.70-6.90 (3 H, m, Ar-H); Sc (50 
MHz, CHCI3) 22.9 (CH3, CH(CH3)), 55.7 (CH3, OCH3), 66.4 (CH2), 110.8 (CH, C-6),
111.5 (CH, C-3), 120.7 (CH, C-5), 129.05 (C, C-4), 148.8 (C, C -l, C-2  and CO); m/z 
253 (A /, 33.2), 167 (5.5, -OCONH'Pr), 153 (14.2, -CONH'Pr -CH3), 137 (27.9, 
CH2OCONH'Pr), 136 (2.6, -CONH'Pr -OCH3), 106 (10.7, -CH2OCONH'Pr -OCH3), 
105 (7.0, -CONH'Pr -2 *OCH3), 87 (3.7, -OCONH'Pr -2xOCH3).
OCH3 
1 OCH3
4-Hydroxymethyl-l,2-dimethoxybenzene phenylcarbamate (171b)
A  solution o f  4-hydroxymethyl-l,2-dimethoxybenzene (169)
(1.1176 g, 6.64 mmol) and phenyl isocyanate (1.6666 g,
13.99 mmol) in dichloromethane (2 0  ml) was reacted as 
outlined in procedure A. After 18 h a crude product 
(1.072 g) was obtained. This was crystallised from methanol 
to give colourless platelets (0.8404 g, 2.92 mmol, 44%), 
m.p. 118.5-119.1 °C (Found: C, 66.67; H, 5.87; N, 4.71%;
A /,  278.1163. C16H 17NO4 requires C, 66.89; H, 5.96; N,
4.87%; M, 278.1157); R f 0.53 [S i02, CHCI3]; v ^ /c m ' 1 
(KBr) 3320 and 3140 (NH), 3080 and 3000 (Ar), 2960 and
OCONH
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2940 (CH3 and CH2), 1720 (C =0), 1600, 1540, 1510 and 1440 (Ar), 1220, 1050 and 
1025 (C-O), 810 (2 adjacent H on an aromatic ring), 760 and 700 (5 adjacent H on an 
aromatic ring); 5h (200 MHz, c/tf-DMSO) 3.80 and 3.82 (6  H, s, CH3), 5.15 (2 H, s, 
CH2), 7.01 (1 H, s, 3-H), 7.02 (1 H, t, J  10.9, p-Ar-H), 7.07 (2 H, m, 5-H and 6 -H), 
7.33 (2 H, m, m-Ar-H), 7.57 (2 H, m, o-Ar-H), 9.80 (1 H, s, NH); 6C (50 MHz, d6- 
DMSO) 55.6 (CH3), 66.0 (CH2), 111.7 (CH, C-3), 112.5 (CH, C-6 ), 118.3 (CH, o-Ar),
121.2 (CH, C-5), 122.5 (CH, p-Ai), 128.9 (C, C-4), 128.9 (CH, m-Ar), 139.3 (C, s-Ar),
148.8 and 148.9 (C, C -l and C-2), 153.6 (C, CO); m/z 278 (A /, 5.5), 168 (38.8, - 
CONHPh), 151 (100.0, -OCONHPh), 105 (2.8, -CONHPh -2xOCH3), 89 (1.7, - 
OCONHPh -2*OCH3).
OCONH
5-Hydroxymethyl-l,2-dimethoxy-4-ntirobenzene isopropylcarbamate 
(172a)
General procedure A was applied to a solution o f  5- 
hydroxymethyl-l,2-dimethoxy-4-nitrobenzene (170)
(0.3057 g, 1.43 mmol) and isopropyl isocyanate 
(0.2759 g, 3.24 mmol) in dichloromethane (30 ml). This 
generated a crude product (0.4077 g), which was 
crystallised from chloroform/hexane to yield pale yellow  
needles (0.3054 g, 1.02 mmol, 72%), m.p. 149.5-
150.8 °C (Found: C, 52.21; H, 6.03; N, 9.18%; A /,
298.1178. C bH isN A ; requires C, 52.34; H, 6.08; N, 9.39%; M, 298.1164); R f 0.36 
[SiCh, CHC1J; Vnax/cm"* (KBr) 3300 (NH), 3100, 3080 and 3010 (ArH), 2960 and 2940 
(CH2), 2870 (CH), 2840 (OCH3), 1690 (C =0), 1580, 1540, 1515 and 1450 (Ar), 1330 
(N 0 2), 1280, 1220 and 1085 (C-O), 880 (isolated H on an aromatic ring); 6h (200 MHz, 
t/6-DMSO) 1.09 (6  H, d, J 6 .6 , CH(C#3)2), 3.64 (1 H, m, C/f(CH3)2), 3.88 and 3.91 (6  
H, s, OCH3), 5.32 (2 H, s, CH2), 7.18 (1 H, s, 6 -H), 7.36 (1 H, bd, J  7.7, NH), 7.68 (1
H, s, 3-H); 6c (50 MHz, tfe-DMSO) 22.6 (CH3, CH(CH3)2), 42.5 (CH, CH(CH3)2), 56.1
and 56.3 (CH3, OCH3), 62.2 (CH2), 108.2 (CH, C-3), 110.5 (CH, C-6 ), 128.2 (C, C-5),
139.3 (C, C-4), 147.8 (C, C-2 ), 153.5 (C, C -l), 154.9 (C, CO); m/z 299 (A / [ l x l3C], 
0.5), 298 (3.2, A/*), 252 (12.0, -N 0 2), 212 (0.9, -CONH'Pr), 196 (38.1, -OCONH'Pr).
185
5-Hydroxymethyl-l92-dimethoxy-4-nitrobenzene phenylcarbamate (172b) 
The reaction o f  5-hydroxymethyl-l,2-dimethoxy-4- 
nitrobenzene (170) (0.3492 g, 1.64 mmol) and phenyl 
isocyanate (0.3956 g, 3.32 mmol) in dichloromethane 
(25 ml) was performed as outlined in procedure A. This 
resulted in a deep orange solid, which was dissolved in 
chloroform/methanol ( 10 :1), to which sufficient hexane 
was added to induce crystallisation, pruducing bright 
yellow rods (0.3229 g, 1.12 mmol, 68%), m.p. 148.9-
150.2 °C (Found: C, 57.93; H, 4.78; N, 8.20%;
332.1014. CieHieNiOe requires C, 57.83; H, 4.85; N,
8.43%; Mt 332.1009); R f 0.55 [S i02, CHC13]; v ^ /c m ' 1 (KBr) 3380 (NH), 3005 (ArH), 
2940 (CH2), 2840 (OCH3), 1725 (C =0), 1590, 1575, 1520 and 1440 (Ar), 1325 (N 0 2), 
1210 and 1070 (C-O); SH (200 MHz, </<rDMSO) 3.93 and 3.96 (6  H, s, CH3), 5.50 (2  H, 
s, CH2), 7.05 (1 H, tm, J  5.8,/?-Ar-H), 7.33 (3 H, s and m, 6 -H and w-Ar-H), 7.52 (2 H, 
m, o-Ar-H), 7.76 (1 H, s, 3-H), 9.90 (1 H, bs, NH); 6C (50 MHz, ^ D M S O ) 56.2 and
56.4 (CH3), 63.0 (CH2), 108.3 (CH, C-3), 111.6 (CH, C-6 ), 118.5 (CH, o-Ar), 122.8
(CH, /?-Ar), 127.0 (C, C-5), 128.9 (CH, ro-Ar), 139.0 (C, s-Ar), 139.8 (C, C-4), 148.1 
(C, C-2), 153.1 (C, C -l), 153.4 (C, CO); m/z 332 (A /, 7.6), 255 (4.8, -Ph), 240 ( 1.0 , - 
NHPh), 212 (0.6, -CONHPh), 196 (100.0, -OCONHPh), 194 (0.3, -NHPh -N 0 2), 182 
(1.2, -CH2OCONHPh), 150 (6.2, -OCONHPh -N 0 2), 136 (56.1, - CH2OCONHPh -
n o 2).
2-Hydroxymethylthiophene (175)
A  solution o f  2-thiophenecarboxaldehyde (173) (1.4703 g,
13.11 mmol) in Analar methanol (200 ml) was cooled in an 5 
ice/salt bath and stirred vigorously as a solution o f  sodium 
borohydride (0.7302 g, 21.01 mmol) in Analar methanol 
(20 ml) was added dropwise over a 15 min period. The majority o f  the methanol was 
then evaporated under reduced pressure, at room temperature, and the residue was 
added to water (20 ml). The resulting solution was extracted with diethyl ether 
(3 x 30 ml), and the combined organic fractions were washed with water (2 x 20ml), 
dried, filtered and concentrated to give a yellow oil. Purification was accomplished by
OCONH
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distillation at reduced pressure (an efficient vacuum needs to be used to ensure that 
distillation occurs at a low temperature, so avoiding degradation o f  the product) to give 
a colourless oil (1.2801 g, 11.21 mmol, 85%), b.p. 52-53 °C (0.2 mbar) (Found: C, 
52.27; H, 5.41; S, 22.17%; AC, 114.0130. CjHeOS requires C, 52.60; H, 5.30; S, 
22.08%; A/, 114.0139); R f0.25 [S i02, CHC13]; v ^ /c m -1 (KBr) 3340 (OH), 3110 (ArH), 
2940 and 2880 (CH2), 1540 and 1440 (Th ring modes), 1385 (OH), 1260 (H bend), 
1215 and 1160 (CO), 825 (thiophene ring breathing); Sh (2 0 0  MHz, CDCI3) 3.56 (1 H, 
bs, OH), 4.70 (2 H, s, CH2), 6.95 (2 H, d, J  3*r4n  3.3 and Js-h ^ h  3.3, 3-H and 5-H), 
7.25 (1 H, dd, J  *h-3-h 3.3 and J  *h-5-h 3.3, 4-H); 5C (50 MHz, CDCI3) 59.3 (CH2), 
125.24 (CH, C-3 and C-5), 126.63 (CH, C-4), 143.83 (C, C-2); m/z 114 (AC, 57.3), 97 
(60.7, -OH).
5-Hydroxymethyl-2-nitrothiophene (176)
A  solution o f  sodium borohydride (0.7969 g,
21 .0 1  mmol) in methanol (2 0  ml) was cooled in an 
ice/salt both. This was added dropwise to a cooled a
solution o f  5-nitro-2-thiophenecarboxaldehyde (174) (1.5315 g, 9.74 mmol) in Analar 
methanol (100 ml). The volume o f the mixture was then reduced, under vacuum at room 
temperature, to 20  ml, and water (2 0  ml) was added.The mixtrure was extracted with 
ether (3 x 30 ml). This extract was washed with water (2 * 50 ml), dried, filtered and 
concentrated, at room temperature, to give a brown oil. Purification by distillation gave a 
pale yellow oil (0.6482 g, 4.07 mmol, 41%), b.p. 248 °C (>1 mbar) (Found: AC, 
158.9954. C5H5NO3S requires M, 158.9990); R f 0.18 [S i0 2> CHC13]; v ^ /c m ' 1 (thin 
film) 3370 (OH), 3100 (ArH), 2930 and 2880 (CH2), 1540 and 1435 (Th ring modes), 
1340 (NO2), 1210 and 1160 (CO), 1030, 1010 and 820 (H deformation); 8 h  (200 MHz,
CDCI3) 4.25 (1 H, bs, OH), 4.74 (2 H, s, CH2), 6.82 (1 H, d, J 4 .2 , 4-H), 7.63 (1 H, d, J
4.2, 3-H); 8c (50 MHz, CDCI3) 59.5 (CH2), 123.2 (CH, C-3), 129.0 (CH, C-4), 149.8 
(C, C-2), 154.3 (C, C-5); m/z 158 (W , 55.8), 141 (2.4, -OH), 126, (0.3, -OH -O).
2-Hydroxymethytthiophene isopropylcarbamate (177a)
Procedure A was followed using 2- 
hydroxymethylthiophene (175) (0.4312 g, 3.78 mmol) 
and isopropyl isocyanate (0.5839 g, 6.99 mmol) in 
distilled dichloromethane (20 ml). After 18 h the crude
OCONH
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product was recovered and recrystallised from methanol to give colourless needles 
(0.1748 g, 0.87 mmol, 23%), m.p. 41.8-42.5 °C (Found: C, 54.17; H, 6.56; N , 7.27; S, 
16.04%; A / ,  119.0676. C9H 13NO2S requires C, 54.25; H, 6.58; N, 7.03; S, 16.09%; M, 
119.0667); R f 0.67 [S i0 2, CHCI3]; v ^ /c m ' 1 (KBr) 3290 (NH), 3100 and 3065 (ArH), 
2970 and 2910 (CH2), 2880 (CH), 1710 and 1675 (C =0), 1550 and 1460 (Th ring 
modes), 1255 (H bend), 1075 (C-O); 5h (200 MHz, CDCI3) 1.14 (6  H, d, J 6 .5 ,  CH3), 
3.82 (1 H, m, C//(CH3)2), 5.22 (2 H, s, CH2), 4.69 (1 H, bs, NH), 6.97 (1 H, dd,
3.5 and J  441-5.H 5.0, 4-H), 7.07 (1 H, m, 3-H), 7.28 (1 H, dd, J  541441 5.0 and J  541341
1.2, 5-H); 5c (50 MHz, CDCI3) 23.0 (CH3), 43.1 (CH, CH(CH3)2), 60.6 (CH2), 126.6 
and 126.8 (CH, C-3 and C-5), 127.7 (CH, C-4), 138.8 (C, C-2), 155.2 (C, CO); m/z 119 
(W , 3.0), 97 (100.0, -OCONH'Pr).
2-Hydroxymethytthiophene phenylcarbamate (177b)
2-Hydroxymethylthiophene (175) (0.5158 g,
4.52 mmol) and phenyl isocyanate (1.0214 g) in a 
solution o f  dichloromethane (2 0  ml) were reacted by 
procedure A for 1 h (an exotherm was noted on addition 
o f  the isocyanate). The crude product was purified by 
gravity column chromatography [Si0 2, CHCI3] to give a 
white solid (1.2485 g), which was crystallised from dichloromethane/hexane to give 
colourless needles (0.6573 g, 2.82 mmol, 62%), m.p. 75.1-75.7 °C (Found: C, 54.17; H, 
6.56; N, 7.27; S, 16.04%; A /  233.0520. Ci2H ,iN 0 2S requires C, 54.25; H, 6.58; N, 
7.03; S, 16.09%; K f  233.0492); R f 0.56 [S i02, CHCI3]; W c m ' 1 (KBr) 3270, 3190 and 
3140 (NH), 3100, 3080 and 3040 (ArH), 2960 and 2940 (CH2), 1685 (C =0), 1600, 
1540, 1500, 1470 and 1440 (Ar), 1235 and 1110 (C-O), 830 (H deformation), 760 and
710 (5 adjacent H on an aromatic ring); 8 h  (200 MHz, CDCI3) 5.29 (2 H, s, CH2), 6.94
(1 H, dd, J 44M4T 3.8 and J m -m  6.1, 4-H), 7.02 (1 H, tt, Jp&-atu 6.5 Jpa-oti 1.9, p-Ai- 
H), 7.07 (1 H, m, 3-H), 7.25 (2 H, m, m-Ar-H), 7.27 (1 H, bd, J  6.1, 5-H), 7.37 (2 H, 
bd, J  7.9, o-Ar-H); 5c (50 MHz, CDCI3) 61.1 (CH2), 118.8 (CH, o-Ar), 123.5 (CH, p- 
Ar), 126.8 and 126.9 (CH, C-3 and C-5), 128.26 (CH, C-4), 128.97 (CH, m-Ar), 137.67 
(C, s-Ar and C-2), 153.19 (C, CO); m/z 233 (A/', 4.1), 156 (0 . 1, -Ph), 113 (2.0, - 
CONHPh), 97 (100.0, -OCONHPh), 83 (0.3, -CHjOCONHPh).
OCONH
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5-Hydroxymethyl-2-nitrothiophene isopropylcarbamate (178a)
P r o c e d u r e  A  w a s  e m p l o y e d  w i t h  5 -
h y d r o x y m e t h y l - 2 - n i t r o t h i o p h e n e  ( 1 7 6 )  ( 0 . 6 4 8 2  g ,
4 . 0 7  m m o l ) ,  i s o p r o p y l  i s o c y a n a t e  ( 0 . 5 9 7 6  g ,
7 . 2 0  m m o l )  a n d  d i c h l o r o m e t h a n e  ( 2 0  m l )  a s  
s t a r t i n g  m a t e r i a l s .  A f t e r  1 8  h  t h i s  y i e l d e d  a  c r u d e  p r o d u c t  ( 0 . 9 1 2 1  g ) ,  w h i c h  w a s  
c r y s t a l l i s e d  f r o m  m e t h a n o l  t o  g i v e  p e a c h  p l a t e l e t s  ( 0 . 6 8 6 1  g ,  2 . 8 1  m m o l ,  6 9 % ) ,  m . p .  
8 5 . 5 - 8 6 . 0  ° C  ( F o u n d :  C ,  4 4 . 2 0 ;  H ,  4 . 9 1 ;  N ,  1 1 . 4 7 ;  S ,  1 3 . 3 4 % ;  A <  2 4 4 . 0 4 8 7 .  
C 9H 0 N 2O 4 S  r e q u i r e s  C ,  4 4 . 2 5 ;  H ,  4 . 9 5 ;  N ,  1 1 . 4 7 ;  S ,  1 3 . 1 3 % ;  Mt 2 4 4 . 0 5 1 8 ) ;  R f  0 . 4 6  
[ S i 0 2 ,  C H C I 3] ;  V m a x / c m -1 ( K B r )  3 3 2 0  ( N H ) ,  3 1 0 0  ( A r - H ) ,  2 9 7 0  a n d  2 9 4 0  ( C H 2 ) ,  2 8 7 0  
( C H ) ,  1 6 9 0  ( C = 0 ) ,  1 5 0 0  a n d  1 4 5 0  ( T h  r i n g  m o d e s ) ,  1 3 3 0  ( N 0 2 ) ,  1 2 5 0  a n d  1 0 3 5  ( H  
b e n d ) ,  1 1 7 0  a n d  1 0 8 5  ( C - O ) ;  8 h  ( 2 0 0  M H z ,  C D C I 3)  1 . 1 0  ( 6  H ,  d ,  J 6 . 6 ,  C H 3 ) ,  3 . 7 5  ( 1  H ,  
m ,  C t f ( C H 3 ) 2 ) ,  4 . 9 1  ( 1  H ,  b s ,  N H ) ,  5 . 1 2  ( 2  H ,  s ,  C H 2 ) ,  6 . 6 2  ( 1  H ,  d ,  J 4 . 1 ,  4 - H ) ,  7 . 7 1  ( 1  
H ,  d ,  J  4 . 1 ,  3 - H ) ;  6 C  ( 5 0  M H z ,  C D C I 3)  2 2 . 8  ( C H 3)  4 3 . 4  ( C H ,  C H ( C H 3 ) 2 ) ,  6 0 . 5  ( C H 2) ,
1 2 6 . 0  ( C H ,  C - 3 ) ,  1 2 8 . 3  ( C H ,  C - 4 ) ,  1 4 7 . 7  ( C ,  C - 2  a n d  C - 5 ) ,  1 5 4 . 9  ( C ,  C O ) ;  m/z 2 4 4  
( A / ,  2 . 5 ) ,  1 8 6  ( 0 . 5 ,  - N H i > r ) ,  1 4 2  ( 7 8 . 0 ,  - O C O N t f P r ) ,  1 4 0  ( 0 . 6 ,  - N H ' P r  - N 0 2) ,  1 2 8  
( 0 . 4 ,  - C H 2O C O N H i » r ) ,  1 1 2  ( 1 8 . 9 ,  - C O N H ' P r  - N 0 2 ) ,  9 6  ( 1 9 . 8 ,  - O C O N t f P r  - N 0 2 ) ,  8 2  
( 1 . 4 ,  - C H z O C O N H ' P r  - N 0 2 ) .
5-Hydroxymethyl-2-nitrothiophene phenylcarbamate (178b)
5 - H y d r o x y m e t h y l - 2 - n i t r o t h i o p h e n e  ( 1 7 6 )
( 0 . 3 4 5 2  g ,  2 . 1 7  m m o l )  a n d  p h e n y l  i s o c y a n a t e  
( 0 . 6 2 0 8  g, 5 . 2 1  m m o l )  w e r e  r e a c t e d  b y  
p r o c e d u r e  A ,  i n  a  s o l u t i o n  o f  d i s t i l l e d  
d i c h l o r o m e t h a n e  ( 1 0  m l ) ,  f o r  5  d a y s .  T h e  c r u d e  q  ^  
p r o d u c t  w a s  p u r i f i e d  b y  f l a s h  c o l u m n  
c h r o m a t o g r a p h y  [ S i 0 2 ,  E t O A c / p e t .  e t h e r ]  t o  g i v e  a n  i n i t i a l  i m p u r i t y  ( 0 . 0 4 6 8  g )  R f  0 . 5 8  
[ S i 0 2 ,  C H C I 3] ,  a n d  w i t h  i n c r e a s i n g  p o l a r i t y ,  t h e  r e q u i r e d  p r o d u c t  a s  a n  o r a n g e  s o l i d  
( 0 . 3 9 6 1  g ) .  A  f i n a l  i m p u r i t y  ( 0 . 1 9 7 9  g )  R f  0 . 1 4  [ S i 0 2 ,  C H C I 3]  w a s  o b t a i n e d  o n  f u r t h e r  
e l u t i o n  w i t h  C H C I 3 . T h e  r e q u i r e d  p r o d u c t  w a s  c r y s t a l l i s e d  f r o m  d i c h l o r o m e t h a n e  f o r m i n g  
y e l l o w  p l a t e l e t s  ( 0 . 1 8 7 4  g ,  0 . 6 7  m m o l ,  3 1 % ) ,  m . p .  1 2 0 . 9 - 1 2 1 . 9  ° C  ( F o u n d :  C ,  5 1 . 4 0 ;  H ,  
3 . 4 6 ;  N ,  1 0 . 0 0 ;  S ,  1 1 . 7 5 % ;  A / ,  2 7 8 . 0 3 6 6 .  C u H i o N ^ S  r e q u i r e s  C ,  5 1 . 6 1 ;  H ,  3 . 6 1 ;  N ,  
1 0 . 0 3 ;  S ,  1 1 . 4 8 % ;  M, 2 7 8 . 0 3 6 1 ) ;  R f  0 . 4 8  [ S i 0 2 ,  C H C I 3] ;  W c m ' 1 ( K B r )  3 3 4 0  ( N H ) ,
O C O N H
O C O N H
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3100, 3080 and 3050 (ArH), 2960 and 2920 (CH2), 1725 (C =0), 1600, 1540 and 1485 
(Ar), 1330 (N 0 2), 1215 (CO); 8h (200 MHz, 4s-DMSO) 5.38 (2 H, s, CH2), 7.04 (1 H, 
tt, J p«-wH 7.4 J pftoH 1.2, p-Ar-H), 7.28 (2 H, m, ro-Ar-H), 7.29 (1 H, d, J  4.6, 4-H), 
7.57 (2 H, m, o-Ar-H), 7.91 (1 H, d, J 4.6, 3-H); 8C (50 MHz, </<j-DMSO) 61.33 (CH2), 
119.26 (CH, o-Ar), 123.79 (CH, p-Ar), 127.76 (CH, C-3), 129.40 (CH, C-4), 129.54 
(CH, m-Ar), 139.46 (C, s-Ar and C-5), 148.40 (C, C-2), 153.67 (C, CO); m/z 278 (A/, 
22.9), 186 (0.9, -NHPh), 158 (1.6, -CONHPh), 142 (96.7, -OCONHPh), 112 (25.0, - 
CONHPh -N 0 2), 96 (29.9, -OCONHPh -N 0 2), 84 (22.4, -CH2OCONHPh -N 0 2).
2-Amino-5-hydroxymethyUhiophene (179)
A  sample o f  2-nitro-5-hydroxymethylthiophene (176)
(0.1312 g, 0.53 mmol) was placed in a 3-necked flask 
which was evacuated and placed under a hydrogen ^  
atmosphere. Addition o f  degassed Analar methanol (5 ml), followed by 5 min vigorous 
stirring led to complete dissolution o f  the starting material. A  freshly prepared solution o f  
Raney nickel (0.5 ml, 0.6 g ml-1, 0.3 g), was added and the reaction mixture stirred for 
15 min. The catalyst was then removed by filtration through a Celite pad, and the filtrate 
was evaporated to give a pale brown oil (0.0523 g, 0.40 mmol, 76%), which darkened 
within seconds on standing and could not be further purified. This was tentatively 
identified as the named product, R f 0.16 [S i02, EtOAc/pet. ether, 2:1]; 5h (90 MHz, 
CDC13) 3.7 (6 H, s, CH3), 4.5 (2 H, s, CH2), 6.2 (1 H, d, J 4.2, 3-H), 6.7 (1 H, d, J 4 .2 , 
4-H).
4-Amino-5-hydroxymethyl-l,2-dimethoxybenzene (180)
A  portion o f  palladium on carbon catalyst (10%, 0 .316g), 
was placed in a 3-necked flask, and the flask then 
evacuated and placed under a hydrogen atmosphere.
Degassed Analar methanol (20 ml) was added to the 
system, followed by a solution o f  5-hydroxymethyl-l,2- 
dimethoxy-4-nitrobenzene (170) (0.1240 g, 0.58 mmol) 
dissolved in degassed Analar methanol (10 ml). After VA h
o f  stirring the catalyst was removed by filtration, and the solvent was removed to give a 
colourless oil, which solidified on standing and then decomposed rapidly to give a brown
OH
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s o l i d  ( 0 . 0 9 7 6  g ,  0 . 5 4  m m o l ,  9 2 % ) ,  R f  0 . 3 2  [ S i 0 2 ,  E t O A c / p e t .  e t h e r ,  1 : 1 ] ;  8 h  ( 9 0  M H z ,  
C D C I 3)  3 . 7  ( 6  H ,  s ,  C H 3 ) ,  4 . 5  ( 2  H ,  s ,  C H 2 ) ,  6 . 2  ( 1  H ,  s ,  3 - H ) ,  6 . 5  ( 1  H ,  s ,  6 - H ) .
2-Bromo-5-nitrothiophene (194), 3-Bromo-5-nitrothiophene (190), 2,3- 
Dibromo-5-nitrothiophene (191) and 3,4-Dibromo-5-nitrothiophene (193)
1 9 01 9 4
1 9 31 9 0
T o  a  s o l u t i o n  o f  2 - n i t r o t h i o p h e n e  ( 1 9 2 )  ( 0 . 3 3 3 0  g ,  2 . 5 8  m m o l )  a n d  b r o m i n e  ( 0 . 1 3  m l ,
2 . 4  m m o l )  i n  d i c h l o r o m e t h a n e  ( 5  m l ) ,  i r o n  t r i c h l o r i d e  ( 0 . 1 2 4 2 g )  w a s  a d d e d  a n d  t h e  
m i x t u r e  w a s  s t i r r e d .  A f t e r  4 6  h  t h e  v o l a t i l e s  w e r e  e v a p o r a t e d ,  t h e  r e s i d u e  w a s  
r e s u s p e n d e d  i n  d i c h l o r o m e t h a n e  ( 1 0  m l ) ,  a n d  t h e  s o l i d  w a s  r e m o v e d  b y  f i l t r a t i o n .  
E v a p o r a t i o n  o f f  t h e  v o l a t i l e s  f r o m  t h e  f i l t r a t e  g a v e  a  b r o w n  p o w d e r ,  w h i c h  w a s  s e p a r a t e d  
b y  p r e p a r a t i v e  T L C  [ S i 0 2 ,  C H C I 3]  t o  g i v e  t h r e e  f r a c t i o n s  i s o l a t e d  a s  b r o w n  s o l i d s .
2 . 3 - D i b r o m o - 5 - n i t r o t h i o p h e n e  ( 1 9 1 )  ( 0 . 0 6 4 6  g ,  0 . 2 3  m m o l ,  8 % ) ,  R f  0 . 8 3  [ S i 0 2 ,  C H C 1 3 ] ;  
5 h  ( 9 0  M H z ,  C D C I 3)  8 . 3  ( 4 - H ) .
3 . 4 - D i b r o m o - 5 - n i t r o t h i o p h e n e  ( 1 9 3 )  ( 0 . 0 4 2 0  g ,  0 . 1 4  m m o l ,  6 % ) ,  R f  0 . 5 3  [ S i 0 2 ,  C H C 1 3 ] ;  
5 h  ( 9 0  M H z ,  C D C I 3)  7 . 6  ( 2 - H ) .
2 - B r o m o - 5 - n i t r o t h i o p h e n e  ( 1 9 4 )  a n d  3 - b r o m o - 5 - n i t r o t h i o p h e n e  ( 1 9 0 )  ( 0 . 2 0 2 8  g ,  
0 . 9 6  m m o l ,  3 7 % ) ,  R f  0 . 4 2  [ S i 0 2 ,  C H C I 3] ;  5 H  ( 9 0  M H z ,  C D C 1 3)  7 . 1  ( 1  H ,  d ,  J  6 . 0 ,  3 - H  
[ 2 - b r o m o - 5 - n i t r o ] ) ,  7 . 6  ( 2 H ,  [ d ,  J  6 . 0 ,  4 - H ,  2 - b r o m o - 5 - n i t r o ]  a n d  [ d ,  J  2 . 4 ,  2 - H ,  3 -  
b r o m o - 5 - n i t r o ] ) ,  8 . 2  ( 1  H ,  d ,  7 2 . 4 ,  4 - H ,  [ 3 - b r o m o - 5 - n i t r o ] ) .
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Ethyl 2-cyano-4-oxopent-2-enoate (200)
Into a flame dried 3-necked flask was placed dry 
tetrahydrofuran (40 ml), which was cooled in an ice/salt bath.
A  solution o f  titanium tetrachloride (2.2 ml, 20 mmol) in dry 
carbon tetrachloride (5 ml) was added dropwise and the mixture was stirred. After 1/4 h 
a solution o f  butanedione (196) (0.4304 g, 5.00 mmol) and ethyl cyanoacetate (195) 
(1.1324 g, 10.01 mmol) in dry tetrahydrofuran (5 ml) was added and stirring was 
continued for a further 1V4 h. Finally a solution o f pyridine (3.2 mmol, 40 mmol) in dry 
tetrahydrofuran (5 ml) was added and the reaction mixture was allowed to warm to room 
temperature. After 120 h water (10 ml) was added and the mixture was extracted with 
ethyl acetate (2 x 30 ml). The organic extracts were dried, filtered and concentrated to 
give a brown oil (0.8023 g, 4.80 mmol, 96%), R f 0.25 [SiCh, EtOAc/pet. ether, 1:3]; Sh 
(90 MHz, CDC13) 1.3 (3 H, t, J  8 .2 , CH2C # 3), 2.1 (3 H, s, COCH3), 3.5 (1 H, s, CH),
4.3 (2 H, q, J 8 .2 , C //2CH3).
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8.5 Experimental for Chapter 6
Ditertiarybutyl N-benzyloxycarbonyl L-glutamate (211)
0
Standard procedures for amino acid protection194 gave only poor yields, these methods 
were altered to improve the yield obtained. The named product was obtained by 
preparing a suspension o f  A-benzyloxycarbonyl L-glutamic acid (210) (5.7444 g, 
16.88 mmol) in dichloromethane (15 ml), in a glass pressure vessel. An acetone/dry ice 
bath was applied and concentrated sulphuric acid (98%, 4 drops) was added. This was 
followed by addition o f  isobutylene (-15  ml), condensed using a cold finger. The vessel 
was sealed and allowed to warm to room temperature. After 15 d no solid remained, 
hence the system was again cooled on an acetone/dry ice bath and the seal was removed. 
After warming to room temperature the reaction mixture was poured into 
dichloromethane (50 ml), saturated sodium bicarbonate solution (50 ml) was added and 
the two phases were mixed. The two layers were separated and the aqueous layer was 
extracted with dichloromethane (2 x 30 ml). Combining the organic fractions, drying, 
filtration and concentration gave a colourless oil (10.0114 g). Purification by flash 
column chromatography [SiC>2, EtOAc/pet. ether, 1:2 ] gave the pure product as a 
colourless oil (8.7505 g, 22.23 mmol, 92%) (Found: C, 64.35; H, 8.16; N, 3.74%; M R \ 
394.2223. C2iH3iN 0 6 requires C, 64.10; H, 7.94; N, 3.56%; MH, 394.2236) ; R f 0.72 
[S i0 2, EtOAc/pet. ether, 1:2); W c m ' 1 (KBr) 3344 (NH), 3066 (ArH), 2978 and 2934 
(CH3 and CH2), 1732 (C =0), 1584, 1522, 1504 and 1454 (Ar), 1256, 1224 and 1154 
(C-O), 698 (5 adjacent H on an aromatic ring); 8h (200 MHz, CDCb) 1.43 (18 H, s, 
CH3), 1.70-2.40 (4 H, m, CH2CH2), 4.26 (1 H, m, CH, CHCRi), 5.09 (2 H, m, ArCH2),
5.53 (1 H, bd, J  8.2, NH), 7.30 (5 H, m, Ar-H); 8C (50 MHz, CDC13) 27.9 and 29.0
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(CH3), 31.5 (CH2, CH2CH2), 54.0 (CH, CffCH2), 66.8 (CH2, ArCH2), 80.6 and 82.2 (C, 
C(CH3)3), 128.1 and 128.5 (CH, o-Ar, m-Ar and p-Ar), 136.4 (C, s-Ar\ 156.0 (C, 
OCONH), 171.2 and 172.0 (C, C 0 2C(CH3)3); m/z 394 (M I*, 0.1), 337 (0.4, -'Bu +H), 
320 (0.1, -O'Bu), 292 (1.6, -C 02'Bu), 264 (4.3, -'Bu -OfBu), 236 (36.7, -'Bu -C 0 2'Bu), 
220 (7.4, -O'Bu -C 02'Bu), 192. (34.2, -2xC 02'Bu), 108 (6.8, PhCH20 ) , 107 (9.9, 
PhCH2).
Ditertiarybutyl L-glutamate (212)
Modifications to the standard deprotection 
procedure195 were found to give higher yields and 
shorter reaction times. To obtain the named 
product, palladium on carbon (10%, 0.7625 g) 
was added to a dried flask which was then 
evacuated and placed under a hydrogen 
atmosphere. Degassed Analar ethanol (100 ml) 
was added followed by ditertiarybutyl A-benzyloxycarbonyl L-glutamate (211) (8.7505 g, 
22.23 mmol). After 18 h stirring the catalyst was removed by filtration through a Celite 
pad, and the volatiles were evaporated to give a pale yellow oil (4.6685 g). Distillation 
gave the pure product as a colourless oil (3.3940 g, 13.08 mmol, 59%), b.p. 79-82 °C 
(0.2 mbar) (Found: A/*, 259.1796. Ci3H25N 0 4 requires M, 259.1784); R f 0.28 [S i02, 
EtOAc/pet. ether, 1:4]; Vmax/cm'1 3385 and 3320 (NH), 2978 and 2935 (CH3 and CH2), 
1731 (C =0), 1255 and 1155 (C-O); 5 h ( 2 0 0  MHz, CDC13) 1.44 and 1.47 (18 H, s, CH3), 
1.60-2.10 (2 H, m, CHCtf2), 2.36 (2 H, t, J7.6, CH2C 0 2), 3.33 (1 H, m, CH); 6C (50 
MHz, CDC13) 27.9 and 27.9 (CH3), 23.0 and 31.8 (CH2), 54.2 (CH), 80.1 and 80.9 (C, 
C(CH3)3), 172.4 and 174.8 (C, CO); m/z 158 (10.6, -C 02'Bu), 130 (20.3, -'Bu -O'Bu 
+H), 129 (3.1, -'Bu -O'Bu), 128 (1.8, -'Bu -O'Bu -H), 102 (100.0, -'Bu -C 0 2'Bu +H), 
101 (1.7, -'Bu -C 0 2'Bu), 100 (3.0, -'Bu -C 02'Bu -H).
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n h 2
4-Hydroxymethylaniline tertiarybutyldimethylsilyl ether (214)
A  standard protection methodology199 was employed 
whereby a flask was charged with 4-aminobenzyl alcohol 
(209) (2.6361 g, 21.40 mmol) and imidazole (2.1378 g,
31.40 mmol). The system was placed under a nitrogen 
atmosphere and the solids were dissolved in distilled 
dichloromethane (7 ml). Addition o f  a solution o f  
tertiarybutyldimethylsilylchloride (3.2368 g, 21.47 mmol) in 
distilled dichloromethane (5 ml), followed by stirring for
5 min completed the reaction. The resulting mixture was washed with water ( 3 x 3 0  ml), 
dried, filtered and concentrated to give a pale yellow oil (7.5669 g). Purification by 
distillation gave a colourless oil (4.1998 g, 20.06 mmol, 94%), b.p. 124-126 °C (1 mbar) 
(Found: C, 65.58; H, 9.71; N, 5.95% M ,  238.1570. CoH^NOSi requires C, 65.77; H, 
9.76; N, 5.90%; M, 237.1549); R f 0.50 [S i02, EtOAc/pet. ether, 1:2); v ^ /c m 1 (CHC13) 
3470 and 3390 (NH), 3015 (ArH), 2985 and 2965 (CH3), 2900 (CH), 2880 (OCH2), 
1630 (NH), 1260 (C-O), 1100 (Si-O); 8h (200 MHz, CDCI3) 0.07 (6 H, s, Si(CH3)2),
0.89 (9 H, C(CH3)3), 3.57 (2 H, bs, NH2), 4.60 (2 H, s, CH2), 6.60 (2 H, m, 2-H and 6- 
H), 7.08 (2 H, m, 3-H and 5-H); 6C (50 MHz, CDC13) -5.1 (CH3, Si(CH3)2), 18.4 (C, 
C(CH3)3), 26.0 (CH3, C(CH3)3), 65.0 (CH2), 114.9 (CH, C-3 and C-5), 127.7 (CH, C-2 
and C-6), 131.3 (C, C-4), 145.4 (C, C-l); m/z 238 Q /t  [ l x 13C], 2.3), 237 (10.0, M*), 
222 (1.7, -CH3), 180 (34.0, -fBu), 106 (100.0, -OTBDMS).
N.N Diethylaminocarbonylamino-4-hydroxymethylbenzene 
tertiarybutyldimethylsilyl ether (230)
A  flask was evacuated and filled with nitrogen. To this was 
added a solution o f 4-hydroxymethylaniline 
tertiarybutyldimethylsilyl ether (214) (0.1921 g, 0.92 mmol) 
and distilled triethylamine (229) (0.1241 g, 1.22 mmol) in 
distilled dichloromethane (5 ml). This system was cooled in 
an ice/salt bath prior to the careful addition o f  a solution o f  
triphosgene (0.0916 g, 0.32 mmol) in distilled 
dichloromethane (5 ml). After 1 h, diethylamine (1.4263 g,
19.50 mmol) and dibutyltin diacetate (2 drops) were added
and the system allowed to warm to room temperature. On completion o f  the reaction
OTBDMS
HN .N
O
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18 h later, the reaction mixture was washed with water (3 x 25 ml), dried, filtered and 
concentrated to give a pale yellow oil (0.3034 g, 0.90 mmol, 98%) (Found: A /,  
336.2236. C isIfe^ O iS i requires M, 336.2233), R f 0.56 [SiC>2, EtOAc/pet. ether, 1:2]; 
V m a x / c m '1 (thin film) 3024 (ArH), 2988 and 2942 (CH2 and CH3), 2868 (CH), 1714 
(C =0), 1595 and 1452 (Ar); 8h (200 MHz, CDCb) 0.09 (6 H, s, Si(CH3)2), 0.87 (9 H, 
C(CH3)3), 0.95 (3 H, t, J  9.0, CH2C //3), 1.10 (3 H, t, J  8.4, CH2C //3), 2.52 (2 H, q, J  
9.0, CtfzCH,), 3.33 (2 H, q, J 9.0, CflbCHs), 4.60 (2 H, s, ArCH2), 6.43 (1 H, bs, NH), 
7.22 and 7.29 (4 H, m, Ar-H); Sc (50 MHz, CDC13) -3.12(CH3, Si(CH3)2), 19.5 (C, 
C(CH3)3), 22.6 (CH3, CHjCHs), 23.0 (CH3, CH2CH3), 27.6 (CH3, C(CH3)3), 40.0 (CH2, 
CH2CH3), 47.0 (CH2, CH2CH3), 66.3 (CH2, ArCH2), 124.3 and 128.6 (CH, C-2, C-3, C- 
4 and C-5), 136.5 (C, C -l), 145.65 (C, C-4r), 165.2 (C, CO); m/z 337 (MS/, 2.8), 336 
(2.8, IS ), 321 (3.4, -CH3), 280 (20.0, -2*CH2CH3 +2H), 279 (78.6, -2><CH2CH3 +H), 
207 (3.9, -fBu -NEt), 179 (2.2, -'Bu -CONEt), 165 (3.9, -'Bu -NCONEt), 76 (4.7, 
CsK.).
Diphenyl N-benzyloxycarbonyl L-glutamate (236)
m-Ar m-Ar
o-Ar o-Ar
j-Ar
o-Aro-Bz
m-Bz s-Bz | m-Ar
m-Ar
j-Ar
o-Arp-Bz o-Bz
m-Bz
To a suspension o f  A-benzyloxycarbonyl L-glutamic acid (5.6341 g, 20.04 mmol) (210) 
in dichloromethane (150 ml), phenol (233) (3.7784 g, 40.14 mmol) and
dicyclohexylcarbodiimide (231) (9.0124 g, 43.68 mmol) were added and the mixture was 
stirred. After 18 h glacial acetic acid (1 ml, 17 mmol) was added, followed, after 30 min, 
by a portion o f  Analar methanol (1ml, 21 mmol). The precipitate was filtered o ff 1 h later, 
and the filtrate was evaporated to dryness. The residue was taken up in ethyl acetate 
(50 ml) and washed with saturated sodium bicarbonate solution (2 x 50 ml), citric acid 
solution (5%, 2 x 50 ml) and water (2 x 50 ml). Drying, filtration and evaporation o f  the 
organic solvents gave a colourless gum (12.2595 g), which solidified on cooling.
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Purification by pressure assisted gravity column chromatography [S i02, EtOAc/pet. 
ether, 1:4) gave an impurity (0.9440 g) and the required product as a white solid 
(7.1788 g), which was crystallised from ethyl acetate/hexane to give colourless needles 
(5.9721 g, 13.78 mmol, 6 8%), m.p. 87.6-88.9 °C (Found: C, 69.75; H, 5.29; N, 3.21%. 
C25H23NO6 requires C, 69.93; H, 5.34; N, 3.23%); R f 0.62 [Si(>2, EtOAc/pet. ether, 
1:2]; VnVcm ' 1 (KBr) 3432 (NH), 3058 and 3032 (ArH), 2928 (CH2) and 2854 (CH2 and 
CH), 1784, 1774, 1756 and 1700 (C =0), 1590 and 1486 (Ar), 1310, 1290, 1274, and 
1260 (C-O [C 0 2Ph]), 1196 (C -0  [OCONH]), 746, 798 and 688  (5 adjacent H on an 
aromatic ring); Sh (2 0 0  MHz, CDC13) 2.15-2.85 (4 H, m, CH2CH2), 4.87 (1 H, m, 
CHCH2), 5.30 (2 H, ArCH2), 6.80-7.50 (15 H, m, Ar-H and Bz-H); 6c (50 MHz, CDCI3) 
21.7 (CH2, CHCH2), 31.0 (CH2, C H ^ O ^ , 58.7 (CH, CHCH2), 6 8 .6  (CH2, ArCH2),
121.0 (CH, o-Ar), 126.3 (CH, p-Ai), 128.3, 128.6 and 128.6 (CH, o-Bz, m-Bz, p-Bz), 
129.5 (CH, m-Ar), 134.8 (C, s-Bz), 150.0 and 150.8 (C, s-Ai and OCONH), 169.6 and 
172.9 (C, C 0 2C(CH3)3); m/z 340 (M* -OPh, 0.1), 246 (0 .8 , -2 ><OPh -H), 232 (0.1, -OPh 
-PhCH20  -H), 218 (0.3, -OPh -COjPh -H), 204 (0.4, -OPh -PhCH2OCO -H), 107 (2.6, 
PhCH20 ) ,  94 (5.5, PhOH), 93 (1.2, PhO).
Diphenyl L-glutamate (237)
Palladium on carbon (10%, 0.0216 g) was 
placed in a 3-necked flask, and the system 
was evacuated and placed under a hydrogen 
atmosphere. Analar methanol (10 ml) was 
added, followed by a solution o f diphenyl N- 
benzyloxycarbonyl L-glutamate (236)
(0.5233 g, 1.20 mmol) in Analar methanol 
(10 ml). After VA h stirring the catalyst was 
filtered off through a Celite pad and the 
filtrate was evaporated to give a white powder (0.3213 g). The crude product was 
crystallised from dichloromethane/hexane to give colourless needles (0.2136 g,
0.71 mmol, 59%), m.p. 83.4-84.6 °C (Found: A /,  299.1153. C 1 7 H 1 7 N O 4  requires M, 
299.1158); R f 0.75 [S i02, EtOAc/pet. ether, 1:1]; Vnux/cm’1 (KBr) 3259 ( N H ) ,  2926 
( C H 2) ,  1766 and 1714 ( C = 0) ,  1592 and 1492 (Ar), 1196 and 1176 (C-O), 738 and 692 
(5 adjacent H  on an aromatic ring); 8h (200 MHz, C D C I 3 )  2.30-2.60 (4 H ,  m, C H 2C H 2) ,
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4.47 (1 H, m, C//CH2), 7.00-7.50 (10 H, m, Ar-H); 5C (50 MHz, CDC13) 24.8 and 29.3 
(CH2), 55.7 (CH, CHCH2), 121.2 (CH, o-Ar), 126.3 (CH, p -A i\  129.6 (CH, m-Ar),
150.2 (C, j-Ar), 170.7 and 178.5 (C, CO); m/z 299 (A /, 0.1), 206 (0.5, -OPh), 205 (0.4, 
-OPh -H), 177 (14.0, -C02Ph -H), 176 (0.1, -C 02Ph -2><H), 122 (0.1, PhC 02H), 121 
(0.2, PhC 02), 94 (32.3, PhOH), 93 (1.3, PhO), 77 (3.9, Ph).
4-Hydroxymethylphenolbis(tertiarybutyldimethylsilyl ether) (241)
A  sample o f  4-hydroxybenzyl alcohol (239) (0.8926 g,
7.19 mmol) and imidazole (0.8457 g, 12.42 mmol) was placed 
in a flask under a nitrogen atmosphere and the solids 
dissolved in distilled dichloromethane (20 ml). Addition o f  a 
solution o f  tertiarybutyldimethylsilylchloride (1.0965 g,
7.27 mmol) in distilled dichloromethane (5 ml), followed by 
stirring for 18 h completed the reaction. Evaporation o f  the 
volatiles gave a residue which was distilled to give a 
colourless oil which solidified on cooling (0.5384 g,
1.59 mmol, 22%), b.p. 108-110 °C (1.0 mbar); R f 0.88 [S i0 2, EtOAc/pet. ether, 1:2]; 5h 
(90 MHz, d4-MeOH) 0.1 (6H, s, Si(CH3)2), 0.2 (6H, s, Si(CH3)2), 0.9 (9 H, C(CH3)3),
1.0 (9 H, C(CH3)3), 4.8 (2 H, s, CH2), 6.8 (2 H, m, 3-H and 5-H), 7.2 (2 H, m, 2-H and 
6-H); imidazole signals detected at 7.3 (6 H, m, 4-H and 5-H), 7.70 (3 H, 2H).
Ditertiarybutyl 4-hydroxymethylphenyloxycarbonyl-L-glutamate (243)
rOH
/ \
A  round-bottomed flask was placed under a nitrogen atmosphere. To this was added a 
solution o f  ditertiarybutyl L-glutamate (212) (0.5040 g, 1.95 mmol) in distilled 
dichloromethane (8 ml), followed by a solution o f  distilled triethylamine (0.9124 g,
9.02 mmol) in distilled dichloromethane (8 ml). The solution was stirred vigorously as a 
solution o f  triphosgene (0.21541 g, 0.89 mmol) in distilled dichloromethane (8 ml) was 
added. After 1 h a solution o f  4-hydroxybenzyl alcohol (239) (0.3172 g, 2.56 mmol) in 
distiled dichloromethane was added and stirring continued for a further 17 h. After this 
time the reaction mixture was washed with water, dried, filtered and concentrated to give 
a yellow oil (0.8321 g). This was purified by gravity column chromatography [Si02, 
EtOAc/pet. ether, 1:2] to give the required product as a colourless oil (0.4989 g, 
1.21 mmol, 62%) (Found: C, 61.53; H, 7.85; N, 3.54%. C21H31NO7 requires C, 61.60; 
H, 7.63; N, 3.42%); R f 0.40 [S i0 2, EtOAc/pet. ether, 1:1]; W c m ' 1 (thin film) 3615 
(OH), 3429 (NH), 2981 and 2933 (CH2 and CH3), 2874 (CH), 1732 (C =0), 1489 (Ar), 
1368 (CH3), 1212 (C-O), 1155 (OH); 5 h (200 MHz, CDC13) 1.45 and 1.49 (18 H, s, 
CH3), 1.80-2.40 (2 H, m, CH2CH2), 4.30 (1 H, m, CH), 4.61 (2 H, s, C //2OH), 5.85 (1 
H, bd, J  8.18, NH), 7.08 (2 H, m, 2-H and 6-H), 7.81 (2 H, m, 3-H and 5-H); 8C (50 
MHz, CDC13) 27.8 and 31.5 (CH3), 28.0 and 28.1 (CH2, CH2CH2), 54.1 (CH), 64.5 
(CH2, CH2OH), 80.9 and 82.5 (C, C(CH3)3), 121.6 (CH, C-2 and C-6), 127.9 (CH, C-3 
and C-5), 138.3 (C, C-4), 150.2 (C, C -l), 171.0, 171.3 and 172.2 (C, CO); m/z 234 (A f  
-'Bu -C 0 2'Bu -OH, 0.8), 206 (0.9, -2*C 02'Bu -H), 122 (3.9, CH2PI1CO2), 107 (50.1, 
C6H4CH2OH), 106 (27.3, CeHtCHjO), 93 (4.9, CeHtOH).
Iodomethylbenzene (267)
The crude product was obtained by the method o f  Olah et a r  [Into a ,
s '
flask which contained a nitrogen atmosphere was placed a solution o f  
benzyl alcohol (266) (2.07 ml, 20.0 mmol), sodium iodide (3.00 g,
20.0 mmol) and distilled triethylamine (2.78 ml, 20.4 mmol) in acetonitrile 
(20 ml). This was stirred vigorously as chlorotrimethyl silane (2.58 ml,
20.4 mmol) was added dropwise. An exotherm developed after 5 min and 
the reaction was complete after 1% h. The reaction mixture was then poured into ethyl 
acetate (100 ml), washed with water (50 ml) and brine (2 x 50 ml), dried over sodium 
sulphate, filtered and concentrated to give a yellow oil (2.4493 g)]. This crude sample 
was purified by dry column flash chromatography [SiC>2, hexane] to give the required 
product (2.41 g, 11.1 mmol, 55%). Further elution with ethyl acetate gave starting
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N  C 0 2Me
material (0.75 g, 6.9 mmol, 35%). The product was isolated as a pink oil (Found: AC, 
216.9502. C7H7I requires AC, 216.9514); R f 0.43 [S i02, hexane]; Vmax/cm' 1 (thin film) 
3045 and 3005 (ArH), 2980 and 2965 (CH2), 1590, 1560, 1460 (Ar); 5h (200 MHz, 
CDCI3) 4.42 (2 H, s, CH2), 7.32 (5 H, m, Ar-H); 5C (50 MHz, CDCI3) 5.48 (CH2), 126.0 
(CH, C-4), 127.7 (CH, C-2 and C-6 ), 128.9 (CH, C-3 and C-5), 138.4 (C, C -l); m/z 217 
(AC, 0 .2 ), 90 ( 100 .0 , -I), 77 (42.3, -CH2I).
Methyl 4-hydroxy-2-quinolinecarboxylate (271)
Hydrogen chloride gas catalyst: A solution o f 4- 
hydroxy-2-quinolinecarboxylic acid hydrate (270)
(0.6600 g, 3.19 mmol) in Analar methanol (150 ml) 
was cooled in an ice/salt bath. A stream o f  hydrogen 
chloride gas was passed through the solution for 30 
min, followed by a stream o f  nitrogen gas for a further 30 min. The volatiles were then  
removed under vacuum, and saturated sodium bicarbonate solution (~60m l) was added  
to the resulting salt. This aqueous solution was extracted with ethyl acetate (3 x 50 ml). 
The organic extracts were dried, filtered and concentrated to give an orange p o w d e r 
(0.3809 g, 1.87 mmol, 59%), m.p. 203.6-205.1 °C (Found: AC, 203.0594. C11H9NO3 
requiresM, 203.0582); R f 0.42 [S i02, EtOAc]; Vnux/cm*1 (KBr) 3446 (OH), 3055 (A rH ), 
2956 and 2930 (CH2), 2850 (OCH3), 1740 (C =0), 1605, 1560, 1514 and 1471 (A r), 
1354 (OH), 1266, 1228, 1137 and 1112 (CO), 758 (5 adjacent H on an aromatic ring); 
8h (200 MHz, CDCI3) 4.01 (3 H, s, CH3), 6.69 (1 H, bs, OH), 7.40 (1 H, dd, J  7-h^-h 8.1 
and J  7tH-6-h 6.9, 7-H), 7.73 (1 H, ddd, J  6-H-7-H 6.9, J  6-i«-h 7.4 and J  1.4, 6 -H), 
7.98 (1 H, d, 7  7.4, 5-H), 8.14 (1 H, dd, J  wt-7-H 8.1 and J  8+^ -6-h 1.4, 8 -H); 5C (50 M H z, 
CDCI3) 53.6 (CH3), 110.2  (CH, C-3), 119.7, 124.2, 124.8 and 132.9 (CH, C-5, C-6 , C-l 
and C-8 ), 126.0 (C, C-4a), 137.8, 140.2 and 156.7 (C, C-2, C-4 and C-8a), 162.8 (C, 
CO); m/z 203 (AC, 44.8), 171 (15.1, -CH3 -OH), 143 ( 100 .0 , -C 0 2CH3).
Sulfuric acid catalyst. 4-hydroxy-2-quinolinecarboxylic acid hydrate (270) (0.4771 g, 
2.30 mmol) and concentrated sulfuric acid (98%, 1 ml) were added to Analar m ethanol 
(150 ml). After 2 h heating at reflux all the carboxylic acid had dissolved. The reac tio n  
was brought to completion by addition o f another portion o f  sulfuric acid (98%, 2 ml) 
and a further 70 h heating at reflux. Once the solution had cooled it was neutralised by 
addition o f  saturated sodium bicarbonate solution ( - 2 0  ml), and the volatiles w ere
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removed by evaporation. The white residue was extracted with hot ethyl acetate 
(6 x 35 ml) to give a white powder (0.2354 g), which was purified by gravity column 
chromatography [SiC>2, EtOAc] to give an impurity (0.0985 g) R f 0.66 [SiC>2, EtOAc] 
and the required product (0.0564 g, 0.29 mmol, 13%), the analysis o f  which was 
consistent with that o f  a known sample.
Coupling with 1,3-diisopropylcarbodiimide: A solution o f  4-hydroxy-2-
quinolinecarboxylic acid hydrate (270) (0.3770 g, 1.82 mmol) in Analar methanol 
(100 ml) was cooled in an ice/salt bath, and a solution o f  1,3-diisopropylcarbodiimide 
(0.2938 g, 2.33 mmol) in distilled dichloromethane (10 ml) was added. The reaction was 
allowed to warm to room temperature and stirred. After 48 h most o f  the methanol 
(-80% ) was removed by evaporation and ethyl acetate (50 ml) was added. This mixture 
was then washed with water (3 x 50 ml), dried, filtered and concentrated to give a 
yellow powder, which was triturated with diethyl ether to give a pale yellow powder 
(0.1234 g, 0.61 mmol, 34%), analysis o f which was consistent with a known sample, but 
showed signs o f  remaining 1,3-diisopropylcarbodiimide and 1,3-diisopropylurea.
Coupling with 1,3-dicyclohexylcarbodiimide (231): A  flask was charged with 4- 
hydroxy-2-quinolinecarboxylic acid hydrate (270) (0.4836 g, 2.33 mmol), 1,3- 
dicyclohexylcarbodiimide (231) (0.6847 g, 3.32 mmol) and Analar methanol (100 ml). 
The mixture was stirred for 24 h, then another portion o f  1,3-dicyclohexylcarbodiimide 
(231) (0.5604 g, 2.71 mmol) was added and stirring was continued for a total o f  48 h. 
Since the reaction was still incomplete the system was heated at reflux for a further 4 h, 
before being allowed to cool. SiC>2 was added to the solution and the volatiles were 
removed. The solid was then placed upon a SiC>2 column and purified by gravity column 
chromatography [SiC>2, EtOAc/pet. ether, 1:2]. This yielded the least polar compound as 
a yellow oil (0.2445 g), R f 0.69 [Si02, EtOAc], and with increasing polarity 
[EtOAc/methanol, 10:1] the more polar impurity (0.0456 g) R f 0.53 [Si02, EtOAc] and 
the required product as a yellow solid (0.1233 g, 0.61 mmol, 26%). Analysis was 
consistent with a known sample, but showed signs o f  remaining 1,3- 
dicyclohexylcarbodiimide (231).
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4-Hydroxy-2-hydroxymethylquinoline (272)
A  sample o f  4-hydroxyquinoline-2-carboxylic acid hydrate 
(270) (4.9309 g, 23.80 mmol) was placed in a 3-necked 
round-bottomed flask, which was flame dried and placed 
under a nitrogen atmosphere. The system was then cooled 
to -78° C and distilled tetrahydrofuran (100 ml) was added.
A  solution o f  lithium aluminium hydride (1.0 M in THF,
40.0 ml, 40.0 mmol) was added dropwise over the period o f  5 min and the reaction 
mixture was allowed to warm to room temperature. After 20 h the system was cooled in 
an ice/salt bath and water (5 ml) was added dropwise. The volatiles were removed to 
give a solid which was extracted with pyridine (4 x 30 ml). After evaporation o f  the 
pyridine, saturated sodium bicarbonate solution (50 ml) was added to the residue 
(4.9571 g) and the solution was extracted with ethyl acetate (3 x 50 ml). The combined 
organic extracts were dried, filtered and concentrated to give a red gum (2.9849 g), 
which was recrystallised from methanol to give yellow platelets (0.2358 g, 1.34 mmol, 
6%), m.p. >360 °C (Found: C, 68.04; H, 5.45; N, 7.70%; A / ,  175.0618. Ci0H9NO2 
requires C, 68.61; H, 5.18; N, 8.00%; A/, 175.0633); R f 0.58 [S i0 2, EtOAc/methanol, 
2:1]; Vmax/cm"1 (KBr) 3120 (OH), 2935 (CH2), 1597, 1544, 1492 and 1469 (Ar), 1361 
and 1319 (OH), 1076 (CO), 841 (isolated H on an aromatic ring), 754 (5 adjacent H on 
an aromatic ring); 8h (200 MHz, d^-DMSO) 4.55 (2 H, d, J  5.6, C /f2OH), 5.82 (1 H, t, J
5.6, CH20 // ) ,  6.12 (1 H, s, 3-H), 7.32 (1 H, ddd, J  7-H-6-H 7.3, J  7-h -s-h  7.6 and J  7-H-5-H
1.6, 7-H), 7.5-7.8 (2 H, m, 5-H and 6-H), 8.1 (1 H, dd, J  8* -7-h 7.6 and J  0.9, 8- 
H), 11.58 (1 H, bs, ArOH); 8C (50 MHz, J^DMSO) 60.3 (CH2), 105.5 (CH, C-3), 
118.4, 123.0, 124.9 and 131.6 (CH, C-5, C-6, C-7 and C-8), 125.1 (C, C-4a), 140.2 (C, 
C-8a), 153.4 (C, C-4), 171.1 (C, C-2); m/z 175 (A /, 100.0), 174 (60.3, -H), 173 (56.9, - 
2xH), 158 (3.8, -OH), 157 (3.7, -OH -H), 144 (26.7, -CH2OH), 128 (11.7, -CH2OH - 
OH +H ).
OH
OH
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8.6 Experimental for Chapter 7
8.6.1 Materials
Microtitre plates (Linbro, ICN flow)
Multichannel pipette (Costar)
Tip box, autoclavable (ICN flow)
Pipette tips (ICN flow)
Petri dishes, 5 cm and 10 cm (Sterilin)
Universal containers, 30 ml and 100 ml (Sterilin)
Plastic lunch box 
Growth medium
Trypsin (0.25% + EDTA 1 mmol)
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma)
Sorensen's glycine buffer (0.1 M glycine, 0.1 M NaCl adjusted to pH 10.5 with 1 M  
NaOH)
Dimethylsulphoxide (DMSO)
DMSO dispenser (Well-fill, Denley)
ELIZA plate reader (Bio-Rad or ICN-Flow)
8.6.2 Cell lines
Two human colon-carcinoma cell lines were used: HT 29 was obtained from the ATCC 
(Rockville, MD) and BE from Dr. N. Gibson (School o f  Pharmacy, University o f  
Southern California, Los Angeles, CA). Both were grown as monolayer cultures in a 
mixture o f  Ham's F10 and Dulbecco's modified Eagle's medium (50:50, Life 
Technologies, Paisley, UK) supplemented with glutamine (2 mM) and FCS (10%). Both 
cell lines had a doubling time o f  about 24 h.
8.6.3 Cytotoxicity assay: Protocol
8.6.3.1 Plating out cells
Growth medium was removed from cell culture and trypsin (2 ml) was added. If after a 
couple o f  minutes the cells had not loosened, the culture was warmed to 37 °C until the 
cells started to detach from the universal container. The trypsin was removed and the 
cells were then collected in growth medium (10 ml) containing serum and counted using
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the Coulter counter. Dilution o f  the cells to the required concentration (which depends 
on the cell line) with medium, allowing 20 ml per microtitre plate was then carried out. 
The resulting cell suspension was transfered to a 10 cm petri dish from which 200 pi was 
added to each well o f  the central 10 columns o f  a flat bottomed 96 well plate (80 wells 
per plate) using a multichannel pipette, starting with column 2 and ending with column 
11 (3 x 103 cells per well for HT 29 and 5 x 103 cells per well for BE). 200 pi o f  growth 
medium was added to the eight wells in column 1 and column 12 as controls. The plates 
were placed in a plastic lunch box and incubated in a humidified atmosphere at 37 °C for 
two days so that the cells would be in the exponential phase o f  growth for drug addition.
8.6.3.2 Drug addition
A  serial 5-fold dilution o f the cytotoxic drug was prepared in growth medium to give 4 
concentrations, starting at 1 mmol. If the drug had previously shown high toxicity then 
the dilutions were taken to 10-fold, eight concentrations were prepared and/or a lower 
starting concentration o f  the drug was used. Two plates was used for each drug to give 
duplicate determinations within one experiment.
The medium was then removed from the wells in columns 2 to 11. This was achieved 
using a hypodermic needle attached to a suction line. The cells in the eight wells in 
columns 2 and 11 were fed with 200 pi o f fresh growth medium and these cells were 
used as controls. The cytotoxic drugs were then added to the cells in columns 3 to 10. 
Four wells were needed for each drug concentration. This allowed four compounds at 
four dilutions, or two compounds at eight dilutions, to be screened in one plate. The 
drug solutions were transferred to 5 cm petri dishes and 200 pi added to the wells in 
columns 3 to 10. The plates were returned to the lunch box and incubated for 24 h.
8.6.3.3 Growth period.
At the end o f  the drug exposure period, the medium was removed from all the wells 
containing cells and the cells were fed with 200 pi o f  fresh medium, and incubated for 
4 d.
8.6.3.4 Estimation of surviving cell numbers
The plates were fed with 200 pi o f  fresh medium and 50 pi o f  MTT (5 mg ml'1 in PBS 
and filter sterilised) was added to all wells in columns 1 to 11. The plates were then 
wrapped in aluminium foil and incubated for 4 h in a humidified atmosphere at 37 °C.
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This is a minimum incubation time and plates can be left for up to 8 h. The medium and 
MTT were then removed from the wells and the MTT-formazan crystals were dissolved 
by addition o f  200 pi o f  DMSO to all wells in columns 1 to 11. Glycine buffer was added 
(25 pi per well, 0.1M, pH 10.5) to all wells containing DMSO. Absorbance was 
recorded at 570 nm immediately since the product is unstable. The wells in column 1, 
which contained medium, MTT but no cells were used to blank the plate reader.
8.6.3.5 Analysis of results
Analyses were conducted either manually or using Softmax analysis software (Molecular 
Dynamics Corporation). In each case a graph was plotted o f  absorbance (y-axis) against 
drug concentration (x-axis). The mean absorbance reading from the wells in columns 2 
and 11 were used as the control absorbance and the IC50 concentration was determined 
as the drug concentration required to reduce the absorbance to half that o f  the control.
8.6.4 Hypoxic cytotoxicity assay
For estimation o f  the oxic:hypoxic cytotoxicity ratio, cells were grown on glass petri 
dishes for drug exposure under hypoxic conditions and on plastic petri dishes for oxic 
conditions. Cells were plated out at a density o f  1 x 105 cells per 5 cm petri dish for the 
HT 29 cells and a density o f  2 x 105 cells per 5 cm petri dish for the BE cells. The cells 
were allowed to attach and grow for 2 d. The medium was removed from the dishes and 
replaced with 2 ml o f  fresh medium containing the drug. Then the dishes were exposed 
to the drug for 3 h in a humidified atmosphere in oxic (2% CO2  in air) or hypoxic (2% 
CO2  in N 2 ) conditions. The medium was removed and the dishes were fed with fresh 
medium and incubated for 36 h. After removal o f  the medium, cells were detached with 
trypsin (1 ml per dish). After 5-10 min, medium was added (1 ml) and the number o f  live 
cells counted using the Coulter counter.
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